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SUMMARY 
BACKGROUND !
A variety of individual and population based approaches to prevention and 
management of obesity are required and there is an increasing interest in 
functional foods and natriceuticals. Conjugated linoleic acid (CLA) has 
generated enormous interest in this context due to their ability to modulate 
PPAR’s and the associated metabolic processes. 
  !
AIMS & METHODS !
This study aimed to investigate the effects of CLA supplementation in a 
randomised, double blind crossover trial on inflammation, vascular function 
and metabolic profiles in subjects with the metabolic syndrome. !!
RESULTS !
This study utilised a cross-over design to investigate any differences in 
outcomes using 9,11 CLA isomer in comparison to the CLA mixture. The 
results revealed no significant differences at baseline between the two 
groups and a relatively small number of significant outcomes (peripheral 
SBP, aPWV, HDL-cholesterol, adiponectin, platelet aggregation and HOMA 
B). As there was a lack of substantial differences in the two treatments and 
an inconsistency in specifying these differences to a specific isomer, further 
analysis was undertaken combining the data from both groups and 
comparing the outcomes at baseline and at the end of the treatment using a 
paired‘t’ test. Results from this sub analysis showed a significant increase in 
circulating sRAGE levels (‘p’=0.002) along with reductions in aortic PWV 
(‘p’=0.003) and markers of endothelial and platelet function. There were no 
changes in body composition or insulin sensitivity although adiponectin 
levels were elevated (‘p’=0.003) and resistin levels decreased markedly 
(‘p’<0.005) following the treatment.  !!
CONCLUSIONS !
Dietary supplementation with CLA seems to produce a number of vascular 
benefits which are noted to be independent of its metabolic effects and 
mediated possibly by attenuating inflammation through changes in 
circulatory sRAGE. This is of considerable clinical relevance and may open 
new perspectives and offer effective strategies to reduce the CVD burden in 
the metabolic syndrome. !
!
!  11
!
ACKNOWLEDGEMENTS 
The study was conducted at the Clinical Research Facility, University 
Hospital of Wales, Cardiff. The work would not have been possible without 
the support of many people. As only a few can be mentioned I offer my 
sincere gratitude to all who have helped. 
First and foremost I would like to express my gratitude to my supervisor Dr 
Aled Rees for the valuable advice, generous support and supervision 
provided during the crucial stages of this project. I would also like to thank 
my other supervisor, Dr Marc Evans and Professor Colin Dayan for their 
guidance at various stages of this project.  
I am grateful to Dr Keith Morris (Department of Applied Sciences, Cardiff 
Metropolitan University) for his endless help and advice throughout the 
course of this project. I would also like to thank Dr Sam Rice, Dr Neera 
Agarwal and Dr Manish Khanolkar for their help with vascular, platelet 
studies and support throughout this project. I would like to thank Kate Craig 
and her team for their help with patient care at the Clinical Research facility 
in Cardiff. 
I would like to express my gratitude to all the patients who volunteered to 
participate in this study, as this project would not have been possible without 
their help.  
Lastly, I would like to thank my wife Bharati and my sons Praneet and Vineet 
for their immense patience and understanding throughout the course of this 
project and to you I dedicate this thesis.  
!
!  12
!
Abbreviations 
ATP III  Third Adult treatment Panel 
AHA   American Heart Association 
Aus Diab Study Australian Diabetes Obesity and Lifestyle Study 
Aix   Augmentation Index 
ADP   Adenosine diphosphate 
AGEs   Advanced Glycation End products 
ARB   Angiotensin receptor blockers 
ACS   Acetyl Coenzyme A synthetase 
ALE   Advanced lipoxidation products 
BOLD   Bariatric Outcomes Longitudinal Database 
BMI   Body Mass Index 
BP   Blood pressure 
BD   twice a day 
CHD   Coronary heart Disease 
CVD   Cardiovascular Disease 
CRP   C - reactive protein 
CLA Conjugated linoleic acid 
Co A   coenzyme A 
0C   degree centigrade 
cm   centimetre 
CV   coefficient of variance 
DPS   Diabetes Prevention Study 
!
!  13
DREAM  Diabetes Reduction Assessment with Ramipril and    
   Rosiglitazone medication Study 
EGIR   The European Group for the Study of Insulin Resistance 
EASD   European Association for the Study of Diabetes 
ET-1   Endothelin -1 
eNOS   endothelial nitric oxide synthetase 
ELISA  Enzyme Linked Immunosorbant Assay 
ECG   Electrocardiogram 
FFA   Free Fatty Acids 
FPG   Fasting Plasma Glucose 
FPI   Fasting Plasma Insulin 
gm   grams 
HbA1c  Glycated Haemoglobin  
HDL-C  High density Lipoprotein- Cholesterol 
hs CRP  high sensitivity C- Reactive protein 
HOMA-IR  Homeostatic Model Assessment- insulin resistance 
HCL   Hydrochloric Acid 
IL-6   Interleukin-6 
IL-1   Interleukin-1 
IL-8   Interleukin-8 
ICAM-1  Intercellular adhesion molecules 
IR   Insulin Resistance 
IGT   Impaired Glucose Tolerance 
IFG   Impaired Fasting Glucose 
!
!  14
IDF   International Diabetes Federation  
IHD   ischaemic heart disease 
Ig E   Immunoglobulin E 
IMP   investigational medicinal product 
Kg   Kilograms 
LDL   Low Density lipoprotein 
MAP   Mitogen activated protein 
MAP-K  Mitogen activated protein- Kinase 
MCP-1  monocyte chemo attractant protein-1 
MRFIT  Multiple Risk Factor Intervention Trial 
MI   Myocardial Infarction 
MHRA  Medicines and Healthcare Products Regulatory  
   Authority 
m2   square meter 
mmol/l  millimoles/litre 
mg   milligrams 
mL   millilitres 
M   Molar 
mm Hg  millimetre of mercury 
NEFA   Non Esterified Fatty Acids 
NF-κB  Nuclear Factor kappa Beta 
NHLBI  National Heart, Lung and Blood institute 
NCEP -ATP III  National Cholesterol Education Programme Third Adult 
   Treatment Panel 
!
!  15
NHANES  The National Health and Nutrition Examination Survey 
NO   Nitric oxide 
ng   nanograms 
OGTT   Oral Glucose Tolerance Test 
PKC   Protein Kinase C 
PPAR- α  Peroxisome proliferator activated receptor- alpha 
PPAR- β/δ  Peroxisome proliferator activated receptor - beta/ delta 
PPAR- γ  Peroxisome proliferator activated receptors - gamma 
PUFA   polyunsaturated fatty acids 
PAI-1   Plasminogen activator inhibitor-1 
PWV   Pulse Wave velocity 
aPWV   Aortic pulse wave velocity 
bPWV   Brachial pulse wave velocity 
PI3-K   Phosphoinositide - 3 – Kinase 
PG   Prostaglandin 
PBS   Phosphate buffered solution 
pg   picograms 
PRP   Platelet rich plasma 
RAGE   Receptor for advanced glycation end products 
sRAGE  Soluble Receptor for advanced glycation end products 
ROS   Reactive oxygen species 
sVCAM  soluble Vascular adhesion molecules 
sICAM  soluble intercellular adhesion molecules 
SA-A   serum amyloid associated protein 
!
!  16
SR-A   scavenger receptor pathway 
TG   Triglycerides 
TZDS   Thiazolidenediones 
TRIPOD  Troglitazone in prevention of Diabetes 
t-PA   tissue plasminogen activator 
TXA2   Thromboxane A2 
TNF α   Tumour necrosis factor- alpha 
T2DM   Type 2 diabetes mellitus 
VCAM  Vascular cell adhesion molecules 
VSMC   Vascular smooth muscle cell 
vWF    von Willebrand factor 
VLDL   Very low-density lipoprotein 
WHO   World Health Organisation 
WOSCOPS  West of Scotland Coronary Prevention Study 
!
!
!
!
!
!
!
!
!
!
!
!  17
List of Figures 
Figure No  Title                  page No 
1.1  The Metabolic syndrome: The ‘Deadly Quartet’       23  
1.2  Insulin resistance syndrome and clusters of        23 
  cardiovascular risk factors  
1.3  Age-Specific Prevalence of the Metabolic        35 
  Syndrome among US Adults  
1.4  Type-2 diabetes mellitus, hypertension and        38 
  hyperlipidaemia: relation to reduced fetal growth 
1.5  Odds ratio for developing impaired glucose tolerance       39 
  according to birth weight 
1.6  Odds ratio for developing metabolic syndrome according  39 
  to birth weight 
1.7  Progression of insulin resistance and its         44 
  consequences 
1.8  Association of insulin resistance with cardiovascular      46           
  risk factors and Atherosclerosis 
1.9  Insulin action mediated by the PI3 kinase and       49 
  MAP kinase signaling pathway 
1.10  Hemodynamic changes in arterial stiffening       52 
1.11  Pathogenesis of hypertension in the         55 
  hyperinsulinaemic state 
1.12  Adipocytokines, Inflammation and Atherosclerosis      57 
1.13  The risk of diabetes and cardiovascular         66 
  disease in metabolic syndrome 
!  18
1.14  Formation of AGE           67 
1.15   Maillard Reaction           68 
1.16  AGE binding to its receptor RAGE        70 
1.17  Mechanism of action of PPARs         83 
1.18  Biologically Active CLA isomers         88 
!
2.1  Study plan/Flow chart         105 
2.2  Chronolog platelet aggregometer used to       115 
  quantify platelet aggregation 
2.3  Showing the use of a hand held tonometer to      118  
  obtain pulse waves 
!
3.1  Flow of participants through each phase of the      129 
  study 
3.2  Model for statistical Analyses        132 
3.3  Effect of 9, 11 CLA/CLA mix treatment on      144 
  aPWV and bPWV 
3.4  Changes on BP following 8 weeks of treatment      144 
  with 9, 11 CLA/CLA mix in the metabolic syndrome 
3.5  Effect of 9, 11 CLA/CLA mix therapy on lipid      146 
  profiles in subjects with the metabolic syndrome 
3.6  Effect of 9,11 CLA/CLA mix on adipokines in       146 
  subjects with the metabolic syndrome 
!
!
!  19
List of Tables !!
Table No.  Title                  page No !
1.1  WHO definition of the metabolic syndrome        24 
1.2  EGIR definition of the metabolic syndrome        25 
1.3  NCEP ATP III Definition of the metabolic syndrome       26 
1.4  Summary of abnormalities in the metabolic syndrome       27 
1.5  IDF definition of the metabolic syndrome         28 
1.6  Similarities and differences between diagnostic        29 
  criteria for the metabolic syndrome 
1.7  Consensus statement 2009 criteria         31 
1.8  Vasoactive substances and the endothelium        47 
1.9  Tissue distribution of PPAR isoforms         82 
1.10  List of Endogenous PPAR ligands               87 
1.11  Summary of Key clinical Trials            94 
1. Demonstrating reproducibility of platelet aggregation       117 
  studies 
3.1  Adverse events recorded during the study         130 
3.2  Comparison of Baseline demographic and         133 
  anthropometric data 
3.3   Baseline vascular markers for the study          134 
  population 
3.4  Baseline Adipokines and Metabolic Biochemical        135 
  Parameters 
3.5  Changes in sRAGE, Inflammation, Endothelial          137 
  and Platelet function  
!  20
3.6  Effect of 9,11 isomer Vs CLA mix on vascular       138 
  outcomes in subjects with the metabolic syndrome       
3.7  Changes in body composition, Lipid profiles        139 
  and Adipokines (9,11 isomer Vs CLA mix)              
3.8   Effects of CLA on Insulin sensitivity and β-cell        140 
  function (9, 11 isomer Vs CLA mix) 
3.9  Results of vascular outcomes for the entire cohort      143 
3.10  Effect of 9, 11 CLA/CLA mix therapy on lipid       145 
  profiles in subjects with the metabolic syndrome 
3.11  Effects of 9, 11 CLA/ CLA mix on insulin              147 
  sensitivity and β-cell function 
3.12  Correlation Analysis for the Combined Data       148 
3.13  Regression analysis of aPWV vs difference       150 
  Sp-Selectin and vWF 
3.14  Regression analysis of sRAGE vs difference       151 
  in HOMA-IR 
!
!
!
!
!
!
!
!
!
!  21
!
Chapter 1 - General Introduction  
!
1.1 Historical Overview - The Metabolic Syndrome 
The Metabolic syndrome was first described more than a century ago. Eskil 
Kylin, a Swedish physician, recognised that high blood pressure, 
dysglycaemia and elevated uric acid levels frequently appeared in patients 
at the same time in the early part of the 20th century (1). He hypothesised 
that this syndrome arose from metabolic abnormalities related to the 
development of diabetes and / or cardiovascular disease and led to an 
increase in the incidence of coronary heart disease (CHD) in the middle of 
the 20th century with an associated increase in morbidity and mortality. The 
concept of risk factors was developed to combat this clinical problem with 
the hope that identification and treatment of causal risk factors would lead to 
a reduction in the incidence of cardiovascular disease (CVD).  
!
Such clustering, however did not receive further attention until 1988, when 
Gerald Reaven introduced the concept of insulin resistance in his Banting 
lecture under the name of ‘syndrome X’ (2). The following year, Kaplan 
described four important features in the development of type 2 diabetes and 
CVD i.e. upper-body obesity, glucose intolerance, hypertriglyceridemia and 
hypertension, and called them ‘the deadly quartet’ (3) (Figure1.1). 
!  22
%  
Figure 1.1: The Metabolic syndrome: The ‘Deadly Quartet’  
(Adapted from Kaplan et al, Arch Intern Med. 1989; 149(7):1514-1520) 
!
The otherwise named ‘insulin resistance syndrome’ represents similar 
features (Figure 1.2) consisting of clusters of cardiovascular disease risk 
factors and their relationship to insulin resistance (4). 
%  
Figure 1.2: Insulin resistance syndrome and clusters of cardiovascular 
risk factors (Adapted from Hafner et al. Diabetes 1992) 
!
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!
1.2 Definition of the metabolic syndrome 
The term ‘metabolic syndrome’ was introduced later, and slightly different 
definitions were proposed by the World Health Organization (WHO) (5) and 
the Third Report of National Cholesterol Education Program Adult Treatment 
Panel (NCEP ATP III) (6). The WHO definition of metabolic syndrome was 
written by diabetologists with the core feature of glucose intolerance (Table 
1.1).  
!
1.2.1 WHO definition of the metabolic syndrome 
Table 1.1: The 1999 World Health Organization definition of the metabolic 
syndrome. 
Glucose intolerance, Impaired glucose tolerance (IGT) or diabetes 
and/or insulin resistanceª together with two or more of the following: 
• Raised arterial pressure ≥ 140/90 mmHg 
• Raised plasma TG (≥1.7 mmol/l) and/or low HDL-cholesterol (<0.9 
mmol/l men;   <1.0 mmol/l women) 
• Central obesity (males: waist to hip ratio >0.90; females: waist to hip 
ratio 
>0.85) and/or BMI >30 kg/m² 
• Microalbuminuria (urinary albumin excretion rate ≥ 20g/min or 
albumin:creatinine ratio ≥ 30mg/g) 
ªInsulin resistance measured under hyperinsulinaemic euglycaemic 
conditions, glucose uptake below lowest quartile for background 
population under investigation.
!  24
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!
1.2.2 The European Group for the study of Insulin Resistance (EGIR) 
definition for the metabolic syndrome 
The European Group for the study of Insulin Resistance (EGIR) proposed a 
modified version of the WHO definition to be used in non- diabetic subjects. 
Both these definitions included a measure of insulin resistance which was 
not practical for use in large populations. The EGIR included fasting insulin 
to estimate insulin resistance and replaced impaired glucose tolerance (IGT) 
with impaired fasting glycaemia (IFG) (Table 1.2) (7). 
!
Table 1.2: EGIR Definition of the metabolic syndrome 
!
!
Over the years the definition of the metabolic syndrome based on WHO 
guidelines or the ATP III criteria has been used in many publications. 
!
!
Fasting hyperinsulinaemia (highest 25%) and at least two of the  
following criteria: 
•  Fasting plasma glucose ≥6.1 mmol/l (excluding diabetes) 
•  Blood pressure ≥140/90 mmHg or treated for hypertension 
•  Triglycerides >2.0 mmol/l or HDL-cholesterol <1.0 mmol/l or  
    treated for dyslipidemia 
•  Waist circumference ≥94 cm in men and ≥80 cm in women
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!
1.2.3 The 2001 ATP III (Adult Treatment Panel III) definition of the 
metabolic syndrome 
!
Table 1.3: NCEP ATP III Definition of the metabolic syndrome 
!
!
In 2001, the USA National Cholesterol Education Program (NCEP) Adult 
treatment panel III (ATP III) comprising mainly of cardiologists and 
lipidologists, provided a definition of the metabolic syndrome, with a follow –
up in 2004, replacing the glucose tolerance test with fasting glucose (Table 
1.3). This definition gained more acceptance as it is easy to use in clinical 
practice, as well as in epidemiological studies and clinical trials. 
!
Three or more of the following five risk factors: 
• Central obesity (waist circumference) 
             Men                  > 102 cm 
             Women             > 88 cm 
• Triglycerides                ≥ 1.7 mmol/l 
• HDL-cholesterol 
             Men                  < 1.03 mmol/l 
             Women             < 1.29 mmol/l 
• Blood pressure             ≥ 130/ ≥ 85 mmHg 
• Fasting glucose            ≥ 5.6  mmol/l
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!
The major difference between NCEP ATP III definition and that provided by 
the WHO is that the WHO definition includes insulin resistance / 
hyperglycaemia as a categorical component, while it is one of the five 
optional risk factors in the NCEP ATP III definition. The NCEP ATP III criteria 
also recognised the association between the above components of the 
metabolic syndrome and both pro-inflammatory and pro-thrombotic states 
although these are not required for defining the metabolic syndrome. 
!
Table 1.4: Summary of abnormalities that can be present in the metabolic 
syndrome 
!
!
The international Diabetes Federation (IDF) added its definition to the 
literature in 2005, placing more emphasis on central obesity as the core 
measurement and building upon the less glucocentric criteria of the NCEP 
ATP III. Ethnic-specific cut - off points were also incorporated into the 
definition, further increasing its practical utility (8). 
Abdominal Obesity Elevated Uric Acid Elevated free fatty acids
Insulin resistance (IR) /  
Hyperglycaemia
Pro inflammatory state
Dyslipidaemia
Pro thrombotic state 
Hypertension
Endothelial Dysfunction 
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1.2.4 International Diabetes federation (IDF) definition of the metabolic 
syndrome 
Table 1.5: IDF definition of the metabolic syndrome 
!
The new IDF definition for the metabolic syndrome resolved the 
controversies and inconsistencies of previous definitions and eventually 
provides a standard definition which could be used across research and 
clinical groups. 
!
The American Heart Association / National Heart, Lung and Blood institute 
(NHLBI) revised the glucose criterion in the NCEP ATP III definition in 2005 
(9).Looking at all four groups (WHO 1999, ATP III, EGIR and IDF) of 
diagnostic criteria for metabolic syndrome, it can be concluded that waist 
• Central obesity: waist circumference (Europid men: ≥94 cm;Europid 
women:  ≥80 cm)** 
    PLUS at least two of the following components: 
•  Raised  TG level: ≥ 1.7 mmol/l OR on treatment for this abnormality 
• Reduced HDL-cholesterol: < 1.03 mmol/l in men; < 1.29 mmol/l in 
women or on specific treatment for this lipid abnormality 
•  Raised blood pressure: systolic BP ≥ 130 mmHg or diastolic BP ≥ 85 
mmHg  or treatment of previously diagnosed hypertension 
•  Raised fasting plasma glucose ≥ 5.6 mmol/l OR previously diagnosed 
type 2 diabetes (If above 5.6 mmol/l, OGTT is strongly recommended but 
is not  necessary to define presence of the syndrome) 
**Waist circumference: with ethnicity specific values for other group
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circumference / obesity, dyslipidaemia, hypertension and glucose intolerance 
are the main metabolic abnormalities with different values suggested for 
certain components (Table 1.6). 
Table 1.6: Similarities and differences between diagnostic criteria for the 
metabolic syndrome 
!
Component Similarities Differences
Waist 
circumference 
(cm) 
!
Blood pressure     
(mmHg) 
Triglycerides 
(mmol/l) 
HDL-C (mmol/l) 
!
!
!
Plasma glucose 
(mmol/l) 
!
!
!
Others
IDF, EGIR (men ≥94, 
women ≥80) 
!
IDF, ATP III 
(≥130/85 ) 
!
IDF, ATP III, WHO 
( ≥1.7 ) 
IDF, ATP III 
(men <1.03, women 
<1.29) 
!
EGIR, ATP III 
(FPG ≥6.1 mmol/l) 
!
!
!
-
ATP III (men >102,                
women >88 ) 
WHO (BMI ≥30 kg/m²) 
EGIR, WHO ( ≥140/90 ) 
!
EGIR ( >2.0 ) 
!
EGIR (HDL-c <1.0) 
WHO (men <0.9, women <1.0) 
!
!
!
IDF (FPG ≥5.6 mmol/l) 
WHO (any glucose 
intolerance) 
High fasting insulin (EGIR) 
!
Microalbuminuria (WHO)
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Controversy exists regarding the usefulness of the concept of the metabolic 
syndrome, specifically whether the concept of the syndrome is at all useful to 
individuals, clinicians, researchers or policy makers and, if so, how the 
syndrome should be defined ( Gale et al 2005 & 2008, Kahn et al 2005, 
Alberti et al 2008, Borch-Johnson & Wareham et al 2010 ). 
!
There is little doubt that the individual components of the metabolic 
syndrome cluster together and that this clustering of components is 
associated with an increased risk of both diabetes and cardiovascular 
disease. Thus the metabolic syndrome has considerable utility in placing the 
emphasis on the importance of ectopic fat location, allowing appropriate 
lifestyle changes to be encouraged and identification and treatment of other 
components where appropriate. The presence of the metabolic syndrome 
should also highlight the need for estimating an individual’s absolute 
cardiovascular risk with appropriate treatment if the cardiovascular risk is 
greater than the threshold set for the population. Furthermore, identification 
of the presence of the metabolic syndrome heightens awareness for both the 
individual and clinicians of the risk of associated diseases and trigger an 
active strategy focused on life style to attenuate the effects of risk factors 
and associated diseases. 
!
A further revision of the criteria was thus presented in 2009 in a consensus 
statement from the IDF, NHLBI, the World Health Federation, the 
International Atherosclerosis Society and the American Heart Association 
(AHA) (10) (Table 1.7).  
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!
Table 1.7 Consensus statement 2009 criteria (Alberti, Eckel, Grundy, 
Zimmet, Fruchart et al) 
&  
!
The European Association for the study of Diabetes (EASD) and the 
American Diabetes Association (ADA) did not contributed to the consensus 
statement as a result of polarisation of views between different professional 
groups. 
!
!
!
!
Central obesity: waist circumference according to population and country 
specific definitions: (≥ 102 cm (North American men) ≥ 88cms (North 
American women) ≥94 cm (Europid men) ≥80 cm (All women other than 
North Americans) 
•Raised TG level: ≥ 1.7 mmol/l OR on treatment for this abnormality 
•Reduced HDL-cholesterol: < 1.03 mmol/l in men; < 1.29 mmol/l in 
women or on specific treatment for this lipid abnormality 
•Raised blood pressure: systolic BP ≥ 130 mmHg or diastolic BP ≥ 85 
mmHg or treatment of previously diagnosed hypertension 
• Raised fasting plasma glucose ≥ 5.6 mmol/l OR previously diagnosed 
type 2 diabetes 
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1.3 Epidemiology  
With increases in obesity and an ageing population, the metabolic syndrome 
is a growing problem worldwide. However, describing the global burden of 
the metabolic syndrome can be challenging and the prevalence rates have 
varied according to the definition used and population studied. Cut off points 
for each feature of the syndrome are likely to differ between populations in 
terms of their clinical risks. Furthermore, there are limited data for certain 
populations and for the young and elderly, as most of the studies were 
based in developed countries or urban areas of developing countries.  
!
Ethnicity, age and gender clearly have a great impact on the prevalence of 
the metabolic syndrome, and this variation may be due to differences in 
genetic susceptibility, diet, obesity, and intrauterine development. The 
difference in prevalence rates for the metabolic syndrome using WHO, EGIR 
and ATP III is demonstrated from a large Australian Diabetes, Obesity and 
Lifestyle study (Aus Diab study) (11) and a Finnish study (12).  
!
Using both WHO and ATP III criteria, Ford and Giles reported approximately 
20% of individuals were classified as having the syndrome by WHO criteria 
but not by the ATP III criteria, and vice versa (13). Meigs et al. (14) have 
shown using WHO and ATP III criteria that the prevalence of the metabolic 
syndrome is different between men and women, even among a high risk 
population for the metabolic syndrome such as Mexican-Americans. 
!
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The prevalence of the metabolic syndrome increases with age. For example, 
in the National Health and Nutrition Examination Survey (NHANES III) in the 
U.S, the overall prevalence of the metabolic syndrome among adults aged 
20 years and over was 24% whilst in those aged more than 50 years old the 
prevalence was 44% (15). There are ethnic variations with South Asians in 
particular tending to have higher intra abdominal fat at lower BMIs making 
them more susceptible to type 2 diabetes, hypertension and CHD (36): for 
example, in 1988, Mckeigue et al showed a higher prevalence of type 2 
diabetes and the metabolic syndrome in Bangladeshies compared with 
Europeans in East London (16). These findings were replicated in a larger 
population based survey of 4858 men and women - the Southall and Brent 
studies in West and Northwest London (17). Furthermore, migrant African 
Caribbeans who participated in the above study had higher prevalence rates 
of hypertension and type 2 diabetes.  
!
Another study in Asian subjects reported increased prevalence of the 
metabolic syndrome using the IDF definition (46.3%) compared with ATP III 
criteria (30.5%), and the prevalence was higher in women than in men (18).  
!
In South Korea, although central obesity was only 0.2% in men and 27.3% 
in women respectively (lower than in the United States), the prevalence of 
the metabolic syndrome was similar to the North Americans. According to 
the ATP III criteria, 29.4% of Korean subjects above 40 years of age have 
the metabolic syndrome (19). 
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Most recent studies apply the new IDF definition for diagnosing the 
metabolic syndrome. Harzallah et al. reported a higher prevalence of the 
metabolic syndrome amongst an Arab population using IDF criteria (45.5%) 
compared with WHO (28.7%) and ATP III (24.3%).The prevalence was also 
significantly higher in women than in men (20). Of 9669 subjects in Greece, 
the age-adjusted prevalence of the metabolic syndrome was 24.5% (ATP III) 
which increased to 43.4% using the new IDF definition (21). Another study in 
Asian subjects reported increased prevalence of the metabolic syndrome 
using the IDF definition (46.3%) compared with ATP III criteria (30.5%), and 
the prevalence was higher in women than in men (22). 
!
Applying the new IDF criteria clearly results in an increase in the prevalence 
of the metabolic syndrome, and this may have significant implications for 
public health. The higher rate could be due to the predominant focus on 
central obesity which is measured by waist circumference. In the Finnish 
Kuopio Ischemic Heart Study, the prevalence of the metabolic syndrome 
varied between 9% and 14% depending on whether ATP III or the WHO 
criteria were used.  
!
Whilst the use of different definitions of the metabolic syndrome makes 
comparisons across studies and ethnic groups difficult, there is no doubt that 
profound ethnic differences exist in the prevalence and clustering of cardio 
metabolic risk factors. 
!
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!
The prevalence of the metabolic syndrome varies approximately from 10% 
to 40% amongst different populations with a tendency to increase with age. 
The US National Health and Nutrition Examination Survey (NHANES III) 
reported an age - adjusted prevalence of 24% amongst more than 20,000 
adults, with the numbers increasing significantly with age (23) 
!
!
!  
!
Figure 1.3 - Age-Specific Prevalence of the Metabolic Syndrome among 
8814 US Adults Aged at Least 20 Years, by Sex, National Health and 
Nutrition Examination Survey III, 1988-1994 (Adapted from Earl S. Ford, 
Wayne H. Giles, William H. Dietz JAMA. 2002;287(3):356-359). 
!
Diet and physical activity can also have an effect on the prevalence of insulin 
resistance and the metabolic syndrome independently of obesity.  
!
!  35
In the Framingham Offspring Study the authors reported that whole grain 
intake was associated with a lower prevalence of the metabolic syndrome 
and inversely associated with insulin resistance (24). The Whitehall II study 
of civil servants in Britain showed a similar association between insulin 
resistance, moderate physical exercise and prevalence of the metabolic 
syndrome (25). 
!
1.4 Aetiology of the metabolic syndrome 
The complex pathogenesis of the metabolic syndrome and its key 
components is still to be elucidated completely. It is likely that both genetic 
and environmental factors are involved in the development of the metabolic 
syndrome with a primary focus on insulin resistance and visceral obesity. 
Other factors associated with an increased risk of the metabolic syndrome in 
NHANES III included postmenopausal status, smoking, poor diet and 
physical inactivity (23). 
Various hypotheses have been proposed for the development of the 
metabolic syndrome. 
!
1.4.1 The Thrifty Genotype Hypothesis 
Neel proposed this hypothesis more than three decades ago to explain the 
widespread prevalence of insulin resistance and type 2 diabetes in modern 
society. He hypothesised that insulin resistance / hyperinsulinemia conferred 
a survival advantage during evolution and provided a protective mechanism 
to humans during periods of famine, as it would minimise caloric loss during 
times of famine and facilitated fat storage during times of plenty (26). It has 
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also been suggested that selective insulin resistance within the muscles 
facilitated energy storage within the liver and adipose tissue. However, in an 
environment of persistent calorie excess these characteristics would 
predispose to obesity, the metabolic syndrome and type 2 diabetes (27). 
!
1.4.2 Reaven / Cahill Hypothesis 
Cahill & Reaven proposed that insulin resistance limited protein / muscle 
breakdown thus allowing hunting to continue rather than as a means to 
minimise calorie loss for survival (28). 
!
1.4.3 Barker’s Hypothesis – The foetal origins of adult disease 
Using data from the county of Hertfordshire, where detailed records were 
kept by midwives since 1911, Barker suggested that insulin resistance, type 
2 diabetes and the metabolic syndrome seen in adults are the results of an 
adverse intrauterine and neonatal environment and are therefore 
manifestations of a thrifty phenotype. Barker suggested that a thrifty 
genotype might be induced by malnutrition during fetal and early life. In 
particular, intrauterine growth restriction leading to low birth weight may be 
associated with an increased risk in adulthood of insulin resistance, glucose 
intolerance, type 2 diabetes and dyslipidaemia (figure 1.4). He showed that 
the prevalence of the metabolic syndrome reduced progressively from 30% 
to 6% as birth weight rose from less than 2.5 to more than 4.1 kg (figure 1.5 
& 1.6). This has led to the hypothesis that these diseases are ‘programmed’ 
in utero in response to an adverse environment.  
!
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Figure 1.4 Type 2 (non-insulin-dependent) diabetes mellitus, 
hypertension and hyperlipidaemia (syndrome X): relation to reduced 
fetal growth.  (Adapted from DJP, Hales CN, Fall CHD, Osmond C, Phipps 
K, Clark PMS. Diabetologia, 1993; 36: 62–7). 
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!    
Figure 1.5 Odds ratio for impaired glucose tolerance or type 2 diabetes according to 
birth weight among 370 men aged 64 years born in Hertfordshire (adjusted for BMI). 
!
!  
Figure 1.6 Odds ratio for the metabolic syndrome according to birth weight among 
407 men born in Hertfordshire (adjusted for adult body mass index). 
(Adapted from The thrifty phenotype hypothesis, CN Hales, DJP Barker, Br Med 
Bull (2001) 60 (1): 5-20). 
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1.4.4 The ‘Common Soil’ Hypothesis !
Stern suggested that atherosclerosis and type 2 diabetes share many of the 
same genetic and environmental antecedents and therefore should be 
considered as a consequence of the metabolic syndrome, i.e. from a 
common soil (30). Thus, fetal programming effects with resultant thriftiness 
and hence the propensity to develop obesity as a consequence of modern 
day life may result in obesity and complex metabolic disease. Alternatively, 
central obesity with reduced insulin action and inflammation may be an 
essential early step resulting in clustering of various metabolic risk factors for 
the development of diabetes and cardiovascular disease. 
!
However, there is a continuing debate as to the relative importance of 
genetic versus environmental factors in determining foetal growth and 
subsequent adult susceptibility to type 2 diabetes and the metabolic 
syndrome (29). 
!
1.5 Pathogenesis of the Metabolic Syndrome 
Insulin resistance and central obesity are believed to be underlying factors 
causing the metabolic syndrome. 
1.5.1 Insulin Resistance and the Metabolic Syndrome 
There is clear evidence supporting a major role for insulin resistance in the 
development of the metabolic syndrome.  
!
!
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Insulin resistance, the associated hyperinsulinaemia and hyperglycemia, 
body fat redistribution and adipocyte cytokine changes (adipokines), 
dyslipidaemia, haemostatic alterations, low grade inflammation and high 
blood pressure may all lead to the development of atherosclerotic 
cardiovascular disease. The exact aetiology of insulin resistance is not 
completely understood, although it is believed to be genetically 
predetermined and exacerbated by physical inactivity, obesity and aging. 
!
1.5.2 Obesity, adipocytokine dysregulation and the metabolic 
syndrome 
Increasing central adiposity is associated with an increased risk of morbidity 
and mortality (31). Even in people of nearly normal weight, increased central 
adiposity may increase the risk for a wide range of chronic conditions 
including type 2 diabetes, hypertension, dyslipidaemia, gall bladder disease, 
osteoarthritis and in women, breast cancer. In one study, waist 
circumference, but not BMI, was a predictor for developing hypertension, 
dyslipidaemia and the metabolic syndrome (32, 33), while in a second it was 
a predictor of myocardial infarction (34). 
Adipose tissue was historically considered to be a passive depot for the 
storage of excess calories. During fasting, adipocytes through lipolysis break 
down triglycerides with release of fatty acids to meet the energy needs of the 
body. However, during the post prandial state the balance shifts back toward 
lipogenesis. More recently, adipose tissue has been shown to function as an  
!
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active metabolic organ capable of producing various chemical cytokines 
such as interleukin – 6 (IL-6), tumour necrosis factor alpha (TNFα) and other 
adipokines including leptin, adiponectin and plasminogen activator inhibitor 
(PAI-1) all of which, among other things, may be important for the 
development  of the metabolic syndrome.  
!
The location of the excess fat plays an important role, with intra abdominal / 
visceral fat playing a critical role in determining insulin sensitivity and 
atherogenic lipid profile. Intra - abdominal adipose tissue is more sensitive to 
free fatty acid (FFA) mobilisation stimuli than subcutaneous fat with insulin 
being the principal inhibitor of lipolysis. The FFAs mobilised from adipose 
tissue are mainly taken up by the liver and esterified into triglycerides and 
incorporated into very low density lipoproteins (VLDL).The triglyceride rich 
VLDL particles are metabolised by lipolysis with delivery of fatty acids to 
peripheral cells. This process is finely regulated and the rate of FFA 
mobilisation is in tune with the energy needs of the body.  
!
Excessive mobilisation of FFA from the expanded adipose tissue in patients 
with the metabolic syndrome raises plasma levels of FFA. High levels of FFA 
decrease peripheral glucose uptake due to the Randle effect (the reciprocal 
uptake of glucose and FFA in tissues). In addition, elevation of FFA 
increases glucose output from the liver by stimulating gluconeogenesis and 
glycogenolysis. 
!
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!
The pro inflammatory cytokine TNF-α has been shown to be an important 
regulator of insulin sensitivity while IL-6 is believed to be the main driver of C 
reactive protein (CRP) release from the hepatocytes. IL-6 has also been 
shown to impair insulin signalling in mouse hepatocytes (135,136). 
!
Adipocytes secrete leptin in response to nutritional status and adipose tissue 
mass. Leptin is predominantly secreted by subcutaneous adipose tissue and 
plays an important role in appetite regulation and energy expenditure 
through its effects on hypothalamic leptin receptors. Resistin is another 
adipocytokine that has been implicated in the pathogenesis of type 2 
diabetes and its complications (137). 
!
Visceral obesity is also associated with a reduction in adiponectin levels and 
thus a loss of its anti inflammatory, anti diabetic and anti atherosclerotic 
properties (35). Over time, insulin resistance is associated with more 
components of the metabolic syndrome, including increased plasminogen 
activator inhibitor-1 (PAI-1) mediated thrombotic tendency, hypertension, 
hyperuricemia and a characteristic dyslipidaemia.  
!
Adipose derived secretory proteins, collectively referred to as adipokines, 
may thus have an important role in the development of insulin resistance, 
appetite, inflammatory responses and thrombosis in overweight subjects 
with visceral obesity. 
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1.6 Clinical implications of the Metabolic Syndrome 
As stated previously, subjects with the metabolic syndrome are at increased 
risk for the development of type 2 diabetes and cardiovascular events (12, 
15). 
!
Increasing evidence suggests that the progression of insulin resistance to 
type 2 diabetes parallels the progression of endothelial dysfunction to 
atherosclerosis (Figure 1.7). 
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Figure 1.7 (Adapted from Hsueh and Law, Am J Cardiol. 2003; 92:3J–9J) 
!
It is increasingly clear that impaired Insulin sensitivity is not confined to the 
major tissues that regulate glucose metabolism (skeletal muscle, liver and 
adipose tissue), but also present in cells that play an important role in 
cardiovascular regulation i.e. vascular endothelium, platelets, macrophages 
and smooth muscle cells. 
!
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1.6.1 Metabolic Syndrome and Cardiovascular disease – Overview 
Each of the components of the metabolic syndrome is associated with an 
increased risk of CVD but in combination they increase the risk several fold. 
The Paris Prospective Study and the Interheart studies showed central 
obesity as measured by waist-hip ratio or waist circumference to be a better 
predictor of cardiovascular disease and mortality than BMI, and suggested 
that such measurements should replace BMI as an indicator of obesity (49, 
50). Many studies have shown that patients diagnosed with the metabolic 
syndrome, by either the ATP III or WHO definition (or by their modifications), 
have more prevalent CVD or are at greater risk of developing it and this 
excess risk remained after adjustment for other conventional risk factors 
(138-145). In the Framingham study, the metabolic syndrome alone predicts 
about 25% of new CVD cases (141, 147). Stern et al estimates that 
individuals with the metabolic syndrome are twice as likely to die of 
cardiovascular complications compared to those without (146). This 
association was however highlighted much earlier by Gerald Reaven who, in 
1988, reported abnormalities of blood pressure regulation and lipid 
abnormalities in insulin resistant individuals and proposed that clustering of 
these risk factors accounted for the development of type 2 diabetes and 
cardiovascular disease (2). Subsequently alterations in the fluid and cellular 
phases of both thrombotic and inflammatory processes have been shown to 
be associated with insulin resistance with the entire process being driven by 
obesity. 
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1.6.2 Atherothrombosis is defined as atherosclerotic plaque disruption with 
superimposed thrombosis formation leading to cardiovascular events 
including myocardial infarction, stroke and peripheral vascular disease. At 
the molecular level, atherosclerosis is a multi-step process involving the 
interaction of many different complex cascades. These include endothelial 
function, inflammation, lipoprotein metabolism, coagulation and oxidative 
stress. (Figure 1.8) 
!
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Figure 1.8 Association of Insulin resistance with cardiovascular risk 
factors and Atherosclerosis (Adapted from Macfarlane et al JCEM; 
2001:86; 713). 
!
!
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!
Considerable ‘cross talk’ exists between these processes, resulting in a 
complex ‘cause or consequence’ phenomenon with positive feedback on one 
another. It is difficult to unravel the impact that these processes have on one 
another, and is crucial to our understanding of the pathophysiology of 
atherosclerosis in patients with the metabolic syndrome. 
!
1.6.3 Endothelial Dysfunction 
Besides providing a physical barrier between the vessel wall and lumen, the 
endothelium secretes a number of mediators that regulate vessel tone, 
platelet aggregation, coagulation and fibrinolysis (table 1.8). 
!
Table 1.8 - Vasoactive substances and their effect on the endothelium 
!
The most important of these mediators is nitric oxide (NO) which is a major 
vasodilator with multiple vascular protective effects. These include inhibition 
of vascular smooth muscle cell (VSMC) growth and migration, monocyte 
adhesion, inflammation and oxidation, platelet aggregation and thrombosis.  
!
!
Vasodilators Vasoconstrictors
Nitric oxide Angiotensin II
Endothelium-derived hyperpolarising 
factor
Endothelin
C-type natriuretic peptide
Kinins
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In contrast, angiotensin II induces expression of adhesion molecules like 
intercellular adhesion molecules (ICAM-1) and vascular adhesion molecules 
(VCAM-1) which enhance the adhesion of monocytes to the endothelial 
surface, stimulates platelet aggregation and thrombosis and also induces 
inflammation and oxidative stress through the generation of superoxide 
radicals.  
!
During this process of endothelial activation, soluble forms of cell adhesion 
molecules are shed into the circulation such as sVCAM-1, sICAM-1 and sE-
selectin. Increased levels of these soluble cell adhesion molecules have 
been detected in plasma of subjects with CVD, T2DM and IR (148) and 
have been associated with increased risk of CVD mortality in subjects with 
T2DM (149). This has lead to a wider use of soluble cell adhesion molecules 
as a surrogate marker of disease activity in CVD. Endothelial dysfunction is 
an early step in the atherogenic process in patients with the metabolic 
syndrome with insulin resistance playing an important role and insulin itself 
potentially contributing to vascular damage. 
!
Insulin causes vasodilatation through a direct effect on blood vessels 
mediated by endothelium-derived nitric oxide (NO). Insulin increases 
endothelial NO production through induction of eNOS gene expression that 
is mediated by the phosphoinositide 3-kinase (PI3 kinase) signalling 
pathway (150) (figure 1.9)  
!
!  48
!
PI3-kinase activation also regulates glucose uptake into insulin-dependent 
target tissues, such as skeletal muscle, heart and adipose tissue. Therefore  
a defect in this pathway impairs glucose uptake as well as insulin mediated 
endothelial vasodilatation (151).Vascular insulin signalling is also capable of 
activating potentially proatherogenic mechanisms such as induction of 
endothelin-1 (ET1) expression, mediated primarily by the Mitogen-activated 
protein (MAP) kinase signalling pathway (figure 1.9) 
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!
Figure 1.9 - Insulin action mediated by the PI3 kinase and MAP kinase 
signalling pathways  
!
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In the insulin resistant state, there seems to be a ‘selective resistance’ to the 
potential anti-atherosclerotic mechanisms mediated by the PI3 kinase 
pathway, whilst leaving certain pro atherosclerotic pathways mediated by 
MAP kinase unchecked (152).  
!
Interventions to reverse endothelial dysfunction 
As described previously clustering of both traditional and novel CVD risk 
factors in subjects with the metabolic syndrome initiates a chronic 
inflammatory process accompanied by loss of vasodilator and antithrombotic 
factors with resultant increase in vasoconstrictor and prothrombotic activity. 
Interventions that are known to reduce cardiovascular risk such as treatment 
with statins, angiotensin-converting enzyme inhibitors, angiotensin receptor 
blockers, or Peroxisome Proliferator-activated Receptor (PPAR) ligands, as 
discussed below have been shown to improve endothelial dysfunction. 
!
A sedentary lifestyle is associated visceral adiposity, increased inflammation, 
oxidative stress and endothelial dysfunction. In contrast exercise has been 
shown to improve endothelial function and this is believed to be mediated in 
large part through increased NO bioavailability (326,327,328,329). 
!
Diets low in saturated fat and n-3 fatty acids have been shown to improve 
endothelial dependent vasodilatation (330,331).Studies of combinations of 
antioxidants such as vitamin C, vitamin E and β- carotene have provided 
mixed results (332-336). 
!
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Treatment with Statins has been shown to improve reduce cardiovascular 
risk and reverse endothelial function (335-339). Apart from lowering 
cholesterol, statins have been shown to directly enhance expression and 
activation of the endothelial form of NO synthetase (337-340). Furthermore 
statins have also been shown to protect against the adverse effects of 
inflammation on the vasculature (341,342). Similarly ACE inhibitors and 
angiotensin receptor blockade also improves endothelial function and reduce 
endothelial inflammation and oxidative stress by inhibiting NADP oxidase 
activity and breakdown of bradykinin (343 -347). 
!
Conjugated linoleic acid, a naturally occurring PPAR α & γ ligand can reduce 
cardiovascular risk and improve endothelial function through their effects on 
BP, body composition, inflammation and insulin sensitivity. 
!
1.6.4 Arterial Stiffness  
The arterial wall consists of the outer adventitia and the connective tissue, 
the smooth muscle and elastin containing media which determines the 
elasticity, and the inner endothelium which plays an important role in 
regulating the vascular tone. Arteries are compliant elastic structures and 
serve to buffer the pressure changes resulting from intermittent ventricular 
ejection into the aorta. They transform the pulsatile flow generated by 
cardiac contraction into a continuous flow of blood in the periphery by 
absorbing a proportion of energy in systole, and releasing it in diastole. The 
elasticity of the proximal large arteries is largely the result of the high elastin 
to collagen ratio within the media of the vessel wall. Arterial stiffness is a 
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term that characterises the reduced ability of arteries to expand and contract 
with cardiac pulsation and relaxation and can therefore arise as a 
consequence of structural changes within the vessel, for example secondary 
to age related elastin fibre degeneration, as well as disease states such as 
diabetes and hypertension affecting the functional properties of the arterial 
wall, which is largely dependent on the endothelium (153). 
!
1.6.4.1 Arterial pressure wave form 
!
!  
!
Figure 1.10 Hemodynamic changes in arterial stiffening. (A) Aortic blood 
pressure waveform of a healthy, normotensive person. The forwards 
travelling wave precedes the (backwards travelling) reflected wave. (B) 
Aortic pressure waveform of a person with arterial stiffness. Due to 
increased pulse wave velocity, the forward travelling wave and reflected 
wave are summated leading to augmented pulse pressure (Reproduced 
from Front. Genet. 13 December 2012) 
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The arterial pressure wave form is a composite representation of the 
pressure waves generated during ventricular systole (1st waveform peak) 
which then travels through the circulation until resistance is encountered at 
the peripheries when it is reflected back upon itself in diastole. The 2nd 
waveform thus represents a summation of reflected waves. Augmentation 
index is defined as the difference between the first and second systolic 
peaks of the central pressure waveforms, expressed as a percentage of the 
central pulse pressure (Figure 1.10). 
!
With increasing arterial stiffness the speed at which the left ventricular 
ejection pressure wave travels through the arterial circulation increases, thus 
resulting in an earlier return of the reflected wave from the peripheries. If the 
reflected wave continues to return less in diastole and more in systole itself, 
this can augment the late systolic pressure on the left ventricle and reduce 
the coronary perfusion during diastole with resultant risk of IHD, 
cerebrovascular disease (due to increased central systolic pressure) and 
cardiac failure (as a result of increased left ventricular load).  
!
Arterial stiffness has been shown to be independently predictive of 
cardiovascular mortality in a number of disease states including glucose 
intolerance / diabetes, hypertension and renal impairment (154-156). There 
is also evidence of a positive correlation between arterial stiffness, high 
sensitivity c-reactive protein (hs CRP) (157) and declining endothelial 
function (158). 
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A number of studies have also demonstrated an association between these 
indices of arterial stiffness and cardiovascular risk factors in subjects with 
the metabolic syndrome (156) and smokers (157). These studies illustrate 
the importance of arterial stiffness in predicting cardiovascular risk. 
!
Arterial stiffness can be assessed by measuring a number of factors 
including central BP, augmentation index (Aix) and pulse wave velocity 
(PWV). There are various invasive and non invasive methodologies to 
measure arterial stiffness and these are discussed in detail in chapter 2. 
!
Interventions to reduce arterial stiffness have been shown to be associated 
with improved survival (159).  
!
!
1.6.5 Hypertension, the metabolic Syndrome and CVD risk 
Several mechanisms (Figure 1.11) have been postulated to explain the 
association between insulin resistance and elevated blood pressure. Insulin 
resistance and its associated hyperinsulinaemia can lead to increased renal 
sodium reabsorption through its effects on membrane - ion transport system 
and by stimulating sympathetic nervous system activity (44, 45). 
Hypertension could also be due to a reduction in synthesis of vasodilatory 
prostaglandins with a relative vasoconstrictive effect (46). 
!
!
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Hypertension is closely associated with obesity and insulin resistance. 
Persistently elevated blood pressure is a risk factor for the development of 
CHD and underlying atherosclerosis (42, 43). 
!
!
 
!
!
!
!
!
!
!
!
!
!
!
!
!
!
Figure 1.11 - Pathogenesis of hypertension in the hyperinsulinaemic 
state.  
!
!
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1.6.6 Metabolic Dyslipidaemia and CVD  
!
Lipid abnormalities play a critical role in the development of atherosclerosis. 
Patients with the metabolic syndrome typically have a dyslipidaemia 
characterised by high triglycerides and reduced levels of cardio protective 
HDL-C levels. They also have a preponderance of small, dense and highly 
atherogenic LDL particles as they are more likely to form oxidised LDL (37).  
!
As discussed previously, visceral obesity gives rise to excess free fatty acids 
(FFAs) which increase hepatic TG synthesis and the production of Apo B-
containing, triglyceride rich VLDL(38).Triglycerides are responsible for an 
associated re modelling of HDL by a process of reverse cholesterol transport 
and esterification leading to a reduction in the cholesterol content of HDL. 
(39). High triglyceride levels are associated with a two fold increase in the 
risk of CHD after adjustment for other conventional risk factors (40). 
Likewise, low levels of HDL-C have been shown to be an independent risk 
factor for CVD (41). 
!
!
!
!
!
!
!
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1.6.7 Inflammation and the metabolic syndrome 
The metabolic syndrome is believed to be associated with low - grade 
systemic inflammation. Many of the adipokines whose expressions are 
altered during obesity lead to inflammation and can promote insulin 
resistance, endothelial dysfunction and ultimately atherosclerosis (160) 
(Figure 1.12). 
! "
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Figure 1.12 Adipocytokines, Inflammation & Atherosclerosis 
Cytokines, in particular IL-1, IL-6 and TNFα are the main inducers of the 
acute phase response. Several studies have shown IL-6 to be the main 
mediator of the inflammatory response.  
!
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Interlukin-6 (IL-6) is secreted by a number of cells including activated 
macrophages and lymphocytes and approximately 25-30% of systemic IL-6 
is derived from the adipose tissue.IL-6 may play an important role in 
atherogenesis and diabetes by virtue of its metabolic effects on reducing 
insulin sensitivity, endothelial effects on inducing adhesion molecules, and 
procoagulant effects by increasing hepatic synthesis of fibrinogen and by its 
direct effect on platelet activation (161). 
!
Tumour necrosis factor alpha (TNF-α) similarly, is another pro-inflammatory 
cytokine secreted by monocytes-macrophages, endothelial cells and to a 
large extent by the adipocytes. It is an important regulator of insulin 
sensitivity. However, the best characterised marker and mediator of CVD & 
inflammation is c-reactive protein (CRP).  
!
1.6.7.1 CRP  
!
CRP is an acute phase reactant and a marker of inflammation. It is 
synthesised in the liver and its production is stimulated by cytokines, mainly 
IL-6 and tumour necrosis factor alpha (TNF-α). Although standard assays for 
CRP lack the sensitivity to determine the levels of inflammation within the 
normal range, the availability of high sensitivity CRP assays has overcome 
this hurdle. Several studies have indicated that elevated levels of CRP are a 
strong indicator of future CVD risk in healthy subjects (162). 
!
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In a cohort of 22000 healthy middle aged men, those with CRP levels in the 
highest quartile had a 2 fold increase in the risk of stroke or peripheral 
vascular disease and a 3 fold increase in the risk of myocardial infarction 
(163). Also, the role of CRP as a marker of vascular risk is consistent across 
different study populations, such as smokers in the Multiple Risk Factor 
Intervention Trial (MRFIT) (165), elderly subjects in the Cardiovascular 
Health Study (166) and postmenopausal subjects in the Women’s Health 
Study (164).  
!
Furthermore, studies have also demonstrated an association between CRP 
and all cause mortality (167). Interestingly, data from the Women’s Heart 
Study has identified elevated levels of CRP to predict the development of 
type 2 diabetes in women and this concept of CRP being recognised as an 
independent predictor of risk for the development of diabetes is further 
strengthened by the West of Scotland Coronary Prevention Study 
(WOSCOPS), wherein raised CRP was shown to predict the development of 
diabetes in middle aged men (168). 
!
Taken together, these studies provide evidence to support the role of 
inflammation in the pathogenesis of atherosclerosis and diabetes. This 
would suggest that anti-inflammatory agents could play an important role in 
the prevention and treatment of atherosclerosis in general and, in particular 
in patients with diabetes and the metabolic syndrome. 
!
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1.6.7.2 Inflammation & Atherothrombosis - Overview 
Among the earliest steps in atherogenesis is the induction on the endothelial 
surface of adhesion molecules such as vascular cell adhesion molecule 
(V-CAM-1), intercellular adhesion molecule (ICAM-1), and selectins (sE-
selectin, sP-selectin) which allows circulating inflammatory cells such as 
monocytes and T-lymphocytes to enter the vessel wall through a process of 
diapedesis. This process is also promoted by monocyte chemo attractant 
protein-1(MCP-1) and interlukin-8 (IL-8) (169,170). 
!
Once resident in the arterial wall, monocytes differentiate into macrophages 
and this is facilitated by macrophage colony stimulating factor (M-CSF). 
Subsequently, these macrophages ingest lipids from oxidised LDL via the 
scavenger receptor pathway (CD-36, SR-A) and develop into lipid-laden 
foam cells (171). Macrophages also provide signals for T lymphocytes, to 
elaborate inflammatory cytokines such as interferon-γ, TNF-α, and IL-1 
leading to further activation and propagation of the atherosclerotic process. 
They also inhibit vascular smooth-muscle cell production of collagen and 
other extracellular matrix components of the fibrous cap, Furthermore the 
lipid laden foam cells which are enriched in tissue factor also elaborate 
matrix metalloproteinases that degrade the collagen thus weakening the 
structure that separates the highly coagulable necrotic lipid core from the 
circulating coagulation system resulting in thrombus formation and acute 
coronary syndromes (169-173). Thus, monocytes / macrophages are critical 
in all phases of atherosclerosis. 
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Similarly, once resident in the intima, T lymphocytes are activated by 
antigens such as oxidised LDL and heat shock proteins. Upon activation, the 
T lymphocytes can produce cytokines, notably CD154, which is capable of 
binding to CD40 ligand on macrophages leading to platelet activation (184). 
!
1.6.8 The role of platelets in atherothrombosis 
!
Platelets play an important role in physiological homeostasis and provide a 
first line defence against injury to the endothelium. Following endothelial 
injury, circulating platelets adhere to the endothelium as a result of 
interaction between glycoprotein 1b/V/IX, a receptor complex expressed on 
the surface of the platelets and von Willebrand factor (vWF) which is an 
important ligand for glycoprotein 1b. Bound platelets release a variety of pro 
thrombotic factors including adenosine diphosphate (ADP), thrombin, 
thromboxane A2 (TXA2) and epinephrine which sustain and amplify the 
initial platelet response leading to the formation of a platelet plug. This 
process is mediated by glycoprotein IIb/IIIa which binds several adhesive 
substrates including fibrinogen and acts as the main receptor for platelet 
adhesion. The interaction between glycoprotein IIb/IIIa and fibrinogen 
represents a key event in thrombus formation (174). More recently, it has 
been shown that this aspect of platelet aggregation is supported by CD 40 
ligand. CD40 ligand interacts with the CD40 receptor on monocytes / 
macrophages, leading to induction of tissue factor, a potent procoagulant, 
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which contributes to the thrombogenicity of the lipid core and when the 
circulating blood contacts the lipid core, a thrombus form (175). 
!
1.6.8.1 CD40  
CD40 has been implicated as an important signal connecting inflammation to 
the thrombotic elements of atherosclerotic pathology (176). 
!
CD40 ligand (CD40L) is a transmembrane protein with a structural similarity 
to TNF-α that, upon engagement with its receptor CD40, elicits a series of 
inflammatory and pro thrombotic responses including over expression of 
adhesion proteins, chemokines, metalloproteinases and tissue factor 
(174-176). Several cells express CD40L including lymphocytes and cells of 
the vascular system such as endothelial cells, smooth muscle cells, 
monocytes and platelets (174-175).  
!
Platelets express CD40L on their surface upon stimulation with agonists 
such as thrombin and collagen; CD40L is then cleaved and circulates as  
soluble CD40L (sCD40L) which binds to the glycoprotein IIb/IIIa complex, a 
process which increases the stability of platelet aggregates and leads to 
further inflammatory processes within the vessel wall.  It is calculated that 
more than 95% of circulating sCD40L is of platelet origin and is an indicator 
of platelet activation (177). Recent studies demonstrated that sCD40L levels 
are elevated in patients at risk of CVD and in those with acute coronary 
syndrome suggesting that it may represent a new marker of atherosclerotic  
!
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progression (176-184). Experiments in animal models of atherosclerosis 
suggest that interruption of many of these pathways such as adhesion 
molecules, CD40/CD40 ligand, and chemokines can limit atherosclerotic 
lesion formation (181-184). Thus enhanced platelet activation may contribute 
to the pathogenesis of atherothrombotic complications of the metabolic 
syndrome. 
!
 Platelets have been shown to retain a functional insulin receptor capable of 
insulin binding and auto phosphorylation (185). Insulin is thought to reduce 
platelet response to various aggregants such as ADP, collagen, thrombin, 
arachidonate and platelet activating factor, and thus is believed to possess 
anti-platelet effects (186). In an insulin resistant state, this protective anti-
platelet effect of insulin is lost. This is supported by studies demonstrating 
reduced platelet insulin receptor number and affinity in subjects with T2DM 
(186). 
!
To summarise, enhanced platelet activation seen in patients with the 
metabolic syndrome is multifactorial. Platelet resistance to the inhibitory 
action of insulin, in association with the intrinsic platelet abnormalities 
induced by hyperglycaemia and oxidative stress, coupled with defective 
endothelial production of anti aggregants such as NO and prostacyclins are 
central in the pathogenesis of platelet dysfunction in subjects with the 
metabolic syndrome.  
!
!
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1.6.9 Haemostatic abnormalities and the metabolic syndrome 
As far as the pro thrombotic state is concerned, patients with metabolic 
syndrome are characterised by elevated fibrinogen and plasminogen 
activator inhibitor 1 (47), which could be linked to enhanced clotting 
activation, However, it is not clear if this occurs in vivo and the underlying 
mechanism is unknown. 
The adipocytes are an important source of plasminogen activator inhibitor-1 
(PAI-1). Its levels correlate with the amount of visceral adipose tissue and 
are positively associated with features of the metabolic syndrome (47). 
There is increasing evidence that tissue plasminogen activator (t-PA) and 
PAI-1 are associated with insulin resistance in the general population. PAI-1 
levels have also been shown to predict type 2 diabetes in the general 
population (47). PAI-1 is an inhibitor of fibrinolysis leading to a pro 
thrombotic state and a resultant increase in the risk of CVD. There is also 
increasing evidence of a link between elevated plasma levels of haemostatic 
factors (fibrinogen, factor VII, Von Willebrand factor) and the risk for CHD 
(48). 
Inflammation is thus being increasingly recognised for its role in the 
pathogenesis of both IR and atherosclerosis. Various studies have now 
shown that atherosclerosis, from its origins to its ultimate complications, 
involves inflammatory cells (T cells, monocytes, macrophages), 
inflammatory proteins (cytokines, chemokines), and inflammatory responses 
from vascular cells (endothelial cell expression of adhesion molecules) 
(187). 
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!
1.7 Dysglycaemia, Receptor for advanced glycation end products  
(RAGE) and vascular disease in the metabolic syndrome 
!
Obesity is one of the strongest predictors of type 2 diabetes. Bonora et al in 
a 10 year follow up of the Bruneck study showed that the relative risk for 
new- onset type 2 diabetes was 9.9 in individuals with a BMI of >30kg/m ² 
compared to individuals with a BMI of  <  25kg/m² (59). 
!
Pooled prospective studies demonstrated that subjects with the metabolic 
syndrome had 6-7% risk for all-cause mortality, 12-17% risk of 
cardiovascular disease and 30-53% risk of diabetes compared to those 
without the metabolic syndrome (61). Many studies confirmed the 
effectiveness of using a definition of the metabolic syndrome to predict future 
type 2 diabetes (62, 63, 64, and 65). 
!
Obese non diabetic subjects who reduced weight have been shown to 
benefit from increases in insulin sensitivity and consequently reduced insulin 
hyper secretion (66, 67).  
!
Data from the West of Scotland Coronary Prevention Study (WOSCOPS) 
study also showed that the odds of developing diabetes and CHD increase 
dramatically with the number of metabolic syndrome components (figure 
1.13) (68). 
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Figure 1.13 The risk of diabetes and cardiovascular disease in subjects 
with the metabolic syndrome Adapted from Sattar N et al. Circulation 
2003; 108: 414-419 
!
Type 2 diabetes on its own is an established risk factor for coronary heart 
disease, the presence of metabolic syndrome in this group of subjects 
accentuates the risk of coronary heart disease as shown by Alexander et al. 
(15). Patients with type 2 diabetes mellitus (T2DM) have a two to four fold 
increase in the risk of CHD and a patient with diabetes but without previous 
myocardial infarction (MI) carries the same level of risk for subsequent acute 
coronary events as a non-diabetic patient with previous MI. Diabetes is 
therefore considered to be a coronary equivalent (189-190).  
!
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A prospective study by Guzder and colleagues reported similar results. The 
risk of cardiovascular disease, including cerebrovascular disease and 
peripheral vascular disease, was also increased (60). 
!
!
Hyperglycemia can cause vascular damage through at least three 
apparently unrelated pathways: advanced glycation end product (AGE) 
formation, activation of protein kinase C (PKC), and sorbitol accumulation by 
way of the polyol pathway (200). Diabetes amongst other conditions is 
associated with an accelerated and excess formation of advanced glycation 
end products (AGEs) which are believed to be primary instigators of the 
inflammatory process. 
!
!
 1.7.1 Formation of AGEs (Maillard Reaction) 
The original Maillard hypothesis on the formation of AGEs proposed that 
chemical modification of proteins by reducing sugars (glycation of proteins) 
in diabetes alters the structure and function of tissue proteins such as type 
IV collagen, laminin and fibronectin resulting in capillary basement 
membrane thickening and hypertrophy of the extravascular matrix, and 
precipitating the development of diabetic complications (191) (Fig.1.14)  
!
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 Figure1.14 Formation of AGE 
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Figure 1.15 - Maillard Reaction 
Glycation involves the formation of chemically reversible early glycosylation 
products with proteins, so called Schiff bases and Amadori adducts (e.g. 
glycated haemoglobin; HbA1C). With time, these early adducts undergo 
slow and complex rearrangements to form advanced glycation end-products 
(AGEs) (Figure 1.15) 
Baynes and colleagues noted the importance of oxidizing conditions and 
reactive oxygen species in the formation of glycoxidation products, the major 
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class of AGEs that accumulate in tissues in diabetes (192-193). Besides the 
formation of carbohydrate intermediates, there is increasing evidence that 
maillard products are also formed via lipid - derived intermediates, resulting  
in advanced lipoxidation products (ALEs) (194). Dyslipidaemia is a common 
phenomenon in subjects with the metabolic syndrome and lipids are an 
important source of protein modifications. So, in these patients both AGEs 
and ALEs may be formed at the same time in atherosclerotic plaques. 
!
Other pathways which may lead to AGE formation is through autoxidation of 
glucose by reactive oxygen species, and through carbonyl compounds 
(195,196). In particular methylglyoxal, a reactive dicarbonyl metabolite of 
glucose, has received considerable attention as the most reactive AGE 
precursor in endothelial cells. Decreased clearance of serum AGEs may 
further increase tissue AGE accumulation and de novo formation, and 
absorption of AGEs from food or smoking may aggravate AGE accumulation 
in renal failure (197-199). 
!
1.7.2 Receptor for advanced glycation end products (RAGE) 
!
Advanced glycation end products bind to cells via a receptor for advanced 
glycation end products (RAGE). RAGE is a multiligand cell-surface protein 
that was isolated from bovine lung in 1992 by the group of Schmidt and 
Stern (204). It  is a member of the immunoglobulin super family of molecules 
possessing variable and constant domains and a short cytoplasmic tail 
which is essential for post RAGE signalling (211) (Figure 1.16). 
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Figure 1.16 - AGE binds to its receptor RAGE 
.  
!
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The exact function of RAGE has yet to be fully characterised. Many cells 
including T-Lymphocytes, endothelial cells, smooth muscle cells, mesangial 
cells and monocytes/macrophages express RAGE. In the majority of healthy 
adult tissues, RAGE is expressed at a low basal level. In contrast, the lung 
exhibits high basal level expression of RAGE suggesting a potentially 
important role for the receptor in maintaining lung homeostasis. RAGE is 
believed to control elastin expression in the lung which is critical for 
maintaining epithelial integrity. Therefore, disruption of RAGE levels has 
been implicated in the pathogenesis of a variety of pulmonary disorders 
including cancer and fibrosis (348-351). Apart from its role within the lung, 
RAGE is also believed to play an important role in embryonal neuronal 
growth, activation and differentiation of ‘T’ cells, mobilisation of dendritic cells 
and osteoclast maturation (352, 353). As mentioned previously, RAGE can 
bind several ligands apart from AGEs including amphoterin and b-amyloid 
substances. 
!
Ligand - RAGE binding activates key cell signalling pathways including 
mitogen activated kinase and transcription factor NF-κβ both in endothelial 
(201) and vascular smooth muscle cells (202). This regulates the expression 
of genes encoding a number of pro inflammatory mediators commonly found 
in atheroma. Activation of the NF-κβ pathway may also cause a switch of  
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endothelial function toward a pro-thrombotic condition that, together with an 
altered platelet metabolism and changes in intra platelet signalling pathways, 
contributes to the pathogenesis of atherothrombotic complications of 
DM(203). As a result of the cross linking of AGE with the endothelium the 
synthesis of a number of new proteins occurs. This mechanism is relevant to 
the development of both macro (209,210) and micro vascular complications 
in the diabetic state (205-208). 
!
Recent studies have identified novel gene splice variants of the human 
receptor RAGE (212-214). One of these encodes the full-length RAGE, 
which has full signalling and AGE binding potential. Another encodes an N- 
terminal truncated form, a membrane-bound isoform that contains no AGE-
binding domain as it lacks the v-domain which is critical for binding of the 
ligand (215). A third splice variant encodes C-truncated soluble RAGE 
(sRAGE), which has AGE-binding properties in the absence of a signalling 
cascade because it lacks the sequences encoding the transmembrane and 
intra cytoplasmic domains (216). At least two potential mechanisms of 
sRAGE production have been identified: either by expression of a splice 
variant of sRAGE or as a result of cleavage from the cell surface through the 
activation of metalloproteinases (ADAM10) (217-218). Experimental studies 
have suggested that sRAGE can act as a decoy for RAGE ligands and thus 
have cytoprotective properties against AGE actions (217-219). Furthermore, 
studies investigating total circulating level of sRAGE have shown that 
sRAGE levels were reduced in non-diabetic subjects with coronary heart 
disease and in those with essential hypertension (220-221). Another 
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Japanese research group also found an inverse correlation between plasma 
sRAGE and carotid atherosclerosis in type 1 and type 2 diabetic subjects 
(222-223).Plasma sRAGE levels have been shown to be decreased in 
patients with the metabolic syndrome and are inversely correlated with 
several components of the metabolic syndrome including BMI, BP, insulin 
resistance index, triglycerides and low HDL levels (224).This remained 
significant even when the non diabetic subjects were extracted suggesting 
an important role for sRAGE even in non diabetic populations (225). 
!
Increasingly RAGE has been proposed as a therapeutic target as up-
regulation of RAGE has been shown to be associated with diverse 
pathological events ranging from atherosclerosis to Alzheimer’s disease 
(346).Currently available therapeutic agents including PPAR-g agonists, 
statins and ACE inhibitors have been shown to be capable of modulating 
RAGE expression (226-229). 
!
Taken altogether, understanding the molecular mechanisms underlying 
RAGE regulation will provide important insights into potential targets for 
prevention and treatment of cardiovascular disease. 
!
!
!
!
!
!
!
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1.8 Management of the metabolic syndrome 
!
Abdominal obesity is the principal factor determining insulin resistance and 
the range of abnormalities associated with the metabolic syndrome. This is 
the reason the ATP III definition of the metabolic syndrome lists waist 
circumference as a diagnostic factor instead of BMI. Weight loss has been 
shown to improve many of the abnormalities associated with the metabolic 
syndrome including insulin resistance, dyslipidaemia, hypertension and 
arterial dysfunction (69, 70, and 71). 
!
1.8.1 Effects of Lifestyle interventions in Diabetes, Hypertension and 
 Dyslipidemia in subjects with the metabolic syndrome 
!
The optimal diet for patients with the metabolic syndrome should focus on 
quantity of calories as well as the quality and composition of the diet. 
Reduction of the amount of saturated fat along with a reduction in portion 
size and consumption of foods rich in dietary fibre have been shown to have 
long lasting effects on the risk factor profile.  
!
The United States Diabetes prevention program (DPP) (72), the Finnish 
Diabetes prevention study (DPS) (73) and the Chinese Da Qing Diabetes 
prevention programme (74) has provided convincing evidence for the 
benefits of lifestyle interventions in the prevention of type 2 diabetes.  
!
!
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The Chinese Da Qing study showed that 68% of the control group compared 
to 43% of those randomised to lifestyle interventions went on to develop type 
2 diabetes during the 6 years of intervention. Similarly both the DPS and 
DPP studies reported that 58% fewer people progressed to type 2 diabetes 
in the intensive lifestyle intervention groups compared to the control group. 
Interestingly only modest weight loss (4-6kgs) was required in the above 
studies to achieve these impressive outcomes. 
!
Weight loss in obese hypertensive subjects was associated with a decrease 
in BP and an improvement in insulin sensitivity (75). Cassano et al have 
shown that small amounts of weight loss in subjects with abdominal obesity 
could lead to dramatic lowering in BP. 
!
The dyslipidaemia in the metabolic syndrome is characterised by elevated 
TG, increased small dense LDL and a decrease in HDL-cholesterol. The 
Framingham offspring study has demonstrated that weight reduction and 
increased physical activity are effective in improving the lipid profiles in these 
subjects. 
!
!
!
!
!
!
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1.8.2 Medical treatment of the metabolic syndrome 
!
Management of patients with the metabolic syndrome should therefore focus 
on various strategies for weight reduction and a combination of diet and 
exercise remains the cornerstone for the treatment of the metabolic 
syndrome. However, despite lifestyle interventions many patients with the 
metabolic syndrome do not achieve targets and need pharmacological 
treatment. Medical treatment should be considered for all cardiovascular risk 
factors that are not normalised following lifestyle modifications and based on 
global risk estimates. 
!
1.8.2.1 Medical treatment of obesity 
!
Drug therapy can be considered in subjects with a BMI of >30kg/m² or lower 
in those with associated co-morbidities. However their widespread use is 
limited by their side effect profile. 
!
Orlistat, an intestinal lipase inhibitor, remains the only medication that is 
currently licensed for the treatment of obesity in the UK. In the Xendos study, 
Orlistat has been shown to reduce the incidence of newly diagnosed 
diabetes in obese subjects with impaired glucose intolerance (77, 78, and 
79). 
!
Sibutramine, a centrally – acting serotonin-nor epinephrine reuptake 
inhibitor, has been shown to improve lipid profile and HbA1c in patients with 
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type 2 diabetes (80). However, in a recent large interventional trial in obese 
patients with the metabolic syndrome (SCOUT study), the risk of non-fatal 
MI and stroke was shown to be higher in the Sibutramine group compared to 
placebo (81). As a consequence, Sibutramine was withdrawn from the 
market. 
!
Rimonabant, an endocannaboid (CB1) receptor antagonist has been 
removed from the market due to side effects, especially depression and 
suicide risk. 
!
Bariatric surgery is a therapeutic alternative that has been shown to cause 
total and lasting resolution of all components of the metabolic syndrome. 
NICE recommends bariatric surgery as a treatment option for adults with 
obesity if they have a BMI of 40 kg/m2 or more, or between 35 kg/m2 and 40 
kg/m2 and other significant disease (for example, type 2 diabetes or high 
blood pressure) that could be improved if they lost weight. Bariatric surgery 
is also recommended as a first-line option (instead of life style interventions 
or drug treatment) for adults with a BMI of more than 50 kg/m2 in whom 
surgical intervention is considered appropriate (82).The first major meta-
analysis in this field showed a weight loss of 47.5% in patients who 
underwent gastric banding, 61.6% for gastric by pass, 68.2% for 
gastroplasty and 70.1% for biliary – pancreatic diversion (BPD) / duodenal 
switch (83). These findings were replicated by a Meta analysis in 2009 and 
also by the Bariatric Outcomes Longitudinal Database (BOLD) study (84, 
85). 
!  77
1.8.2.2 Treatment of Dyslipidaemia 
!
Dietary modifications to replace saturated fats with mono and poly 
unsaturated fats should be encouraged along with an increase in physical 
activity. High intake of poly unsaturated fatty acids (PUFA, fish oils) is 
associated with a reduction in non essential fatty acids (NEFA), triglycerides 
(TG) and very low density lipoprotein (VLDL) levels along with a beneficial 
effect on insulin sensitivity and inflammation (reduced TNF α and NF-κβ 
levels) (86,87). 
!
Fibrates are a group of drugs that  are highly effective in reducing TG, LDL-C 
and increasing HDL-C by acting as ligands for the Peroxisome proliferator 
Activated Receptor alpha (PPAR-α) receptors thereby modulating the genes 
involved in lipid metabolism. 
!
Nicotinic acid has been shown to have a beneficial effect on the lipid triad in 
patients with the metabolic syndrome. However its widespread use is often 
limited by its side effect profile including worsening of glucose tolerance. 
!
Statins are the most effective LDL-C lowering drugs with modest effects on 
HDL-C and TG. Apart from being effective for treating the lipid abnormalities, 
drug treatment should not have any deleterious effects on the other 
components of the metabolic syndrome.  
!
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The therapeutic thresholds for treating dyslipidaemia are the same as the 
general population with lower target values for individuals with diabetes or 
established cardiovascular disease. 
!
1.8.2.3 Treatment of Hypertension in the metabolic syndrome 
Angiotensin converting enzyme (ACE) inhibitors / Angiotensin receptor 
blockers (ARB), β blockers, Calcium channel blockers and diuretics are used 
either as mono therapy or in combination for treatment of hypertension. 
Selection of drugs and combinations are determined in part by their effects 
on other components of the syndrome. 
!
ACE inhibitors / ARBs have been shown to improve insulin sensitivity and 
reduce microalbuminuria unlike β blockers / diuretics which have been 
shown to have adverse effects on lipids and glucose tolerance (88).  
!
Calcium channel blockers have no significant effects on the other 
components of the metabolic syndrome. 
!
Therefore ACE inhibitors / ARBs should be the drugs of first choice in 
patients with the metabolic syndrome without co-existing CVD, followed by 
calcium channel blockers. However cardio selective β blockers should be 
considered in combination with ACE inhibitors / ARBs for patients with 
associated CVD. 
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1.8.2.4 Medical treatment of pre diabetes and type 2 diabetes in 
patients with the metabolic syndrome 
Currently there are no data from controlled drug studies in patients with 
impaired fasting glucose and all studies have been performed in patients 
with impaired glucose tolerance. 
!
In the STOP-NIDDM trial, Acarbose, an α-glucosidase inhibitor was shown to 
reduce progression to type 2 diabetes in patients with impaired glucose 
intolerance (IGT). Furthermore, acarbose reduced the incidence of newly 
diagnosed hypertension, lowered triglyceride levels and reduced major 
cardiovascular events compared to placebo (89). 
!
The beneficial effects of Metformin on various parameters of the metabolic 
syndrome were amply demonstrated in both the DPP and UKPDS studies. 
Insulin resistance / hyperinsulinaemia may have effects on the various 
components of the metabolic syndrome. For example, insulin resistance in 
the skeletal muscle leads to glucose intolerance, increased hepatic 
gluconeogenesis and increased production of triglyceride - rich VLDL, and 
raises blood pressure by various mechanisms. Weight loss with resultant re-
distribution of body fat leads to an improvement in insulin sensitivity which is 
believed to be the ‘’common soil’’ of the metabolic syndrome. The clinical 
importance of insulin resistance lies in the fact that improving insulin 
resistance by various treatment methods may reduce the risk factors of 
subjects with the metabolic syndrome. 
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1.8.3 Peroxisome Proliferator activator receptors (PPARs) – Historical 
aspects 
!
A group of drugs that evoked considerable interest in this context are the 
Peroxisome proliferator-activated receptors (PPARs). PPARs are ligand 
activated transcription factors that attracted enormous scientific and clinical 
interest because of their ability to regulate insulin sensitivity. Furthermore 
they are involved in the regulation of energy homeostasis, lipid metabolism, 
inflammation and atherosclerosis (90-98). 
!
In 1990 Isseman and Green reported the cloning and initial characterisation 
of a novel murine nuclear receptor that is now referred to as PPAR α (99). 
Following this, Wahli et al reported the cloning of Xenopus Laevis ortholog of 
PPAR α in 1992, which like the mouse receptor was activated by micro 
molar concentrations of peroxisome proliferators. They also reported the 
cloning of two closely related orphan receptors encoded by distinct genes, 
which they named PPAR β and PPAR γ (100).  
!
The PPARs are therefore comprised of three subtypes designated as 
PPARα, PPAR γ and PPAR β/δ. PPARs have a broad but isotype-specific 
tissue expression pattern, which account for the variety of cellular functions 
they regulate ( Table 1.9 ). 
!
!
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Table 1.9 Tissue Distribution of PPAR isoforms  
!
!
PPARs are activated by a variety of natural and synthetic ligands some of 
which have been used to treat type 2 diabetes (Thiazolidenediones) (TZDs) 
and dyslipidaemia (Fibrates). Upon activation by endogenous or synthetic 
ligands, PPARs hetero dimerise with the 9-cisretinoic acid receptor (RXR). 
The PPAR–RXR heterodimer undergoes conformational changes, binds to 
Peroxisome Proliferator responsive elements (PPRE) in the promoter region 
of the target genes and alters co activator / co repressor dynamics to 
modulate the transcription machinery, which in turn causes up regulation or 
down regulation of the target genes (101,102) ( Figure  1.17). 
!
PPAR isoforms Tissue Distribution
PPARα Liver,  heart,  skeletal muscle,  
adipose tissue, Endothelial 
cells(EC), Vascular smooth muscle 
cells (VSMC), lymphocytes and 
macrophages
PPARγ 1 Cardiac muscle, skeletal 
muscle,kidney,intestine,VSMC and 
pancreatic β cell
PPARγ 2 Adipose tissue
PPARγ 3 Adipose tissue,colon,macrophages
PPARγ 4 Macrophages
PPAR β/δ Widely expressed in many tissues 
and cell types
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!%  
!
Figure 1.17 Mechanism of action of PPARs 
!
1.8.3.1 PPAR α 
!
PPAR α is expressed abundantly in tissues with a high rate of fatty acid 
oxidation such as the liver, heart and skeletal muscle where it acts as a 
major regulator of fatty acid homeostasis. PPAR-α also significantly 
expressed in the kidney, adipose tissue (especially brown adipose tissue) 
and most cell types present in the vasculature including endothelial cells, 
smooth muscle cells and macrophages. 
!
PPAR α receptors are believed to act as general sensors of overall fatty acid 
load. An increase in the circulating levels of free fatty acids (FFA) 
transcriptionally activate PPARα, which, in turn, up regulates the expression  
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of enzymes involved in mitochondrial and peroxisomal β-oxidation with 
resultant enhanced hepatic fatty acid catabolism and reduced accumulation 
of lipids in liver (103,104,105). Consequently as a result of this they restrict 
the availability of fatty acids for VLDL with a resultant reduction in the 
circulating levels of TGs. In addition, activated PPARα reduces triglyceride 
levels by directly modulating the expression of certain apolipoproteins and 
the critical steps involved in VLDL-TG assembly and secretion 
(105,106,107). 
!
PPAR α activation within the vasculature reduces inflammation by interfering 
with the recruitment of inflammatory cells and also reduces the expression of 
the adhesion molecules ICAM-1, VCAM-1and MCP-1 (108,109,110,111,112). 
In summary PPARα primarily regulates genes involved in lipid metabolism 
and is the molecular target for the fibrate group of drugs. 
!
1.8.3.2 PPAR β/δ 
!
PPAR β/δ is expressed ubiquitously with relatively high levels in the liver, 
skeletal and cardiac muscle, adipose tissue, brain and the vasculature 
(113,114).Unlike PPARα and PPARγ, its physiological function is much less 
studied and understood. However many studies, using recently available 
and potent synthetic ligands such as GW501516 and L165041, and animal 
models suggest that PPAR β/δ is involved in regulating lipid and glucose 
metabolism (115). Currently there are no marketed drugs that target PPAR 
β/δ. 
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1.8.3.3 PPAR γ 
!
PPAR γ receptors are found in insulin - sensitive tissues such as adipose 
tissue, liver, skeletal muscle and macrophages, and primarily regulate 
adipocyte differentiation, insulin action, inflammation and lipid homeostasis 
(93,117,118) 
PPAR γ receptors are expressed in 4 isomeric forms: 
PPAR γ 1 - occurs in white and brown adipose tissue, skeletal muscle, liver 
and cells of the immune system and vasculature. 
PPAR γ 2 - is restricted to white and brown adipose tissue. 
PPAR γ 3&4 – is expressed in macrophages and adipose tissue. 
They serve as receptors for thiazolidenediones (TZDs). 
Thiazolidinediones are predominantly PPAR γ agonists that improve insulin 
sensitivity in the liver, skeletal muscle and adipose tissue. In addition, 
pioglitazone has been shown to improve the lipid profile in these patients 
through its effects on PPAR α. Moreover, TZDs have been shown to exert 
anti inflammatory and anti thrombotic effects, increase arterial compliance 
and decrease carotid intima - media thickness (IMT) (119,120). 
!
Troglitazone, in the TRIPOD (troglitazone in prevention of diabetes) study 
(121), Rosiglitazone in the DREAM (Diabetes Reduction Assessment with  
Ramipril and Rosiglitazone Medication) study (122) and Actos (Pioglitazone) 
in the ACT NOW study in the prevention of type 2 diabetes (123) showed the 
potential of TZDs to reduce progression to type 2 diabetes in subjects with 
impaired glucose tolerance. 
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TZDs, such as Rosiglitazone and Pioglitazone, are associated with weight 
gain but cause a reduction of intra abdominal fat and an increase in 
subcutaneous fat with a resultant improvement in insulin sensitivity 
(124,125). The landmark study ‘ProActive’ showed that Pioglitazone 
significantly reduced the risk of strokes, non fatal MI and deaths in patients 
with type 2 diabetes at high risk of CVD (127). 
!
Thus, thiazolidenediones act on two major pathogenic mechanisms of the 
metabolic syndrome i.e. insulin resistance and intra-abdominal obesity. They 
should thus be effective in preventing CVD (126). 
!
However these two drugs, the antidiabetic TZDs and lipid lowering Fibrates 
affect only a single component of the metabolic syndrome which limits their 
use as monotherapy. Furthermore, their use is often associated with side 
effects especially TZDs which have been associated with an increased rate 
of cardiovascular events (128,129). Rosiglitazone has since been withdrawn 
as a result of such safety concerns.  
!
In recent years extensive efforts have been underway to develop more 
effective and safer single PPAR agonists along with dual, Pan and partial 
agonists and selective peroxisome activator receptor modulators (SPARM) 
compounds that would improve the multiple metabolic abnormalities 
associated with the metabolic syndrome including obesity, insulin resistance 
with associated dysglycaemia, atherogenic dyslipidaemia and inflammation. 
!
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The aim has been to develop drugs with specificity for at least two PPAR 
isoforms (e.g. PPAR α / PPAR γ, PPAR α / PPAR β/δ and PPAR γ / PPAR β/
δ), or PPARs that exhibit cell or tissue specificity which would be more 
efficacious and have relatively less undesirable side effects compared with 
currently used agonists with specificity towards single PPAR isoforms. 
Unfortunately efforts to develop these novel molecules have so far not met 
with much success and a number of trials have to be discontinued due to 
serious safety concerns (130,131,132,133,134). 
!
However, PPARs are also activated by a variety of endogenous and natural 
ligands including n-3 and n-6 fatty acids and eicosanoids. PPAR γ is 
activated by PGJ2 (a prostaglandin) whilst in contrast, PPAR α is activated 
by leukotriene  B4, a few endocannabinoids and phospholipids, as illustrated 
in the following table (table 1.10). 
!
Table 1.10 List of endogenous PPAR ligands 
PPAR α PPAR β/δ PPAR γ
Fatty acids
Arachidonic acid Arachidonic acid Arachidonic acid
Linoleic acid Linoleic acid
Saturated fatty acids Saturated fatty acids Saturated fatty acids
Eicosanoids
Prostaglandins Prostaglandins Prostaglandins
Prostacyclin Prostacyclin
Leukotrienes
Lipoproteins
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These natural ligands modulate PPAR activity and are therefore likely to be 
useful in treating a wide range of metabolic disorders including obesity, 
dyslipidemia, type 2 diabetes and atherosclerosis, hopefully without any 
associated serious side effects or safety concerns. In this context, 
conjugated linoleic acid (CLA), an important dietary polyunsaturated fatty 
acid with reported PPAR α and γ activity has attracted interest because of its 
effects on body composition. Specifically, it has been shown to cause a 
reduction in body fat mass and an increase in lean body mass (230,231). 
CLA has also been shown to have beneficial effects on adipogenesis, 
inflammation (232,233) and insulin sensitivity (234). 
!
1.8.4 Conjugated linoleic acid (CLA) 
CLA is a collective term for a class of conjugated dienoic isomers of linoleic 
acid which are naturally occurring polyunsaturated 18-carbon compounds. 
The isomers of CLA are distinguished by differences in the position and the 
orientation (cis or trans) of the double bonds along the fatty acid chain 
(figure 1.18).                               
!  
!
Figure 1.18  Biologically Active CLA isomers 
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!
It is possible that a number of these CLA isomers have biological activity. 
However, all of the known physiologic effects of CLA are induced by two 
isomers: c9, t11-CLA and t10, c12-CLA. There is also increasing interest in 
the fact that the biological effects of cis-9, trans–11 CLA and trans-10, cis-12 
isomers may be different, with the former exhibiting PPAR α activity whilst 
the t10, c12-CLA has been shown to have effects predominantly on PPAR γ 
receptors (235,236). 
!
!
1.8.4.1 CLA – Historical aspects 
In 1978, Pariza et al (241, 242) reported that grilled ground beef contained 
both bacterial mutagens and a substance that inhibited mutagenesis. They 
went on to identify the new anti carcinogen as conjugated linoleic acid (CLA) 
(243). Interest in CLA was further kindled by this serendipitous observation 
some 30 Years ago. Since then, in various animal models, CLA has been 
shown to reduce or prevent adiposity, improve insulin resistance, inhibit 
adipogenesis, tumour development, and modulate inflammatory reactions 
(242). These observations have led to much speculation about the potential 
role of CLA in human health. Research on CLA has markedly increased over 
the last three decades and possible health benefits for humans continue to 
emerge. 
!
!
!
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1.8.4.2 Sources of CLA in humans 
CLA is produced from linoleic acid in the rumen of cattle, goats, sheep and 
other ruminants. It cannot be made in any substantial quantities by humans 
and the main source of CLA in humans are food products derived from 
ruminants including meat, dairy products and partially hydrogenated 
vegetable oils, where more than 90% of CLA is in the c9-t11 configuration 
(237). The content of CLA in the diet varies considerably and is a direct 
reflection of the diet the animals are fed. Evidence suggests that pasture fed 
cows had 500% more CLA in their milk fat than cows on supplementary 
feeds. Similarly cow’s milk produced from late Spring through early Autumn 
(seasons of rapidly growing green grass) will have almost twice the CLA 
content of milk produced in winter months (239,240).The average 
consumption of CLA in the diet has reduced from between 2-3g per day in 
the diet of 30 years ago to about 100-300 mg / day in the modern diet. This 
reduction of CLA in the diet may partly explain the global epidemic of obesity 
and diabetes (239,240). For humans, the recommended therapeutic daily 
intake of CLA ranges from 1.5 to 3.5 g/day (239,240).  
!
The cis-9, trans-11 and trans-10, cis-12 (t10, c12) isomers, which are 
considered to be the most physiologically active isomers, can also be 
commercially synthesised from linoleic acid rich oils such as sunflower and 
safflower oil (238). These two isomers are usually represented in about 
equal amounts in synthesised CLA, with ten other minor CLA isomers 
representing the remaining 10-15 percent of these mixtures (238). 
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1.8.4.3 Beneficial effects of CLA in humans 
Extensive research has been undertaken to determine the extent of CLA’s 
health benefits in animals and humans as well as the mechanism of action 
through which CLA mediates these processes 
!
1.8.4.3.1 Effects of CLA on Body fat and composition 
Most research studies have supported a beneficial effect of supplemental 
CLA on inducing weight loss. Animal studies on mice, rats, and hamsters 
have shown an alteration in overall body composition following CLA 
supplementation (244,245,246,247). Not only did the studies in laboratory 
animals confirm a benefit of CLA on fat loss, they also showed that the anti 
adiposity characteristics of CLA were stronger in young animals during 
growth than in mature animals (248, 249).   
!
One human study of middle aged men found a significant reduction in 
abdominal fat but no change in the body mass index (BMI) (252). In addition, 
a longer term study indicated a significant decrease in body fat mass after 
12 months of CLA supplementation and a recent meta-analysis indicated 
that CLA is beneficial in reducing body fat mass (256,257).  
!
A 2012 study found that among 80 overweight and obese Chinese subjects, 
two daily doses of CLA (1.7 grams each) for 12 weeks reduced body fat by 2 
percent, though cholesterol levels worsened slightly (324). 
!
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!
The mechanisms underlying the effects of CLA are not yet established. 
However, there are clear indications that the anti adiposity effects are 
specifically mediated by the t10, c12 CLA isomer rather than the c9, t11 CLA 
isomer (255,256). 
!
 In vitro studies using murine adipocyte cell lines (253) as well as primary 
human adipocytes (254) show that t10, c12-CLA supplementation reduces tri 
acyl glycerol accumulation and adipocyte differentiation. These studies are 
supported by in vivo animal studies where t10,c12-CLA has been shown to 
reduce the transcription of several adipocyte-specific genes such as 
adiponectin, glucose transporter 4, leptin, and lipoprotein lipase (LPL) in 
white adipose tissue (254,256). The actions are believed to be mediated by 
the effects of t10, c12-CLA isomer on PPAR γ receptor, because several of 
the adipogenic genes are PPAR γ target genes. 
!
1.8.4.3.2 Effects of CLA on Atherosclerosis 
Atherosclerosis is a chronic inflammatory disease as previously described. It 
has been proposed that CLA can reduce inflammatory gene expression, thus 
altering the signalling pathways that lead to the formation of reactive oxygen 
species (ROS). Furthermore, CLA inhibits the synthesis of arachidonic acid 
and thus modulates the inflammatory response which is generally under the 
control of eicosanoids produced by arachidonic acid (258). To date, most 
animal and human studies on the effects of CLA on atherosclerosis have 
been inconclusive and contradictory (258).  
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Several studies have indicated a decrease in LDL, total cholesterol, 
triglyceride, and fat deposition levels with CLA supplementation (259,260), 
while other studies indicate an increase in HDL with an increase in fatty 
streak development (261) (McGuire and McGuire 2000).  
!
1.8.4.3.3 Effects of CLA on Diabetes and Insulin sensitivity 
Short-term clinical trials indicate that there is a strong isomer - dependent 
relationship, with the t-10, c-12 CLA having a detrimental effect on insulin 
sensitivity (262). However, the c-9, t-11 CLA isomer has been shown to have 
anti-diabetic effects (264). Furthermore, interventions that provided 
supplements that contained a 50:50 combination of both CLA isomers 
(trans-10, cis-12 and cis-9, trans-11 CLA) have, in general, produced mixed 
results on insulin sensitivity (263). Similarly, various animal studies have 
shown a wide range of effects related to blood glucose levels, insulin 
sensitivity, and insulin resistance (265). 
!
1.8.4.3.4 Immune Response Modulation  
The effects of CLA in the modulation of immune responses have several 
positive implications for human health. CLA has been shown to modulate the 
production of eicosanoids, prostaglandins, cytokines, and immunoglobulin’s.  
Specifically, CLA reduces the concentration of immunoglobulin E (IgE) and 
thus reduces allergic reactions (266). Overall, CLA modulates allergic and 
infectious immune responses by different pathways and different 
mechanisms of action. 
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 Table 1.11 Summary of key clinical trials using CLA in human subjects 
STUDY OBJECTIVES / 
DESIGN
KEY OUTCOMES
Treatment with dietary trans10 
cis12 conjugated linoleic acid 
causes isomer-specific insulin 
resistance in obese men with 
the me tabo l i c synd rome. 
Diabetes Care.  2002 ; 25 (9):
1516-21 
Randomized, double-
bl ind control led tr ial , 
abdominally obese men 
(n = 60) were treated with 
3.4 g/day CLA (isomer 
mixture), purified t10c12 
C L A , o r p l a c e b o . 
Eug l ycemic – hype r 
i n s u l i n a e m i c c l a m p , 
serum hormones, lipids, 
and anthropometry were 
assessed before and after 
12 weeks of treatment.
t10, c12 CLA increased insulin 
resistance (P < 0.01) and glycaemia 
(P<0 .001) and reduced HDL 
cholesterol (P < 0.01) compared with 
placebo. The CLA mixture did not 
change glucose metabolism, body 
composition, or weight compared 
with placebo but lowered HDL 
cholesterol (P < 0.05).
Supplementation with 
conjugated linoleic acid causes 
isomer-dependent oxidative 
stress and elevated C-reactive 
protein: a potential link to fatty 
acid-induced insulin resistance. 
Circulation. 2002: 8; 106(15):
1925-9 
60 men with metabolic 
s y n d r o m e w e r e 
randomized to one of 3 
g r o u p s r e c e i v i n g 
t 1 0 , c 1 2 C L A , a C L A 
mixture, or placebo for 12 
weeks in a double-blind 
placebo-controlled trial. 
I n s u l i n s e n s i t i v i t y 
(euglycaemic clamp), 
serum lipids, in vivo lipid 
pe rox ida t i on p lasma 
vitamin E, plasma C-
reactive protein, TNF-α, 
and IL-6 were assessed 
b e f o r e a n d a f t e r 
treatment.
Supplementation with t10c12 CLA 
m a r k e d l y i n c r e a s e d 8 - i s o -
PGF(2alpha) (578%) and C-reactive 
protein (110%) compared with 
placebo (P<0.0001 and P<0.01, 
respectively) and independent of 
changes in hyperglycemia or 
dyslipidemia
The CLA isomer, t10c12-CLA, is 
inverse ly assoc iated wi th 
changes in body weight and 
serum leptin in subjects with 
type 2 diabetes mellitus. J 
Nutr. 2003,133:257S-60S
In this double-blind study, 
subjects with type 2 
diabetes mellitus were 
randomized into one of 
two groups receiving 
e i ther a supp lement 
containing mixed CLA 
isomers (CLA-mix; 8.0 g 
daily, 76% pure CLA; n = 
12) or a supplement 
containing safflower oil 
(placebo; 8.0 g daily 
safflower oil, n = 9) for 8 
wk.
t10c12-CLA, but not c9t11-CLA, was 
inversely associated with body 
weights (P < 0.05) and serum leptin 
(P < 0.02). These findings strongly 
suggest that the t10c12-CLA isomer 
may be the bioactive isomer of CLA 
to influence the body weight changes 
observed in subjects with type 2 
diabetes
Effects of cis-9,trans-11 CLA 
supplementation on insulin 
sensitivity, lipid peroxidation,and 
proinflammatory markers in 
o b e s e m e n . A m J C l i n 
Nutr. 2004; 80(2):279-83 
25 abdominally obese 
men received 3 g c9,t11 
CLA/d or placebo (olive 
oil) for 3 months in a 
randomised, doub le-
blind,placebo-controlled 
study
CLA preparation containing the 
purified c9,t11 CLA isomer increased 
i n s u l i n r e s i s t a n c e a n d l i p i d 
peroxidation compared with placebo 
in obese men.
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S u p p l e m e n t a t i o n w i t h 
trans10cis12-conjugated linoleic 
a c i d i n d u c e s h y p e r p r o 
insulinaemia in obese men: 
close association with impaired 
i n s u l i n - s e n s i t i v i t y . 
Diabetologia 2004, 47:1016-101
9
5 7 n o n - d i a b e t i c 
abdominally obese men 
were randomised to 
receive 3.4g t10c12CLA, 
CLA-isomer mixture or 
control oil for 12 weeks. 
Insulin sensitivity, intact 
pro-insulin, insulin, the 
proinsulin: insulin ratio, C-
peptide, glucose and 
a d i p o n e c t i n w e r e 
assessed before and after 
supplementation.
Supplementation with t10c12CLA 
increased proinsulin (p<0.01), the 
proinsulin : insulin ratio (p<0.05) and 
C-peptide concentrations (p<0.001) 
in comparison with control subjects. 
Adiponectin, however, did not 
change significantly. The change in 
proinsulin, but not the proinsulin: 
insulin ratio, was related to impaired 
insu l i n sens i t i v i t y ( r= -0 .58 , 
p<0 .0001 ) , i ndependen t l y o f 
changes in insulin, C-peptide, 
glucose, adiponectin and BMI.
Effects of two conjugated 
linoleic Acid isomers on body fat 
mass in overweight humans. 
Obes Res 2004, 12:591-598
V o l u n t e e r s w e r e 
randomized over f ive 
groups receiving daily 
either 3 g of high oleic 
acid sunflower oil, 1.5 g of 
cis-9,trans-11 (c9t11) 
CLA, 3 g of c9t11 CLA, 
1.5 g of trans-10,cis-12 
(t10c12) CLA, or 3 g of 
t10c12 CLA administrated 
as triacyl glycerol in a 
drinkable dairy product for 
18 weeks in this placebo-
controlled, double-blind, 
randomised study
A daily consumption of a drinkable 
dairy product containing up to 3 g of 
CLA isomers for 18 weeks had no 
statistically significant effect on body 
composition in overweight, middle-
aged men and women.
CLA supplementation for 1 year 
reduces body fat mass in 
healthy overweight humans. 
Am J Clin Nutr. 2004;79(6):
1118-25.
Long-term supplementation with 
CLA-FFA or CLA-triacylglycerol 
reduces Body Fat Mass in healthy 
overweight adults !
S u p p l e m e n t a t i o n w i t h 
conjugated linoleic acid for 24 
months is well tolerated by and 
reduces body fat mass in 
healthy, overweight humans. J 
Nutr 2005, 135:778-784
A f t e r 1 2 m o i n a 
randomized, double-blind, 
placebo-controlled trial of 
CLA supplementation, 2 
groups received CLA as 
part of a triglyceride or as 
the free fatty acid, and 1 
group received olive oil as 
placebo.
T h i s s t u d y s h o w s t h a t C L A 
supplementation for 24 months in 
healthy, overweight adults was well 
tolerated. It also confirms that CLA 
decreases BFM in overweight 
humans, and may help maintain 
initial reductions in BFM and weight 
in the long term.
Lack o f e f fec t o f d ie tary 
con jugated l ino le ic ac ids 
naturally incorporated into butter 
on the lipid profile and body 
composition of overweight and 
o b e s e m e n . A m J C l i n 
Nutr 2005, 82:309-319
In a crossover design 
study including an 8-wk 
washout period, 16 men 
were fed with modified 
butter naturally enriched 
with CLA
These results suggest that a 10-fold 
CLA enrichment of butter fat does 
not induce beneficial metabolic 
effects in overweight or obese men.
Effects of the individual isomers 
cis-9, trans-11 vs. trans-10, 
cis-12 of CLA on inflammation 
parameters in moderately 
overweight subjects with LDL-
phenotype B.Lipids, 2005; 40 
(9):909-18.
The objective of this study 
was to evaluate the 
i m m u n e - m o d u l a t i n g 
effects of 3 g cis-9, 
trans-11 (c9, t11) vs. 
trans-10, cis-12 (t10,c12) 
C L A i s o m e r s i n a 
population with a high risk 
of coronary heart disease 
in a 13 week study
Daily consumption of 3 g of c9, t11 or 
t10, c12 CLA isomer did not affect 
LPS-stimulated cytokine production 
by PBMC or whole blood and plasma 
CRP levels.
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!
1.8.5 Hypothesis: 
There is thus substantial evidence from animal and experimental studies that 
CLA possesses anti-carcinogenic, anti-atherogenic, anti-diabetic effects and 
anti-inflammatory effects in addition to its beneficial effects on lipids and on 
body fat composition. However, evidence from direct studies on humans 
have been inconclusive (Table 1.11). A clear rationale also exists for the 
hypothesis that improving insulin sensitivity may influence many of the 
components of the metabolic syndrome. Treatment with PPAR ligands such 
as CLA may thus have the potential to optimise both metabolic control and 
cardiovascular risk.  
I hypothesised that CLA may exert its benefits not only by improving insulin 
sensitivity and body composition, but also through indirect mechanisms 
involving changes in sRAGE mediated inflammation and changes in 
adipocytokine profile. To investigate this hypothesis and in order to clarify the 
effects of CLA supplementation in-vivo, a randomised double blind cross 
over study in subjects with the metabolic syndrome was undertaken over a 
22 week period. 
!
T h e e f f e c t o f 6 m o n t h s 
s u p p l e m e n t a t i o n w i t h 
conjugated linoleic acid on 
insulin resistance in overweight. 
J Obesity 2007, 31:1148-1154
 Randomized, double-
blind, placebo-controlled 
trial with change in body 
composition as primary 
end point comprising 118 
s u b j e c t s r e c e i v i n g 
supplementat ion with 
either placebo (olive oil) 
or CLA for 6 months.
CLA does not affect g lucose 
metabolism or insulin sensitivity in a 
population of overweight or obese 
volunteers.
Efficacy of conjugated linoleic 
acid for reducing fat mass: a 
meta-analysis in humans Am J 
Clin Nutr 2007; 85:1203–11.
Given at a dose of 3.2 g/d, CLA 
produces a modest loss in body fat 
in humans.
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1.8.6 Our Study Objectives / Aims 
1.  To assess the effects of CLA supplementation on inflammation and   
     sRAGE expression in subjects with the Metabolic Syndrome 
2.  To determine whether treatment with CLA in a group of patients with   
      the Metabolic Syndrome has a beneficial effect on body composition, 
      metabolic profiles and other markers of cardiovascular risk 
3.   To evaluate the differences between a CLA mixture and 9,11 isomer  
      on the above parameters 
  
This study used the CLA mixture (50:50 cis-9, trans-11 and trans-10, cis-12 
isomers) as this is the one that is commercially available to population 
groups interested in losing weight. The c9, t11-CLA isomer has not been as 
well examined as the t10, c12-isomer in humans and as this is the isomer 
most abundant in natural foods and it is possible to increase the content of 
this isomer in bovine milk via feeding strategies, we found it relevant to 
include this isomer in our study. We did not use the t10, c12-isomer as this 
has been shown in some studies to worsen metabolic profiles (262,263,264). 
!
!
!
!
!
!
!
!
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!
!
!
              CHAPTER 2 
!
!
!
!
!
!
A randomised, double blind, crossover study of the 
effects of CLA isomers on body composition, metabolic 
profiles, inflammation and vascular function in patients 
with the Metabolic Syndrome – Study design 
!
!
!
!
!
!
!
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2.1 Overview  
!
There is evidence from experimental and animal studies that CLA exerts 
beneficial effects on body weight, insulin sensitivity, adipogenesis, tumour 
development, inflammation and vascular function ( 243 -249). The data from 
these studies suggest that CLA could have a beneficial effect on body 
weight, metabolic profiles and vascular risk profile in overweight insulin 
resistant patients. 
!
However, none of these results have been consistently reproduced in 
humans, possibly because of the differences in the dosages, duration and 
types of isomers provided in these studies.    
!
In order to clarify the effects of CLA supplementation in vivo, we conducted a 
clinical trial to investigate direct measures of inflammation including RAGE 
expression, body composition, insulin sensitivity and metabolic profiles as 
well as various markers of cardiovascular risk in subjects with the metabolic 
Syndrome. 
!
The clinical trial described in this chapter compares the effects of our 
investigational medicinal product (IMP), the CLA mixture (50:50 cis-9, 
trans-11 and trans-10, cis-12 isomers) with the cis-9, trans-11 isomer on 
various parameters in subjects with the metabolic syndrome using a 
randomised, double - blind, cross-over study design. 
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2.2 Materials and Methods 
2.2.1 Study approval and funding 
Prior to study commencement, approval to conduct this clinical trial was 
obtained from Cardiff & Vale NHS trust Research and Development 
department (reference number 04/CMC/3239E), the South East Wales 
Research Ethics Committee (reference number  05/MRE09/60)  and the 
Medicines and Healthcare Products Regulatory Authority (EudraCT No:
2005-003197-17) who also, during the course of the study undertook an 
inspection of the trial as part of their routine statutory inspection of clinical 
trial activity at Cardiff and Vale NHS trust (December 2007).Funding was 
obtained form the Diabetes research fund (University hospital Llandough) 
and the medicinal product was provided by Stephan Lipid nutrition, 
Netherlands. The pre-initiation approval process began in 04/07/2005 and 
final approval was obtained in December 2006 following which patient 
recruitment commenced (First enrolment 12/01/2007). The delay in approval 
was mainly related to the clinical trials authorisation as part of the final 
approval process by the MHRA. 
!
2.2.2 Overall study design 
This was a 22 week randomised, double-blind, cross - over study of the 
effects of Conjugated linoleic Acid isomers on inflammation and RAGE 
expression, body composition, metabolic profiles and vascular function in 
patients with the metabolic syndrome.  
!
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!
Thirty patients were randomly assigned to consecutive 2-month treatment 
periods of either 2 grams of cis-9, trans-11 CLA isomer or a CLA mixture 
(50:50 cis-9, trans-11 and trans-10, cis-12 isomers). A washout interval of 6 
weeks separated the two treatment phases. Randomisation was performed 
prospectively by an independent source (St Mary’s Pharmaceuticals, 
Cardiff), with half receiving 9, 11 CLA isomer first and the other half receiving 
the CLA mixture. Patient allocation details were coded and kept confidential 
until the trial was completed.  
!
Subjects underwent detailed metabolic evaluation including measurement of 
insulin sensitivity, glycaemic status and lipid profiles. Systolic, diastolic, and 
mean BP were measured along with markers of inflammation including 
RAGE expression, surrogate markers of endothelial function and measures 
of platelet function. Anthropometric measurements were carried out including 
BMI and waist measurements, and arterial compliance was assessed non-
invasively by means of pulse wave analysis and pulse wave velocity 
measurements at baseline and after each treatment phase. 
  
These measurements were made on entry into the treatment phase and 
again after 8 weeks of treatment with CLA mix followed by 9,11 CLA 
separated by a washout period of 6 weeks and vice versa. Sequential 
measurement of these parameters enabled an assessment of the potential 
mechanisms by which CLA may produce its effects.  
!
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2.2.3 Discussion of the design 
Metabolic Syndrome is a common condition affecting 25% of the population 
based on accepted diagnostic criteria (6). We employed a crossover design 
for this study because a substantial within-subject correlation was 
anticipated, such that smaller sample sizes might be required to detect 
significant differences. The main advantage of the crossover study design is 
that each individual acts as his or her own ‘control’ thus reducing the 
influence of confounding variables. Removing patient variation in this way 
makes cross over trials more efficient than similar sized parallel group trials. 
The main draw back is the potential to carry–over a treatment effect from the 
1st treatment phase to the 2nd. This can be overcome to a great extent by 
ensuring an adequate wash-out period and performing baseline measures 
prior to each treatment phase (267-271). 
!
A dose of CLA of 1 gram twice daily was used in this study as the 
recommended therapeutic daily intake of CLA ranges between 1.5 to 3.5 g/
day (239,240). Furthermore, higher doses used in previous studies were 
shown to be associated with worsening insulin sensitivity (252). CLA has a 
short circulatory half life of a few hours and therefore a washout interval of 6 
weeks was used to separate the two treatment phases to minimise the 
chance of ‘carry over’ into the next treatment phase. Similar dosages and 
washout intervals have been employed in previous studies 
(257,258,259,262-265).  
!
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2.2.4 Study participants - inclusion and exclusion criteria 
Patients with the metabolic syndrome as defined by NCEP ATP III criteria 
with at least 3 of the following (6) were enrolled into the study 
 Fasting plasma glucose > 5.6 mmol/l 
 Serum triglycerides         > 1.7 mmol/l 
 Serum HDL cholesterol   < 1.0 mmol/l 
 Blood Pressure                > 130 / 85 mm Hg 
 Abdominal   Obesity 
         Waist Girth           > 102 cms in males 
                       > 88cms in females 
Patients were excluded from participation if they had pre existing 
diabetes. Exclusion criteria were age less than 18 years or greater than 70 
years, pregnancy, breastfeeding and any intercurrent significant medical or 
psychiatric condition. All patients took their usual medications with dosage 
and timing kept unaltered before and during the study. 
!
2.2.5 Recruitment 
Potential participants were initially identified from the Diabetes Clinics at the 
University Hospital of Wales and Llandough, and eligible subjects were 
invited to participate through a letter from the clinician responsible for their 
care. I provided each potential participant with a patient information sheet 
(see appendix 1) and explained the nature of the study, its purpose, the 
procedures involved, the expected duration, the potential risks and benefits 
involved and any discomfort it might entail.  
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Each subject was informed that participation in the study was voluntary and 
they could withdraw from the study at any time and that withdrawal of 
consent would not affect her subsequent medical treatment or relationship 
with the treating physician. Patients were given adequate time to review the 
patient information sheet and ask questions about any aspects of the study. 
If subjects were still in agreement, informed consent was obtained using a 
participant-investigator signed consent form (appendix 2). All study visits 
took place in the temperature controlled ward area of the Clinical Research 
Facility at the University Hospital of Wales, Cardiff, with each visit lasting 3-4 
hours. 
2.2.6 Interruption or discontinuation of treatment 
The term discontinuation refers to a patient’s non completion of study. 
Information about discontinuation and an explanation why the patient was 
withdrawn from the study was recorded. Patients who discontinued 
prematurely due to side effects were followed until resolution of the event. 
Reasons that a patient could discontinue participation were considered to 
constitute one of the following 
1. Adverse event 
2. Abnormal laboratory value 
3. abnormal test procedure result 
4. protocol violation 
5. subject withdrew consent 
6. subject lost to follow up 
7. administrative problems 
8. Death 
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2.2.7 Treatments and Interventions 
!
Thirty participants were randomised to receive consecutive 8 week treatment 
periods of either 1g BD of cis-9, trans-11 CLA isomer or a CLA mixture 
(50:50 cis-9, trans-11 and trans-10, cis-12 isomers). A washout interval of 6 
weeks separated the two treatment phases. CLA isomer capsules were both 
supplied by Lipid Nutrition and packaged in a licensed pharmaceutical 
laboratory (St Mary’s Pharmaceutical Unit, Cardiff, UK).  
!
Figure 2.1 Study plan / flow chart 
!
!
 
!
!
!
!
!
!
!
!
!
!
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First treatment phase Wash-out Second treatment phase
CLA 9, 11 isomer 
(1g BD x 8 weeks) 
                 
CLA 9, 11 isomer (1g BD x 8 
weeks) 
Group A (n=15)
CLA 
mixture Group B (n=14)
Visit 1 (Day 
1) 
Pre-treatment 
Visit 2 (Day 
56) 
Visit 3 (Day 98) 
Pre-treatment
8 weeks 6 weeks
CLA 
mixture
8 weeks
Visit 4 (Day 154) 
Post-treatment
2.2.8 Measurements 
!
Participants were assessed in the Clinical Research Facility at the UHW at 
four points: baseline tests at visit 1 and at the end of the wash-out phase 
(visit 3) and after each treatment (9, 11 CLA isomer or CLA mixture) phase 
(visits 2 and 4).  
!
Following an overnight fast, subjects were admitted to the Clinical Research 
Facility at 08:00 hours. Pre menopausal patients had a pregnancy test and 
would have been excluded if this was positive. Patients were not assessed if 
they had evidence of recent or ongoing infection as this would skew 
measurement of CRP. 
!
 2.2.8.1 Anthropometric Measurements 
!
Baseline anthropometric data, consisting of blood pressure, height, weight, 
body mass index (BMI), waist circumference and body composition 
measured by bioelectrical impedance were collected. Body height (without 
shoes) was measured to the nearest 0.5 cms using a stadiometer and the 
body weight to the nearest 0.5 kg on a balance beam scale. BMI was 
calculated as weight (kg) divided by height (m²). Standard bio impedance 
was performed using a commercial bio impedance meter (Tanita Body fat 
analyser TBF-305, Tanita Corporation, Japan). 
!
!
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2.2.8.2 Metabolic Biochemistry Measurements 
!
On each occasion blood samples were collected after an overnight fast for 
lipids, glucose, markers of inflammation (RAGE, hs CRP), Adipokines 
(Adiponectin, Resistin and PAI-1) and surrogate markers of endothelial and 
platelet function (eSelectin, pSelectin and von Willebrand factor (vWF).  
!
Serum total cholesterol, HDL-cholesterol and triglycerides were measured 
by an enzymatic-colorimetric method. LDL-cholesterol was estimated from 
quantitative measurements of total and HDL-cholesterol and plasma 
triglycerides (TG) using Friedewald’s equation as follows, [LDL- Chol] = 
[Total Chol] - [HDL-Chol] - ([TG]/2.2 (272). 
!
2.2.8.3 Quantifying glycaemic control, insulin resistance and metabolic 
parameters 
!
The normal response to glucose load is suppression of hepatic glucose 
production and enhancement of glucose uptake in the liver and muscle. In 
subjects with IFG, the impairment of insulin sensitivity in the liver to control 
hepatic glucose output causes the elevated fasting glucose. Insulin 
sensitivity in subjects with isolated IFG showed a significantly increased 
HOMA-IR (Homeostatic Model Assessment) (273-276). HOMA-IR primarily 
reflects hepatic insulin resistance, which is the underlying mechanism of 
increased fasting glucose.   
!
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As opposed to IFG, peripheral insulin resistance i.e. muscle, appears to be 
the main abnormality in the IGT subjects which, along with a defect in ‘early-
phase’ insulin secretion results in an inability to suppress hepatic glucose 
production, leading to an excessive rise in plasma glucose during the first 60 
mins of oral glucose tolerance test (OGTT). (279-281).  
!
The key question of which one is the primary contributor to the development 
and the subsequent maintenance of hyperglycaemia remains controversial. 
Insulin resistance is believed by some, to be the primary abnormality and the 
increased secretory demand on the ß-cells by insulin resistance leads in 
those susceptible to ß-cell dysfunction (277,279,282). Other groups have 
suggested that reduced ß-cell function with decreased insulin secretion is a 
prerequisite for the early and subsequent development of T2DM (290-292 
(283-285). In early type 2 diabetes development, insulin resistance may 
appear to be the more prominent abnormality with a compensatory increase 
in insulin secretion. 
2.2.8.3.1 Measures of insulin secretion and β- Cell mass  
Glycaemic control was assessed by measuring fasting plasma glucose 
(glucose oxidase method).  
Insulin resistance can be defined clinically by measurement of a fasting 
plasma insulin concentration, but lack of standardisation of insulin assays 
precludes defining a specific insulin concentration above which a person is 
defined as insulin resistant.  The measurements of basal insulin or insulin 
levels after an oral glucose challenge alone does not give a sufficiently 
accurate representation of ß-cell function. The gold standard for 
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measurement of insulin sensitivity is considered to be the euglycaemic 
hyperinsulinaemic clamp technique (276). However, in our study we used 
the Homeostatic model assessment to estimate insulin sensitivity / β cell 
function (286). 
!
2.2.8.3.2 Homeostatic Model Assessment (HOMA-B and HOMA-IR) 
Homeostasis Model Assessments (HOMA) estimate steady state ß-cell 
function (HOMA-B) and insulin sensitivity/resistance (HOMA-IR). These 
measures correspond well to non-steady state estimates of ß-cell function 
and insulin sensitivity derived from stimulatory models, such as a 
hyperinsulinaemic clamp, hyperglycaemic clamp or an intravenous glucose 
tolerance test. HOMA-B was calculated using a HOMA calculator version 2.2 
(Diabetes Trial Unit, Oxford University). This is a method assessing ß-cell 
function from basal glucose and insulin. HOMA of beta-cell function and 
insulin resistance was first described in 1985 (286). The insulin resistance 
(HOMA-IR) is calculated from basal plasma glucose and insulin. Both the 
equations are simplified to : HOMA-B% = (20 x FPI)/(FPG -3.5), HOMA-IR = 
(FPI x FPG) / 22.5 for ß-cell function and insulin resistance, respectively 
where FPI is fasting plasma insulin concentration (mU/l) and FPG is fasting 
plasma glucose (mmol/l)(286).   
!
!
2.2.8.3.3 Plasma insulin  
Insulin was measured by a highly specific and sensitive assay (MLT 
Research Ltd, Cardiff, UK) which measures ‘true’ insulin levels, as it does 
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not cross-react with intact and split proinsulin. It employs monoclonal 
antibodies which restrict the cross-reactivity to a minimum. The MLT insulin 
assay is an immuno chemiluminometric assay (ICMA) for the quantitative 
measurement of insulin in human samples. The duration of the assay is 
approximately 2.5 hours. All assays contain control samples to ensure the 
results are within an acceptable range. The MLT insulin assay is a two-site 
immunoassay, employing an insulin specific solid phase antibody 
immobilised on micro titre wells, and a soluble antibody labelled with a 
chemiluminescent acridinium ester which recognises insulin. Plasma is 
incubated in the micro titre well, along with the labelled antibody solution. 
The plate is then washed to remove unbound, labelled antibody and 
measured using a micro titre plate luminometer. The luminescent reaction is 
a flash type (>95% complete in 1 second) which allows the entire plate to be 
read in approximately 5 minutes. The normal range for fasting insulin is 
6-100pmol/L and the CV for the insulin assay is <4.0% with sensitivity of 1.5 
pmol/l and specificity of 100%. 
!
2.2.8.3.4 Plasma total proinsulin  
The MLT Total Proinsulin assay is an immuno-chemiluminometric assay for 
the quantitative measurement of the sum of concentrations of intact, des 
3132 split proinsulin and 32-33 split proinsulin in human samples. The assay 
is able to handle approximately 80 samples in one run and the duration of  
the assay is approximately 3.5 hours.  All assays contain control samples to 
ensure the results are within an acceptable range. The MLT Total Proinsulin 
assay is a two-site immunoassay, employing a solid phase antibody 
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immobilised on micro titre wells, and a soluble antibody labelled with a 
chemiluminescent acridinium ester, which recognises all circulating forms of 
proinsulin.  Plasma is incubated in the micro titre well, along with a buffer 
and after a wash step, labelled antibody solution is added before a second 
incubation. The plate is then washed to remove unbound, labelled antibody 
and measured using a micro titre plate luminometer. The luminescent 
reaction is a flash type (>95% complete in 1 second), which allows the entire 
plate to be read in approximately 5 minutes A calibration curve is constructed 
permitting estimation of proinsulin concentrations in the samples by 
comparison with calibrators of known proinsulin concentration. The normal 
range for fasting proinsulin is < 20pmol/L. The CV for proinsulin assay is 
<5.0% with sensitivity of 0.35 pmol/l and specificity of 100%. 
!
2.2.8.3.5 Pro insulin / Insulin ratio 
Insulin production in normal subjects involves cleavage of insulin from 
proinsulin; 10 to 15 percent of secreted insulin is proinsulin and its 
conversion intermediates. In contrast, the proportion of immuno reactive 
insulin that is proinsulin in type 2 diabetes is increased considerably in the 
basal state (>40 percent). Proinsulin is an insulin precursor which is 
released in small amount under normal conditions. In the fasting state, the 
proportion of proinsulin-like molecules in T2DM is two to three-folds greater 
than in healthy subjects (287). Increased demand on the ß-cells also results 
in the release of less mature ß-cell granules at a time when conversion of 
proinsulin to insulin is incomplete, hence higher levels in the IGT subjects 
(288). Prospective studies have demonstrated that the proinsulin levels and 
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proinsulin to insulin ratio may be used to predict early deterioration in 
glucose tolerance (289,290). It has been seen that the proinsulin to insulin 
ratio is negatively correlated with acute insulin response suggesting that it 
can be used as a surrogate marker of ß-cell dysfunction (291-293). 
Because proinsulin concentration has been associated with beta-cell 
dysfunction, it was also measured in our study. 
!
2.2.8.3.6 Plasma Non Esterified Fatty acids (NEFA)  
Normally there is suppression of lipolysis and a reduction in plasma non 
esterified fatty acids (NEFA) following insulin secretion. In patients with 
insulin resistance there is an increase in fasting NEFA levels which is less 
suppressible to insulin and which can inhibit skeletal muscle glucose 
utilization (294).The assay for determination of NEFA is carried out using the 
Wako NEFA-C kit which relies upon the acylation of coenzyme A (CoA) by 
the fatty acids in the presence of added acyl-CoA- synthetase (ACS). The 
acyl-CoA thus produced is oxidised by adding acyl-CoA oxidase (ACOD) 
with generation of hydrogen peroxide. Hydrogen peroxide in the presence of 
peroxidase (POD) permits the oxidative condensation of 3-methyl-N-ethyl-N-
(b-hydroxyethyl)-aniline (MEHA) with 4-aminoantipyrine to form a purple 
coloured adduct which can be measured colorimetrically at 550nm. Results 
are entered into MultiCalc and calculated using a regression equation. The 
normal range for fasting NEFA is 0.1-0.6mmol/L. The CV for this assay is 
<3.0% with a sensitivity of 0.01 mmol/l.  
Insulin, proinsulin, NEFA, hsCRP and PAI-1 assays were performed by the 
Diabetes Research Unit at Swansea.  
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2.2.8.4 Markers of inflammation, adipokines and endothelial activation 
Serum was prepared by centrifugation of blood at 4000 rpm for 8 minutes 
and the samples were frozen at - 70oC until the analyses. Measurement of 
circulating sE selectin, sP selectins, adiponectin, resistin, sCD40L, vWF and 
sRAGE secretion was quantified using standard ELISA kits purchased from 
R&D systems (Wantage, UK). Briefly, the sandwich ELISA involved the 
adherence of the capture antibody, monoclonal mouse anti-human e-
Selectin, sp-Selectin, adiponectin, resistin, sCD40L, to a maxisorb 96 well 
plate (Nunc, Gibco, UK). 100µL of the capture antibody, in PBS at a 
concentration of 4µg/mL, was added to all wells of the plate, which was 
incubated overnight at room temperature. The plate was washed three times 
with PBS/0.05% Tween 20 (PBS/Tween) before the addition of blocking 
buffer (PBS/ 1% BSA) and incubation at room temperature for 1hr. After 
further washing (x3 in PBS/Tween) 100µL of samples and standards were 
added to the wells of the plate. A seven-point standard curve was 
constructed using recombinant human individual standards (R&D Systems) 
0-1000pg/mL. Each standard and sample was applied to the plate in 
duplicate. The plate was covered and incubated at room temperature for 2 
hrs before washing and the addition of 100µL of biotinylated detection 
antibody (200ng/mL in reagent diluent), the plate covered and incubated at 
room temperature for 2hrs. Following washing, 100µL of a 1/20,000 dilution 
of streptavidin-HRP conjugate (R&D systems) was added to each well and 
left at room temperature for 20 minutes, before washing and the addition of 
100µL of TMB (tetramethylbenzidine, R&D systems) substrate to each well. 
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The plate was covered and incubated at room temperature for 30 minutes. 
To each well 50µL of 1M HCL was added to stop the colorimetric reaction 
and the absorbance of each well was determined at 450nm on a 
spectrophotometer. These assays were performed at the Cardiff 
Metropolitan University clinical laboratory. All assays performed as single 
batches and all intra batch CV were < 5%.The performance characteristics 
of each of these assays are summarised in Table 2.1. 
!
!
Biochemical test characteristics 
!
!
!
!
!
!
!
!
!
!
Test Reference range Sensitivity
Adiponectin (5 –10.0)  0.989 ng/mL
Resistin (4 – 8.0)  0.055 ng/mL
sP Selectin (21-47) 0.5 ng/mL
sE Selectin (25.4–40.9) 0.027 ng/mL
sCD40L (20-700) 10.1 pg/mL 
sRAGE (pg/mL) (442-870) 16.14 pg/mL
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2.2.8.5 Measurement of platelet function 
Platelet activation was measured using a platelet chronolog aggregometer 
and through the measurement of surrogate markers including s CD40 ligand 
and vWF factor. 
!
 
!
!
!
!
!
!
!
!
Figure 2.2: Chronolog platelet aggregometer used in our study to 
quantify platelet aggregation. 
!
2.2.9 Platelet aggregation studies: 
Platelet aggregation is a term used to denote the adherence of one platelet 
to another. This phenomenon can be induced by adding aggregating agents 
to whole blood or platelet rich plasma (PRP). In this study, Platelet 
aggregation was performed on a Chronolog 900 impedance platelet 
aggregometer (Chronolog, Coulter-Beckman UK) (Figure 2.2). 
!
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The chronolog aggregometer has separate channels for quantifying: 
1. Whole blood platelet aggregation  
2. Platelet aggregation in platelet rich plasma (PRP) 
!
!
2.2.9.1 Whole blood platelet aggregation 
I measured whole blood platelet aggregation in our study. This was 
quantified by the electrical impedance method (353). Two fine electrodes are 
immersed in whole blood. Initially, a monolayer of platelets coats the 
electrodes. Addition of an aggregating agent causes additional platelets to 
adhere to the monolayer, leading to increasing electrical resistance or 
impedance between the electrodes. This increase in electrical impedance is 
converted to a DC voltage, which is recorded on a linear strip chart recorder, 
thus allowing the quantification of platelet aggregation in ohms. Whole blood 
collected in citrated vacutainer tube (Beckton Dickinson, Oxford, U.K) was 
used for the study. Blood (0.5 ml) was diluted 1:1 with phosphate buffer 
saline in siliconized cuvettes and these were placed in the heater block 
incubator wells of the aggregometer. 10µl of ADP at 0.2µM concentration 
was used to induce platelet aggregation and the maximum impedance at 10 
minutes was determined and each result is expressed as the mean of 
triplicates. 
!
!
!
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2.2.9.2 Reproducibility of platelet aggregation studies using the 
Chronolog platelet aggregometer 
!
Measurement of platelet aggregation in whole blood by the impedance 
method requires a consistent technique in conducting the tests. I myself 
performed all the platelet aggregation studies after having familiarised with 
the technique. The following results were obtained on sequential samples of 
whole blood from a healthy volunteer, using 10µl of ADP at 0.2µM as an 
aggregating agent (Table 2.1). The mean platelet aggregation was 11.6 
ohms with a variation of about 5%, which is acceptable.    
!
Table 2.1: Demonstrating reproducibility of platelet aggregation studies 
!
!
!
!
!
!
Run Platelet aggregation in Ohms
1 12
2 11.5
3 11.2
4 11.5
5 12
6 11.8
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2.3 Measurement of Arterial Stiffness 
2.3.1 Non invasive Assessment of Arterial stiffness 
There are numerous invasive and non invasive methods to assess arterial 
compliance in vivo. The invasive techniques are more accurate; however 
their widespread use is precluded in research and clinical practice. The non 
invasive methods focus on analysis of arterial waveforms, measurement of 
pulse wave velocity (PWV) and changes in the arterial diameter to 
distending pressure. We used the sphygmocorTM apparatus (AtCor Medical 
Ltd) which utilises analysis of specific components of the arterial pressure 
wave forms acquired using applanation tonometry to measure arterial 
stiffness. This involves placing a highly sensitive pressure transducer 
compressing the artery against a firm structure such as the bone. 
!
!
!  
!
Figure 2.3: Showing the use of a hand held tonometer to obtain pulse 
waves   
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The sensor is then able to detect pressure and volume changes in the 
underlying vessel to generate the peripheral arterial waveform. This 
waveform is calibrated to the conventionally measured peripheral blood 
pressure. The system software applies a validated mathematical transfer 
function to generate the central arterial waveform and measure the central 
blood pressure (158).PWA can then be performed to calculate Augmentation 
index (Aix) and the time to the reflected wave ( TR ). 
!
!
2.3.1.1 Measurement of PWV 
PWV refers to the speed with which the arterial wave travels across a 
specified distance and doppler ultrasound or applanation tonometry can be 
used to record the arterial waveform from a proximal site, e.g. the carotid 
and a distal site, e.g. the femoral artery. The arterial wave will need to 
traverse the abdominal aorta, a vessel that is prone to atherosclerosis to 
travel between these two locations. The time delay for the arrival of the 
arterial wave between the two sites can be calculated by gating to the peak 
of the ‘R, wave of the ECG or by simultaneous measurements at both sites. 
The distance between the two sites is measured and PWV is calculated as 
distance/time in metres per second. 
!
2.3.1.2 Relating changes in Arterial Diameter to distending pressure 
The change in the diameter of the artery can be related to the distending 
pressure and measured using ultrasound, less commonly MRI or 
applanation tonometry through the generation of diameter – pressure curves 
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of the common carotid artery with increasing distensibility indicating a higher 
degree of arterial stiffness. Measurement of AIx by PWA using applanation 
tonometry requires the least training and can be measured with a high 
degree of reproducibility (159), it has been shown to carry significant 
prognostic value. For these reasons, it was decided to measure PWV and 
AIx using PWA to assess arterial stiffness in the present clinical trial. 
!
2.3.1.3 Measurement of Arterial stiffness 
I performed all the measurements to avoid any intra-observer variability. 
Blood pressure was measured at the right brachial artery after 10 minutes 
rest in the seated position. Peripheral pressure waves were then captured 
from the radial artery at the wrist using a transducer connected to the 
sphygmocor apparatus. After 20 sequential waveforms had been acquired, 
with an operator quality index of over 75%, the central waveform was 
derived from an average peripheral waveform using a validated transfer 
factor (259).The AIx and central aortic pressure was derived from analysis of 
this waveform. The estimated aPWV was calculated as the time between the 
foot of the pressure wave and the first reflection point (TR). Pulse wave 
velocity (PWV) was measured by the sphygmocor system by sequentially 
recording ECG-gated carotid and femoral wave forms (for aortic PWV) and 
carotid and radial waveforms (for brachial PWV) as previously described. 
!
2.3.1.4 Reproducibility of AIx using Sphygmocor 
This was determined before commencement of the main study. Each of the 
above measurements was performed twice and averaged prior to data entry.  
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Intra-observer variability on 20 healthy volunteers was determined prior to 
study commencement. The mean difference ± SD between repeated 
measurements of the AIx was 1.5 ± 1.1 %. An example of the study visit 
case report form can be found in the appendix. 
!
2.4 Treatment assignment / randomisation / blinding 
The treatment assigned to each participant was determined according to a 
computer generated randomisation list (Microsoft XL random number 
generator) produced by an independent external pharmacist (St Mary’s 
Pharmaceutical Unit, Llanishen, Cardiff, UK). The participant packs/study 
drugs were labelled with a unique patient identification number. When a 
participant was found eligible for the study and completed all the baseline 
procedures, he/she was allocated a unique patient identification number in 
sequential, chronological order. The participant was then treated with the 
medication labelled with the same number. If a participant was withdrawn 
from the study, his or her identification number was not reallocated. All 
participants and investigators remained blind to treatment allocation for the 
duration of the study. 
!
2.4.1 Emergency procedure for unbinding 
The randomisation code for each patient was delivered to the Pharmacy 
department at the University Hospital of Wales in individual sealed 
envelopes for emergency use only. In the absence of any emergency, patient 
allocation details were kept coded and remained confidential until the trial 
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was complete. Only in the case of a serious adverse event was there a plan 
for the Investigator to open the relevant sealed envelope containing the 
patient’s treatment allocation and only if this would be of help in the 
treatment of the patient.   
!
2.5 Outcome Measures 
The primary outcome measures were defined as changes in inflammation 
and RAGE expression. Secondary outcome measures were defined as 
changes in Body composition (Waist, BMI, body fat and waist 
circumference), insulin sensitivity and β cell function, endothelial markers 
(eSelectin, p-Selectin, and vWF), adipokines, platelet function and metabolic 
profiles. 
!
2.6 Sample Size and power calculation 
Sample size advice was obtained from Dr Keith Morris, Department of 
Applied sciences, Cardiff Metropolitan University. The main outcomes of this 
study were based on the known ability of CLA to regulate NF-κB activity and 
hence NFκB genes, in this case the main outcome was to investigate for the 
first time CLA modulation of RAGE expression. No previous data from 
human studies was available on CLA regulated RAGE expression, however, 
laboratory based studies at Cardiff Metropolitan University, suggested that 
incubation of human monocytes with Conjugated linoleic Acid at 
physiological concentrations, resulted in at least a 28% reduction in surface 
RAGE expression in these cells (295). Based on this estimate it was 
calculated (paired t-test, a required power of 95% and a significant value set 
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at 0.05) that this study required a sample of at least 7 subjects in each 
group. We however felt that this small sample would be better adjusted to at 
least 20 in each group, to take into account for subject loss during the study 
period. Precise estimates of the actual power are not readily available for 
cross-over studies such as this. Twenty nine subjects completed the 
treatment and one withdrew from the study. 
!
2.7 Statistical methods 
All statistical analyses were performed using Minitab version 16. All analyses 
were performed as per pre-established protocol and in line with previous 
guidance on analysis of crossover trials (267 -271) and described in detail in 
chapter 3. 
!
2.8 Procedures and Instructions 
2.8.1 Adverse Event Reporting 
Information about all non-serious and serious adverse events (SAEs), 
irrespective of causality, whether volunteered by the subject, discovered by 
investigator questioning, or detected through physical examination, 
laboratory test or other means, was collected and recorded. An adverse 
event was defined as any undesirable sign, symptom or medical condition 
occurring after starting the study treatment. Study treatment included the 
study drug under evaluation (9, 11 CLA isomer or CLA mixture) given during 
any phase of the trial. Medical conditions/diseases present before starting 
the study were only considered adverse events if they worsened after 
starting the study drug.  
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Abnormal laboratory values or test results constituted adverse events only if 
they induced clinical signs or symptoms or required therapy, or were 
considered clinically significant for any reason, in which case they were 
recorded. Where possible, each adverse event was also described by: 
1. Its duration 
2. The severity grade (mild, moderate, severe) 
3. Its relationship to study drug (suspected, not suspected) 
4. The action(s) taken 
!
2.8.2 Safety Results 
 Overall the study medication was well tolerated. Four adverse events were 
reported during the course of the study (nausea, flare up of gout, 
thrombophlebitis & uveitis), which were mild and self-limiting. One subject 
decided to withdraw from the study due to work commitments and a 
standard protocol was adhered to. Periodic safety reports were provided to 
all regulatory authorities. 
!
2.8.3 End of study Unblinding 
After completion of the final subject’s final visit, a complete electronic 
database was created which contained all the data collected on vascular, 
anthropometric and metabolic parameters. A copy of the database was 
supplied on a CD-ROM to a research governance officer from Cardiff and 
vale NHS trust who undertook a final study closure inspection and confirmed 
source verification of the data. The pharmacy department was then given 
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permission to release the randomisation codes so data analysis could be 
performed. 
!
2.8.4 Project Management and Administrative Procedures 
I was responsible for the day-to-day conduct of the study and co-ordinated 
recruitment, obtained consent, performed the blood sampling and measured 
pulse wave velocity and augmentation index in the study participants. A 
formal meeting took place on a monthly basis with Dr Marc Evans, the 
principal investigator, to discuss all aspects of the study and to plan the work 
for the forthcoming week. Informal discussions regarding any difficulties that 
arose with the project also took place as required. Source data verification 
was undertaken by Dr Marc Evans at regular intervals who cross-checked all 
data entries for the final dataset before study closedown; the data were 
stored securely on the Trust shared drive with daily back up. A copy of this 
was taken on CD by the Sponsor as evidence of the final data before 
permission was granted for release of the randomisation codes.  
!
2.8.5 Auditing Procedure 
As part of Good Clinical Practice, the study protocol and all documentation 
were closely monitored. The study was conducted as outlined in the study 
protocol and in accordance with all applicable government regulations. All 
study documentation was made available for inspection at any time by 
appropriate regulatory authorities. 
!
!
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!
!
CHAPTER 3 
!
!
!
!
!
!
A randomised, double blind, crossover study of the 
effects of CLA isomers on body composition, metabolic 
profiles, inflammation and vascular function in patients 
with the Metabolic Syndrome – Results 
!
!
!
!
!
!
!
!
!
!
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3.1 Overview  
There is a reasonable body of work that suggests that CLA and its isomers 
may have beneficial effects on adipose tissue, inflammation, vascular 
function and metabolic profiles (230-235). IR plays an important role in the 
pathophysiology and therefore subjects with the metabolic syndrome provide 
a particularly good model in which to examine the impact of CLA 
replacement. 
!
To date, a majority of the studies that investigated the effects of CLA have 
utilised animal and tissue culture systems and models. Inconsistencies and 
contradictions have occurred when attempting to reproduce beneficial 
results in human trials. The doses used in animal studies are much higher 
compared to those used in clinical trials and these studies fail to account for 
any in vivo co-activating or co-suppressing interactions. It is therefore not 
always possible to compare and extrapolate results from in vitro and in vivo 
studies. For these reasons it becomes necessary to confirm or refute any in 
vitro observations in vivo.  
!
There have been a number of human studies that examined the effects of 
CLA, however most of these studies were limited by their numbers and 
duration of treatment and in the variables studied. Furthermore, the 
inconsistencies observed in subject based clinical trials may be a feature of 
the sheer variety of CLA doses used in these studies and most studies 
investigating CLA have used a mixture of predominantly 9:11 CLA and 10:12 
CLA which is not typical of ruminant derived dietary CLA, primarily because 
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the individual CLA isomers are costly and difficult to purify. To our 
knowledge, this is the first study to prospectively test the effect of these 
isomers on sRAGE expression in a randomised, double-blind, crossover 
design. We chose a crossover design because a substantial within-subject 
correlation was anticipated, such that smaller sample sizes would be 
required to detect significant differences, and used a washout period of six 
weeks to minimise the potential for a carry over effect, which was not evident 
in this study. This chapter aims to describe the results obtained from a 
clinical trial analysing the effects of CLA and its isomers on inflammation, 
vascular function, body composition and metabolic profile in subjects with 
the metabolic syndrome. The primary outcome measure for this study was 
changes in measures of RAGE expression. The secondary outcome 
measures were to evaluate the effects of CLA therapy on anthropometric 
measures of body composition (Weight, BMI, and fat percentage and waist 
circumference) and adipocytokines, changes in markers of arterial stiffness 
(AIx, BP, bPWV and aPWV), endothelial and platelet function and metabolic 
profiles (lipids, homeostasis model of assessment for insulin resistance). 
!
One hundred and thirty two patients from the diabetes clinics at the 
University Hospital of Wales and University Hospital Llandough were 
screened for trial eligibility of whom seventy one patients fulfilled the 
inclusion criteria. Of these, thirty patients consented to trial participation and 
were eventually randomised. One subject failed to attend the final study visit 
due to work commitments. Twenty nine patients completed the study and 
data on these patients are presented. 
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!
3.2 Patient flow 
!
Figure 3.1 Flow of participants through each phase of the study 
  
!
 
 
!  
!
!
 
!
 
!
 
!
!
!
Randomized (n=30)
CLA 9, 11   
(n=15)
Met inclusion criteria (n=71)
Refused/could not be contacted (n=41)
CLA mixture  
(n=15)
!  129
Screened for eligibility n=132 
Inclusion criteria 
Aged 18 to 75 years 
CLA 9, 11 
(n=15)
CLA mixture 
(n=14)
End of study analysis (n=29)
Excluded (n=61)
Discontinued (n=0) Discontinued (n=1)  
 Due to non-attendance
!
3. Safety, tolerability and compliance !!
Overall the study medication was well tolerated. Four adverse events in 
different patients were reported during the course of the study (nausea, flare 
up of gout, thrombophlebitis & uveitis), which were mild and self-limiting and 
probably unrelated to CLA treatment. 
!
A summary of the adverse events is provided in table 3.1  
!
!
!
Table 3.1   Adverse events recorded during the study 
!
!
4. Statistical Rationale !!
All Statistical analyses were performed using Minitab version 16 (Havertown, 
Pa). All analyses were performed in line with previous guidance on analyses 
of cross over trials as recommended by Altman and others (270-273). Each 
patient received a treatment at a specific time point (period one), and then 
AE 
number
Patie
nt 
 ID
Descripti
on  
 
Start 
date
Finish 
Date
Outco
me
Intensi
ty
Expectedne
ss
Causality Seriousne
ss
1 7 Nausea 
and 
headache
29/01/
07
29/01/
07
Resolv
ed
Mild Unexpected Not 
related
Not 
Serious
2 11 Thrombop
hlebitis at 
venflon 
site
28/04/
07
30/04/
07
Resolv
ed
Mild Expected Not 
related
Not serious
3 35 Uveitis 18/02/
08
20/02/
08
Resolv
ed
Mild Un expected Not 
related
Not serious
4 37 Flare up of 
Gout
09/01/
08
10/01/
08
Resolv
ed
Mild Unexpected  Not 
related
Not serious
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crossed over to receive another treatment at another time point (period 
two). The subjects in this study were randomly allocated into two groups so 
that half (n=15) received the treatments in the order (9, 11 CLA) (period 
one) and then the CLA mixture (period two), while the other half (n=14) 
received treatments in the reverse order, that is, CLA mix followed by 9, 11 
CLA with an intervening wash out period. The effects of the treatments were 
then compared in the same person during the different treatment periods. 
The benefit of using this design is primarily through eliminating the variability 
between the patients, since each person acts as their own control. In 
addition, such a within-subjects comparison of treatments is regarded as 
being more sensitive than between-subject comparisons and consequently, 
the sample size needed for the study is smaller (270-273).  
!
However in a crossover trial, there may be some systematic differences 
between the two periods regardless of the treatment which is termed as a 
period effect. Furthermore, there may be a carry-over of treatment effect 
from one period to the next and in the presence of significant period effects 
or a treatment – period interaction, the data from the second period may 
have to be discarded. If there is no period effect and no treatment-period 
interaction the analysis of a crossover trial is simple.  
!
“Pre statistical” analyses were used to determine whether there were any 
period effects or treatment-period interaction as a result of the crossover 
design. This analysis was simplified by calculating the absolute change for 
each marker tested (mean value at baseline subtracted from the mean value 
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at the highest dose of each isomer for each subject) and testing differences 
between periods with use of two sample t tests or Mann-Whitney test 
comparing the medians. Analyses of the results in this crossover study did 
not reveal any significant period or interaction effects in relation to any of the 
parameters measured.  In addition, a two sample‘t’ test or Mann-Whitney 
test compared the means or medians of within subject differences to 
measure the treatment effects.  
!
Patients were thus randomised into two groups: 
(Group A) - Participants treated with 9, 11 CLA (period 1) initially followed by 
CLA mix (period 2). 
(Group B) - Participants treated with CLA mix (period 1) followed by 9, 11 
CLA (period 2). 
!
Figure 3.2   Analysis utilised the following model 
!
 
 
9:11 CLA  !
 
 
 
 !
!
Period I A (P 1A) – 9, 11 isomer, Period 2A – CLA mix, Period 1B – CLA mix, 
Period 2B – 9, 11 isomer. 
!
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Group B Group A
P2ACLA Mix
Group BGroup A
 P1A
P1B
P2B
:  LA 9:11 CLA
CLA Mix 
3.5 Baseline Demographic and Anthropometric Characteristics !
Twenty nine of the 30 subjects completed the study. Compliance was 97 % 
(capsule count) with no differences between the groups. The treatment was 
well tolerated with no major side effects. During the trial, the subjects were 
advised to continue with their usual medications and I did not record other 
variables including smoking status and dietary habits which could have an 
impact on the various parameters measured. However the crossover nature 
of the study ensures minimal variability, as each participant served as his 
own control. 
Table 3.2 Comparison of Baseline demographic and anthropometric data 
Values are expressed as mean (SD) and when indicated as median and 
range. 
The baseline characteristics indicate that the study cohort was 
representative of the general population with the ms, with a mean BMI in the 
overweight range and associated with an increased mean waist 
circumference. The mean age of the subjects were 51 years in group A and 
53 years in group B. There were no significant baseline differences in body 
composition between the two treatment groups (Table 3.2). 
Characteristic Group A(n=15) 
Mean (±SD)
Group B(n=14) 
Mean (±SD) 
‘p’ Value
Age(Yr) 51.5(8.5) 53.7(8.4) 0.48
Wt(kg) 87.2(3.6) 88.9(4.7) 0.78
BMI(kg/m 31.1(3.6) 29.1(3.8) 0.42
Body fat (%) 35.9(8.3) 33.4(5.5) 0.35
Waist 
Circumference(cm)
105.3(3.8) 103.4(5.1) 0.64
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3.6 Baseline Vascular Parameters of Study participants !
Table 3.3 summarises the baseline vascular parameters for the study 
population. The blood pressure for our study population was in the 
hypertensive range as would be expected with these subjects.   
Table 3.3    Baseline vascular markers for the study population 
!
*Indicates Median and Inter Quartile Range and comparison using Mann- 
Whitney test. 
Characteristic Group A (n=15)  
Mean (±SD)
Group B (n=14)  
Mean (±SD) 
‘p’ Value
Peripheral DBP(mm Hg) 92.3(9.4) 93.9(9.5) 0.65
Peripheral SBP(mm Hg) 130.9(14.2) 139.8(11.5) 0.09
Central DBP(mm Hg)  92.3(9.4)      96(11.7)       0.35
Central SBP(mm Hg) 124.4(12.3) 128.2(11.4) 0.39
AIx (%) 20.2(6.8) 21.2(10.9) 0.78
bPWV(m/sec) 8.5(1.2)     8.6(2.2)      0.85
aPWV(m/sec) 9.0(1.3)     9.0(1.5)    
       
0.88
TR(m/sec) 142.2(12.2)      145.0(10.9)      
 
0.51
sE- selectin(ng/ml) 71.37(30.63) 70.1(35.33) 0.90
sP- selectin(ng/ml) 7.59(2.51) 7.66(2.07) 0.93
vWF(ng/ml) 133.2(23.9) 136.9(29.2) 0.65
sCD40L(ng/ml) 1277(875-1674) * 915(859-971)* 0.64
Platelet aggregation(ohms) 16.9(4.1) 17.1(3.9) 0.88
hsCRP(mg/litre) 1.48(1.3) 2.49(1.6) 0.37
sRAGE(pg/ml) 699.1(220.5) 788.4(223.1) 0.21
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The baseline Augmentation index (AIx) in our study population at baseline 
ranged between 20 % and 21 % compared with a value of 18 % for a similar 
mean aged population. The reference values for Aix using the sphygmocor 
apparatus have been provided by the manufacturer and available at http://
atcormedical.com. There were no statistically significant differences in 
vascular parameters at baseline between both the groups. 
3.7 Baseline Adipokines and Metabolic Parameters (Table 3.4) 
   
 * Indicates Median and Inter Quartile Range and comparison using Mann 
Whitney test.   
Characteristic Group A (n=15) 
Mean (SD)
Group B (n=14) 
Mean (SD)
‘p’ Value
Insulin(pmol/litre)  101 (30.4-141.7)* 71.3 (6.7-119.0)* 0.42
Proinsulin(pmol/litre)  5.6(3.7) 3.7(3.0) 0.35
NEFA(mmol/L)  0.19(0.2) 0.5(0.5) 0.64
Fasting glucose (mmol/L)  6.05 (0.7) 5.6(0.8) 0.17 
HOMA-IR  32.9(25.5) 25.8(21.2) 0.11
HOMA-B  806 (425-1134)* 413 (215-1326)* 0.36
TC(mmol/litre)  5.4(1.18) 5.4(0.96) 0.85
HDL(mmol/litre)  1.09(0.22) 1.07(0.27) 0.87
LDL(mmol/litre)  3.2(0.96) 3.2(1.15) 0.86
Triglycerides(mmol/litre)  2.7(1.55) 2.4(1.28) 0.58
Adiponectin(ng/ml) 6.2(2.66)     4.4(2.78)    
  
0.19
Resistin(ng/ml) 3.2(1.32)     3.7(2.02)    
  
0.45
PAI-1(ng/ml) 2.7(1.02) 3.6(1.47) 0.15
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!
The data in Table 3.4 shows there were no statistically significant differences 
between the groups at baseline as shown by the ‘p’ values. 
!!
8. Summary of Results !!
3.8.1 A crossover design to investigate the differential effects of the 9, 
11 CLA isomer and CLA mixture 
!
A crossover design has the ability to identify differences between the two 
treatments. The first part of the analysis was therefore to compare the 
effects of the 9, 11 CLA isomer and the CLA mixture on both primary and the 
secondary end points.  
!
Analyses of the results in this crossover study did not reveal any significant 
period or interaction effects in relation to any of the parameters measured. 
As previously stated, in the absence of an interaction, a patient’s average 
response to the two treatments is considered to be the same regardless of 
the order in which they were received (270-273). Consequently, the analysis 
of the data was undertaken to identify any treatment effects i.e. differences 
in overall response associated with one treatment in comparison to the 
other.  
!
A negative mean difference in outcomes was suggestive of a 9:11 isomer 
mediated effect and a positive mean difference indicates that the effects are 
primarily associated with the CLA mixture (270-273). 
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3.8.1.1 Effects on primary end points – (Inflammation and sRAGE 
expression, endothelial markers, platelet function) 
A summary of the effects on Primary outcomes for the study is given in Table 
3.5.  
Table 3.5 Changes in sRAGE, Inflammation, Endothelial & Platelet function 
(Comparing 9, 11 isomer Vs CLA mix)  
† - denotes a significant effect 
A negative mean difference = Effect mediated by 9,11 CLA 
A positive mean difference = Effect mediated by CLA mixture 
From these results it is apparent that the two treatments did not significantly 
differ with regards to circulating sRAGE levels and markers of endothelial 
function. However, the results for platelet aggregation were significant 
(‘p’=0.01) and these are shown to be mediated by the CLA mix in 
comparison to the 9, 11 isomer. This was somewhat surprising as it was not 
associated with any changes in surrogate markers of platelet function such 
as sCD40L or sP-selectin levels or measures of endothelial function (sE-
selectin, vWF).  
Variable Mean Difference  
(period1 – period 2)
95% CI for the     
difference
‘p’-value
sRAGE (pg/ml) -22 -308, 264 0.87
hsCRP(mg/litre) 2.1        -3.2, 4.4 0.37
sE-Selectin(ng/ml) 5.6 -11.5, 22.7 0.56
sP-Selectin(ng/ml) 0.1 -1.7, 1.9 0.90
vWF(ng/ml) 1.6    -22.3, 25.4 0.89
sCD40L(ng/ml) 95          -716, 606 0.81
Platelets Aggs(ohms) 2.8         0.6, 5.0 0.01†
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3.8.1.2 Effects on Secondary outcome measures 
3.8.1.2.1 Changes in Vascular Outcomes of the study cohort  
Table 3.6 summarises the vascular outcomes for the crossover cohort. The 
results demonstrate a significantly enhanced treatment effect for peripheral 
SBP (‘p’=0.04) and aortic PWV (‘p’=0.01) and the negative value of the 
mean difference would suggest that these effects are mediated by the 9:11 
CLA isomer. There was however no changes observed with peripheral or 
central diastolic BP, central systolic BP, AIx or TR suggesting that wave 
reflection is not significantly affected. 
Table 3.6 Effect of 9, 11 isomer Vs CLA mix on Vascular Outcomes in 
subjects with the metabolic syndrome 
† - denotes a significant effect 
A negative mean difference = Effect mediated by 9,11 CLA 
A positive mean difference = Effect mediated by CLA mixture 
Variables Mean Difference 
(period1 – period 2)
      95% CI  
for the difference
p-value
P-SBP (mm Hg) -8.50   -16.6, - 35 0.04† 
S-DBP (mm Hg) -1.25     -7.61, 5.12 0.68 
C-DBP (mm Hg) -2.35     -7.85, 3.14 0.38 
C-SBP (mm Hg) -5.33    -12.51, 4.84 0.13 
AIx (%) -1.05     -6.88, 4.78 0.70 
aPWV(m/s) -0.81      -1.47, -0.14 0.01†  
bPWV(m/s) -0.03       -0.47, 0.55 0.88 
TR -1.64    -6.89, 3.61 0.52 
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3.8.1.2.2 Changes in Body Composition, Lipids and Adipokines for the 
crossover cohort 
The results summarised in table 3.7, demonstrates a significant beneficial 
effect on HDL levels (‘p’=0.03) which are shown to be mediated by the 9:11 
isomer as suggested by the negative value of the mean difference. 
Furthermore, treatment with the CLA mixture significantly increased 
adiponectin concentrations (‘p’=0.01). These changes were however not 
associated with significant changes in body composition or other lipid 
parameters or  adipokines. 
Table 3.7 Changes in Body composition, Lipid profiles and Adipokines (9, 11 
isomer Vs CLA mix) 
† - denotes a significant effect  
A negative mean difference = Effect mediated by 9, 11 CLA 
A positive mean difference = Effect mediated by CLA mixture 
Variables   Mean Difference 
(period1 – period 2)
95% 
CI  for the             
difference
p-value
BMI(kg/m -0.11 -0.83,0.61 0.75
WC(cm) -0.66       -3.88,2.57 0.67
TC(mmol/litre) 0.001   -0.59,0.59 0.99
HDL(mmol/litre) -0.12    -0.26,0.00 0.03†
LDL(mmol/litre) -0.59      -0.05,1.23 0.06 
Triglycerides(mmol/litre) -0.63  -1.99,0.72 0.33
Adiponectin(ng/ml) 1.43 0.253,2.62 0.01†
Resistin(ng/ml) -0.20    -0.62,-0.20 0.31
PAI-1(ng/ml) 0.69      -0.84,2.23 0.35
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3.8.1.2.3 Changes in Insulin Sensitivity and β cell function (9, 11 
isomer Vs CLA mix) 
This study also measured fasting glucose, insulin, proinsulin and NEFA 
levels at baseline and following the treatment periods during this crossover 
study in a sub-section of our patient cohort. The proinsulin / insulin ratio’s, 
NEFA and calculated HOMA– B values were used as surrogate measures of 
β cell function and HOMA– IR was used as a marker of insulin sensitivity. 
!
Table 3.8 Effects of CLA on Insulin sensitivity and β-cell function (9, 11 
isomer Vs CLA mix) 
!
† - denotes a significant effect 
A negative mean difference = Effect mediated by 9,11 CLA 
A positive mean difference = Effect mediated by CLA mixture 
Variables Mean Difference 
(period 1- period 2)
        95% CI  
for the difference
p-value
Insulin(pmol/L) 
Grp A (n=10) 
Grp B (n= 9)
-122     -221,76.8 0.20
Proinsulin(pmol/L) 
Grp A (n=10) 
Grp B (n= 9)
-7.03    -19.31,5.24 0.23
NEFA(mmol/L) 
Grp A (n=10) 
Grp B (n= 9)
-0.09   -0.97,0.78 0.82
FPG(mmol/L) 
Grp A(n=15) 
Grp B (n=14)
0.15    -0.770,1.08 0.72
HOMA-IR 
Grp A (n=10) 
Grp B (n= 9)
919       -1263,3102 0.36
HOMA-B 
Grp A (n=10) 
Grp B (n= 9)
2728      1008,4448 0.004†
Pro ins / Ins Ratio 
Grp A (n=10) 
Grp B (n= 9)
-0.13 -0.781,0.521 0.65
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Insulin sensitivity and β-cell function data are presented in Table 3.8. A 
solitary significant CLA mixture mediated effect was observed for HOMA-B. 
However, the changes seen in HOMA-B levels should be interpreted with 
caution given the wide confidence intervals evident and the relatively small 
sample size. 
!
3.8.2  Combined Effects of 9, 11 CLA / CLA mix treatment on primary 
and secondary outcomes (Comparison between Baseline values and 
End of treatment) 
!
This study utilised a cross-over design with no placebo component to the 
study. Furthermore, no significant differences at baseline, period or carry 
over effects between the two groups were observed and a relatively small 
number of significant outcomes reported (peripheral SBP, aPWV, HDL-
cholesterol, adiponectin, platelet aggregation and HOMA B).These 
significant results were found to be mediated by either the 9,11 isomer or 
with the CLA mixture that contained 50% of 9,11 CLA. 
!
 Essentially this part of the study did not suggest any clear overall benefits to 
the use of the expensive and difficult to obtain 9,11 isomer over the CLA 
mixture. However, it was also thought expedient to investigate if combining 
the data from both groups (for which no baseline differences were reported)  
and comparing the outcomes at baseline and at the end of the 16 weeks of 
treatment. Therefore, further analysis of the samples were undertaken to 
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investigate the overall effects of 9, 11 CLA / CLA mix using a paired‘t’ test. 
This was undertaken specifically because of:- 
!
1: The similar baseline characteristics of the sample. 
2: The similarity of the treatments and their likely mode of action and with no 
period or carry over effects observed during the cross-over phase. 
3:To investigate the combined effect of the treatment over the 16 week 
period on the larger sample of 29 subjects. 
!
Comparing the baseline parameters with the end of the treatment phase has 
a number of analytical advantages as it involves increased numbers of 
subjects and entails paired analysis with its enhanced ability to 
detect overall significant differences between the baseline and the end of the 
intervention period. 
The combined results for the entire cohort are presented in the following 
tables. 
!
3.8.2.1 Effects of 9, 11 CLA / CLA mix on inflammation and Vascular 
outcomes – Paired test comparing baseline values with end of 
treatment (visit 4) (Table 3.9) 
Treatment with 9, 11 CLA / CLA mix significantly improved aPWV. This was 
accompanied by a lowering of blood pressure along with significant changes 
in circulating sRAGE, markers of endothelial (sE selectin, vWF) and platelet 
function (sP-Selectin, sCD40l). 
!
!  142
Table 3.9 - Results of Vascular Outcomes for the entire study cohort 
!
!
† - denotes a significant effect 
!
!
Variables Mean Difference 
(visit 4 – visit 1) 
      95% CI  
for the difference
‘P’-value
P-SBP(mm Hg) 0.14   -4.16, 4.44 0.94 
P-DBP(mm Hg) -3.14   -6.38, -0.10 0.05
C-SBP(mm Hg) -3.60   -7.32, 0.12 0.05
C-DBP(mm Hg) -4.22   -8.24, 0.20 0.04†
AIx (%) -0.79   -3.38, 1.80, 0.53
aPWV(m/s) -0.63   -1.02, 0.22, 0.003†
bPWV(m/s) -0.27   -0.60, 0.05 0.10
TR -2.71   -5.91,-0.49, 0.09
sE- selectin(ng/ml) -13.3   -23.8, 2.78 0.01†
sP- selectin(ng/ml) -1.43    -2.2, 0.58 0.002†
vWF(ng/ml) -16.1  -29.2, 3.33, 0.01†
sCD40L(ng/ml) -362   -704, 21, 0.03†
Platelet aggs(ohms) -1.52  -3.05, 0.00 0.05
hsCRP(N=16) -1.76  -4.94, 1.43 0.23
sRAGE(pg/ml) 320   511, 129 0.002† 
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Figure 3.3 Effect of 9,11CLA / CLA mix treatment on aPWV and bPWV (Visit 
1 – Baseline, Visit 4 - Post treatment)  
!  
Figure 3.4   Changes in BP following treatment with 9, 11 CLA / CLA mix in 
the metabolic syndrome 
!  
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3.8.2.2 Changes in Body Composition, Lipids and Adipokines for the 
entire cohort (comparison between baseline data with end of visit 4)  
!
(Table 3.10) - Effect of 9, 11 CLA / CLA mix therapy on Body Composition, 
Lipids and Adipokines in subjects with the metabolic syndrome. 
!
!
†- denotes a significant effect 
!
!
!
!
!
Variables Mean Difference 
(visit 4 – visit 1)
        95% CI  
for the difference
p-value
BMI -0.68 -1.03,0.34, 0.005†
Body fat (%) -1.28 -2.86,0.28, 0.10
WC(cm) -1.31 -3.32,0.70, 0.19
TC(mmol/litre) -0.05 -0.37, 0.26, 0.73
HDL(mmol/litre) 0.04 -0.01, 0.09 0.15
LDL(mmol/litre) -0.25 -0.63, 0.12 0.17
Triglycerides(mmol/
litre) 
0.21 -0.14, 0.57 0.22
Adiponectin(ng/ml) 0.90 -0.34,1.46, 0.003†
Resistin(ng/ml) -1.07 -1.61, 0.52 <0.0005†
PAI-1(ng/ml) 1.20 -0.31, 2.71, 0.10
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Figure 3.5 Effect of 9, 11 CLA / CLA mix therapy on lipid profiles in subjects 
with the metabolic syndrome (Visit 1 – Baseline, Visit 4 - Post treatment) 
!  
Figure 3.6 Effect of 9, 11 CLA / CLA mix on Adipokines (Visit 1 – Baseline, 
Visit 4 - Post treatment) 
!  
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!
Table 3.11 Effects of 9, 11 CLA / CLA mix on insulin sensitivity and β-cell 
function (Comparing baseline data with end of treatment values) 
!
!
There were no significant changes observed in measures of either insulin 
sensitivity or β cell function following treatment with CLA 9, 11 CLA / CLA 
mix. 
!
!
!
!
!
!
!
!
Variables Mean Difference 
(visit 4 – visit 1)
      95% CI  
for the difference
p-value
Insulin(pmol/L) 18.2 - 59.5, 95.8 0.63
Pro insulin(pmol/L) -5.07 - 0.88, 11.0 0.09
NEFA(mmol/L) -0.21 - 0.66, 0.24 0.34
FPG(mmol/L) -0.02 - 0.47, 0.43 0.92
HOMA-IR -13.3 - 42.3, 15.7 0.35
HOMA-β -434 - 1404, 535 0.36
Pro ins / Ins ratio -0.09 - 0.39, 0.21 0.53
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3.9 Correlation Analysis for the Combined Data 
Table 3.12 Pearson’s Correlation coefficients for the change in sRAGE 
versus selected vascular and metabolic parameters investigated, the 
correlation coefficient is given with the significance in brackets. 
!
Analysis of the data shows that sRAGE did not significantly correlate with 
any of the parameters analysed.  However the numbers of subjects are 
small and must be taken into account when interpreting the correlation data.  
variables diff s RAGE 
diff aPWV -0.045, 
 0.812
diff e-Selectin  0.247 
 0.196
diff vWF -0.090 
 0.641
diff sCD40L  0.058 
 0.767
diff WC -0.209 
 0.275
diff HOMA-IR -0.230 
 0.315
diff HOMA-B -0.420 
 0.065
diff Hdl -0.097 
 0.616
diff LDL  0.200 
 0.297
diff adiponectin -0.035 
 0.862
!  148
!
Further statistical extrapolation of the inter-dependence of these variables 
was not undertaken in view of the small numbers. However, the lack of 
significant correlations demonstrated herein, would support further analysis 
through multi regression methods and this is presented in 3.10 below. 
!
3.10 Regression Analysis for the Combined Data 
One of the reasons for undertaking the statistical analysis of such as that 
gathered in this study is to describe relationships between the variables for 
which data has been collected. To investigate which variables investigated 
as part of this study could act as predictors of the significant change in 
aPWV regarded as the dependant variable and sRAGE observed after 9:11 
isomer / CLA treatment, a stepwise regression analysis was undertaken. 
This method involves selecting predictor or predictive variables using an 
automatic procedure that takes the form of a sequence of F-tests or 
alternatively t-tests. Since the significant predictors of the difference in 
aPWV between baseline and end of study were being investigated, likewise 
the predictor variables used were also the differences between visit 1 and 
visit 4. 
The stepwise regression analysis undertaken here demonstrated that the 
only two predictors, namely the difference in Sp-Selectin and difference vWF 
identified as being significant in predicting the improvement in aPWV due to  
9:11 isomer / CLA mix treatment in this metabolic group during the study 
period analysis. The regression equation describes the relationship between 
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the two dependant variables and the explanatory variables selected by the 
stepwise regression. The regression equation is aPWV = 1.14 - 0.141  
Sp-Selectin - 0.00931 vWF. Analysis of variance ANOVA confirmed that this 
relationship was significant (p=0.037)  
!
Table 3.13 Regression analyses of aPWV vs difference Sp-Selectin and 
vWF. 
 
!
!
!
!
!
!
!
!
!
!
For the increase in sRAGE observed after treatment with CLA, the sole best 
predictor selected by stepwise, was the difference in HOMA-IR observed 
during the study period and the regression equation is:- diff sRAGE = - 472 - 
0.117 diff HOMA IR. Analysis of variance ANOVA confirmed that this relationship 
was significant (p=0.041) and the regression analysis is presented in Table 
3.14 
!
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!
aPWV   = 1.14 - 0.141 Sp-Selectin - 0.00931 vWF !
Predictor              Coef   SE      Coef      T       P 
Constant             1.1407    0.2531   4.51    0.000 
Diff Sp Selectin      -0.14073    0.07861   -1.79   0.041 
DIFF vwf_1        -0.009313   0.005936   -1.57   0.086 !!
R-Sq = 17.9%   R-Sq(adj) = 13.6% !!
Analysis of Variance !
Source          DF       SS       MS                F            P 
Regression       2    4.8613    2.4307   2.84   0.037 
Residual Error    26   22.2723   0.8566 
Total           28   27.1336 !
!
!
Table 3.14 Regression analysis of sRAGE vs difference in HOMA-IR 
 !!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
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!
diff sRAGE = - 472 - 0.117 diff HOMA IR !!
Predictor         Coef         SE Coef          T        P     
Constant       -471.9    122.9  -3.84  0.001 
diff HOMA IR  -0.11676  0.05953  -1.96  0.045   !!
S = 537.482   R-Sq = 17.6%   R-Sq(adj) = 13.0% !
Analysis of Variance !
Source                 DF       SS             MS          F          P 
Regression       1   1111538   1111538 3.85 0.045 
Residual Error    18   5199972   288887 
Total           19   6311511 
3.11 Discussion 
Although a number of in vitro and in vivo studies have examined the anti 
obesity and metabolic effects of conjugated linoleic acid, to my knowledge 
this is the first study to prospectively study the effects of CLA isomers on 
sRAGE expression in subjects with the metabolic syndrome. 
!
A crossover design was chosen because a substantial within-subject 
correlation was anticipated such that small sample sizes would be required 
to detect significant changes and this study used a washout period of 6 
weeks to minimise any carry over effects. 
!
Furthermore, differences in the characteristics of the two major isoforms of 
CLA (9:11 and 10:12) have also been reported with some evidence of non-
beneficial effects observed with 10:12 CLA supplementation (262). Hence, 
this study initially investigated the 9:11 isomer in comparison with a 50:50 
mixture of 9:11 and 10:12 isomers in a cross-over design. 
!
Detailed analysis of the cross-over study in relation to SBP, aPWV and HDL 
and suggested that differences observed with regards to these parameters 
were associated with the 9:11 isomer. These lipid and vascular effects 
associated with the 9, 11 isomer are supported by previous published 
studies (91, 95,103,104,105) and it has been proposed that they are 
features of the ability of 9:11 isomer to act as a ligand of the PPARα 
receptor. 
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!
On the other hand the CLA mix was shown to increase adiponectin and 
HOMA-B levels. This could partly be mediated by the effects of the 10, 12 
isomer which constitutes 50% of the CLA mixture. The 10, 12 CLA isomer 
has been shown in previous studies to be responsible for weight loss and 
consequently changes in adipokines which are believed to be mediated 
through their effects on PPAR γ receptors (93, 94, and 98). 
!
The results from the crossover study however showed no significant 
differences between the effects of either the 9, 11 isomer or the CLA mix with 
regards to the other outcomes. This could partly be explained by the small 
sample size, relatively short duration of treatment and that the sample size 
was chosen to primarily observe changes in sRAGE expression. Both the 
treatments were however well tolerated and did not demonstrate any 
adverse outcomes. 
!
The study initially investigated the differences in the outcomes of the 9,11 
and CLA mixture using the cross-over design. However, there was a lack of 
substantial differences in the two treatments and also an inconsistency in 
specifying these differences to a specific isomer. There is also a similarity in 
the actions of the treatments and therefore a further sub-analysis of the data 
was undertaken. This sub-analysis involved combining the two groups and 
analysed the differences in baseline data and the results at the end of the 
treatment period. This sub-analysis was specifically undertaken to determine 
if there was an overall effect on the two groups of the treatment with the 
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lipids after the sixteen weeks of treatment. It could be argued legitimately 
that the presence of the wash-out period required that the analysis should 
have two baselines and hence four analytical stages. However, it could also 
be argued that the subjects received an overall treatment of 16 weeks and 
hence two analytical points were selected, namely, baseline and the final 
end of treatment for the combined groups. The results from the combined 
data revealed a number of beneficial treatment effects as discussed below. 
!
Low grade inflammation has been demonstrated to be associated with IR 
and CVD and is proposed to be a useful clinical marker of CVD risk (296, 
297). Inflammation is believed to be responsible for the development of the 
many complications of the metabolic syndrome including atherosclerosis 
(298). The increased vascular risk associated with the metabolic syndrome 
may be partly initiated by glycated protein binding to their receptor RAGE, 
which through a series of complex reactions induces secretion of 
inflammatory cytokines which activates key cell signalling pathways both in 
endothelial (201) and vascular smooth muscle cells (202). Activation of the 
NF-κB together with an altered platelet metabolism and changes in intra 
platelet signalling pathways, contributes to the pathogenesis of 
atherothrombotic complications in these subjects (203). Recently it has been 
reported that human vascular cells express several RAGE variant proteins, 
including three novel human RAGE transcripts (308), all encoding truncated 
soluble forms of RAGE (sRAGE), consisting of only the extracellular ligand 
binding domain and lacking the cytosolic and transmembrane domains. 
Soluble RAGE (sRAGE) lacks the ability to activate the key signalling 
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pathways and therefore sRAGE has recently emerged as a biomarker in 
several RAGE-mediated vascular disorders, including coronary artery 
disease, diabetes and hypertension (309). Falcone and colleagues also 
showed that endogenously lower levels of sRAGE were associated with 
enhanced risk of coronary artery disease, as detected by angiography and 
suggested that individuals with the very lowest levels of sRAGE displayed 
the greatest overall risk for disease (310). Therefore measurement of 
sRAGE might be a powerful complement to assessment of high sensitivity 
C-reactive protein in subjects predisposed to atherosclerosis. 
!
To our knowledge this is the first clinical study to look at the effects of CLA 
on sRAGE expression in subjects with the metabolic syndrome which was 
the primary objective of this study.  
!
There were no significant differences between the 9, 11 isomer or CLA mix 
on sRAGE expression in our study cohort. However, the combined results 
show a significant increase in sRAGE levels following 9:11 isomer / CLA mix 
supplementation. The increase in sRAGE levels can therefore act as a 
“decoy” receptor and attenuates the inflammatory response mediated by 
RAGE activation as proposed by previous studies (308). 
!
The dietary lipid CLA and its specific isomers are ligands of the nuclear 
transcription factors PPAR and have been shown to suppress NF-κB and 
one of its target genes RAGE in animal models (307). It is possible that 
activation of PPARs with associated changes in BP and lipid profile is in all 
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likelihood responsible for the changes in sRAGE expression in these 
subjects (217,218,219) 
!
Analysis of the combined data (Table 3.12) showed that sRAGE did not 
significantly correlate with any of the parameters measured. However this 
lack of correlation with the other parameters should be interpreted with some 
caution on the basis of a relatively small sample size and as the statistical 
power was based primarily on changes in sRAGE expression which is a 
limitation of this study. The results however support our primary hypothesis 
of the ability of these isomers to regulate circulating sRAGE and suggest a 
role for CLA in reducing vascular risk through attenuating inflammation. This 
seems to be predominantly associated with changes in endothelial and 
platelets function and independent of the changes in the metabolic profile. 
As treatment with CLA has the potential to favourably modulate these risk 
factors, such therapy is likely to confer additional vascular benefits beyond 
improved glycaemic control. This however will need to be confirmed and 
replicated in larger studies. 
!
Arterial stiffness is independently associated with cardiovascular mortality in 
a number of disease states including type 2 diabetes, renal failure and 
hypertension (311-313) and interventions to reduce stiffness such as 
lowering of BP is associated with improved survival (314). Normal blood 
pressure is dependent on the net balance between vasoconstrictor and 
vasodilator forces. In the insulin resistant state as in subjects with the 
metabolic syndrome, there appears to be a selective resistance to the 
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effects of insulin on endothelial NO production mediated by the PI3 kinase 
signalling pathway, whilst leaving the insulin action on ET-1 production 
mediated by the MAP kinase signalling pathway unchecked tilting the 
balance towards a vasoconstrictor influence. Hence, improving insulin 
sensitivity has a potential to reduce blood pressure in these subjects by 
promoting insulin mediated vasodilatation. 
!
Therefore, this study also looked at the effect of CLA supplementation on BP 
(central and peripheral), markers of arterial stiffness (BP, aPWV, bPWV and 
AIx) along with surrogate markers of endothelial (sE-selectin, vWF) and 
platelet function (sCD40L, sP-selectin), all of which are considered to be 
traditional risk factors for atherosclerosis. 
!
Treatment with 9, 11 CLA / CLA mix was associated with a significant 
improvement in aortic PWV(‘p’=0.003) which is considered in 
epidemiological studies to be an important surrogate marker of 
atherosclerotic risk and has been shown to be independently predictive of 
cardiovascular mortality (311). A slowing of aortic PWV was not associated 
with significant changes in AIx or TR. The reduction in aortic pulse wave 
could be explained by changes in BMI and lipid parameters and partly by the 
increase in adiponectin levels which may have contributed to changes in 
vascular function because adiponectin enhances nitric oxide production by 
endothelial cells (324). The change in aortic PWV may be a consequence of 
the reductions in central and peripheral blood pressure and also by 
significant changes in surrogate markers of endothelial (sE-selectin, vWF) 
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and platelet function (sP-Selectin, sCD40l). The BP lowering effects of CLA 
are shown in this study to be independent of improvement in glycaemic 
control and changes in insulin sensitivity. 
!
Conjugated linoleic acid has received considerable attention because of its 
anti diabetic and anti obesity actions. The results from the clinical studies 
have been variable and somewhat conflicting. Riserus et al showed that the 
t10, c12 CLA caused marked insulin resistance, oxidative stress and 
dyslipidaemia in obese men (262). However these effects were not 
replicated in other studies (263,264). We did not therefore use the 10, 12 
isomer in our study. In the present study, we hypothesised that 9,11 CLA 
could improve insulin sensitivity and lipid profile on the basis of recent data 
(263,264) and compared this with the CLA mix containing equal proportions 
of both the isomers which is  found in weight loss products sold over the 
counter. 
!
Insulin, proinsulin, NEFA, HOMA-B and HOMA-IR values remained 
unchanged after CLA supplementation in our study in contrast to other 
studies which reported worsening insulin sensitivity (262,263,264). The 
insulin sensitising effects of CLA are suggested to be mediated via activation 
of PPARγ and subsequent stimulation of adipocyte differentiation. There was 
however no evidence in our study that either isomer adversely or positively 
influenced insulin sensitivity.  
!
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This study utilised HOMA-IR and HOMA-B for measuring insulin sensitivity 
and β-cell function rather than using a more robust method 
(hyperinsulinaemic euglycaemic clamp) and this along with the sample size, 
relatively short duration of treatment and the consequent wide confidence 
intervals with insulin levels may be responsible for the lack of effects on 
insulin sensitivity.  
!
The body fat lowering effects of CLA in experimental animals has led to its 
use as a tool in body weight management in human subjects. The effects of 
CLA on body composition have been divergent (315,316). In contrast to 
findings from other studies (263,264), no significant changes in body 
composition were observed in our study apart from a reduction in BMI when 
the results for both groups were combined. The lack of effect of CLA 
supplementation on body composition may be due to the relatively short 
duration of treatment and the doses of CLA used. 
!
Treatment with CLA has been shown to affect serum lipoprotein 
concentrations both in vitro and clinical studies (262,264,317-319). Within 
the 9, 11 group in this crossover study, there was a significant increase in 
HDL concentrations. These beneficial effects could be mediated by altering 
the rate of de novo lipogenesis and / or the rate of lipolysis or increasing 
carnitine palmitoyl transferase activity all of which are recognised to be the 
consequence of PPARα activation (320,321). However these effects were 
not replicated when data was combined and were not associated with 
significant changes in body composition.  
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Adiponectin levels were noted to be significantly elevated following CLA 
supplementation and were associated with a significant reduction in resistin 
levels. These changes however did not correlate with changes in body 
composition or glycemic control. This is probably not surprising given the 
short time frame of treatment and the doses used in this study. 
!
PAI-1 has been found to be elevated in obesity and subjects with the 
metabolic syndrome. PAI- 1 activity has been observed to decrease with 
reducing body fat or body weight. However no such effect was seen in our 
study. 
!
In conclusion, the data presented in this chapter may support a role for CLA 
supplementation in reducing vascular outcomes and the risk of 
atherosclerosis. The BP, endothelial and platelet effects seem to be 
independent of the improvements in glycaemic control and insulin sensitivity 
and possibly mediated through attenuation of inflammation and up regulation 
of circulating sRAGE. These findings will need to be replicated in larger 
studies before its routine use in subjects with an increased vascular risk. 
!
!
!
  
!
!
!
!
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Chapter 4 General Discussion 
A sedentary lifestyle, excess calorie intake and obesity have contributed to a 
huge increase in the prevalence and incidence of the metabolic syndrome, 
type 2 diabetes and their associated cardiovascular disease. Insulin 
resistance, intra-abdominal obesity, and low grade inflammation are 
accepted to be the ‘common soil’ of the metabolic syndrome. This common 
soil regards diabetes and atherosclerosis as being a complication of the 
metabolic syndrome, both conditions have common genetic and 
environmental antecedents. 
!
There is mounting evidence that centrally located adipose tissue secretes a 
variety of adipocytokines with the capacity to influence appetite, insulin 
resistance, inflammation, blood flow and thrombosis. Adiponectin is believed 
to be an important link between obesity, type 2 diabetes and CVD. AMP 
expression has been shown to improve insulin signalling though the 
activation of AMP kinase signalling and effects on fatty acid oxidation (324). 
AMP kinase has also been purported to have anti inflammatory and anti 
atherosclerotic effects and is known to reduce the expression of adhesion 
molecules and to also increase NO production in endothelial cells (324). 
!
Insulin resistance is associated with a wide array of defects including 
dyslipidaemia, hypertension, glucose intolerance, inflammation and 
associated haemostatic abnormalities that predate the onset of type 2 
diabetes and cardiovascular disease by many years. 
!
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Inflammation as a causal factor in the atherogenic process is currently a 
major topic of interest in the cardiovascular arena. There is abundant 
evidence that inflammation directly mediates activation of the coagulation 
cascade and modulates fibrinolysis. Increased Inflammation leads to the 
release of chemokines, cytokines and the expression of cell adhesion 
molecules. The increased cardiovascular risk associated with the metabolic 
syndrome can therefore be partially explained by enhanced inflammation 
and subsequent thrombosis (296,297). 
  
Thus the metabolic syndrome represents a heterogeneous cluster of 
diseases which need a well tailored but integrated approach.  
!
While weight loss especially reducing central adiposity is crucial to reduce 
the impact of insulin resistance and associated consequences in subjects 
with the metabolic syndrome, maintenance of this weight loss is probably the 
most difficult aspect of any intervention program. However in the majority of 
cases pharmacotherapy will be needed and the drugs should be selected 
with respect to their ability to modulate the ‘common soil’ of the metabolic 
syndrome. 
!
There has been a long search for a single drug which could deal with all 
aspects of the syndrome. It was felt that the TZDs and dual PPARs might 
fulfil this role, as they act on two major pathogenetic factors of the metabolic 
syndrome, i.e. IR and central adiposity. PPARs improve insulin sensitivity in 
the liver, muscle and adipose tissue, promote favourable effects on lipid 
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profiles, exert anti inflammatory and anti thrombotic effects by reducing CRP, 
PAI-1, vWF and NFκB activity and increase adiponectin levels. Unfortunately 
these drugs were associated with serious side effects and the dual PPARs 
had to be withdrawn from the market (132,133,134). 
!
The relationship between fatty acids, atherosclerosis and other inflammatory 
diseases has been well known and increased intake of saturated fatty acids 
has been shown to be positively associated with development of 
atherosclerosis and inflammation (299). In contrast, omega-3 (ω-3) fatty 
acids have shown to be protective against CVD (300). 
!
In the context of the need for alternatives to the prevention and treatment of 
metabolic syndrome and diabetes, the polyunsaturated fatty acid CLA has 
received considerable attention. This is a result of animal experiments that 
report modulation of body composition, anti diabetic and anti atherogenic 
effects associated with its dietary supplementation. These beneficial effects 
of CLA have in part been thought to be mediated through their ability to 
behave as ligands of various isoforms of the PPAR. However, of particular 
interest has been the ability of CLA to act as an activator of both PPARγ and 
PPARα and thereby modulate the transcription of a large number of genes 
with a role in inflammation and immune function.  
!
Several studies of CLA supplementation in human subjects have now been 
published, but in contrast to animal experiments (301,302), there have been 
marked variation between reports on health related outcomes (303,304,305 
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and 306). There have also been reports of some interesting isomer specific 
effects on body weight, lipids and insulin sensitivity and these isomer 
specific effects need further investigation (235,236). 
!
Thesis Aims 
!
The aims of this thesis was to investigate the role of CLA, a 50:50 mixture of 
the 9, 11 CLA and 10, 12 isomers versus 9, 11 CLA alone in regulating 
events crucial in the pathogenesis of atherosclerosis through the ability of 
the lipid and its isomers to modulate both circulating sRAGE levels and 
induced cytokine secretion. The study also studied the effects of CLA 
supplementation on markers of arterial stiffness / endothelial function, body 
composition, adipokines and insulin sensitivity. 
!
I hypothesised that CLA may exert its benefits not only by improving insulin 
sensitivity and body composition, but also through indirect mechanisms 
involving changes in sRAGE mediated inflammation and changes in 
adipocytokine profile. 
!
Role of sRAGE 
  
CLA and its isomers may thus have the ability to regulate and modulate 
atherosclerosis-related events in monocytes, macrophage and endothelial 
cells. However, the mechanisms through which CLA and its isomers exert 
their effects on the vasculature are not fully understood.  
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The results from this study show a significant up regulation of sRAGE levels 
following treatment with 9,11CLA / CLA mix. The results from the combined 
data also showed improvement in markers of endothelial (sE-selectins, vWF) 
and platelet function (sP-selectin). The benefits in vascular function could 
well be driven by changes in adipocytokines and sRAGE expression. These 
changes interestingly appeared to be independent of changes in insulin 
sensitivity. 
!
Inflammation is therefore pivotal in the metabolic syndrome and hence a 
dietary component that has the potential to reduce inflammation in cells such 
as monocytes, macrophages and endothelial cells that are all crucially 
involved in the development of atherosclerosis is of considerable clinical 
relevance. The use of such a dietary component may open new 
perspectives in the development of effective strategies to reduce the CVD 
burden in the metabolic syndrome. 
!
In contrast to findings from other studies (231,232), no changes in body 
composition were observed in our study. An interesting view of this study is 
that the participants were weight stable and judging from the effect on body 
composition in the present study, it could be hypothesised that CLA may be 
useful in inhibiting weight gain rather than in weight reduction. 
!
In contrast to our hypothesis, there were no significant differences between 
the 9, 11 isomer compared with the CLA mix on various parameters except 
with regards to aortic PWV, lipid profiles, HOMA B and platelet function.  
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This could be the result of a possible antagonistic effect of the 10, 12 isomer 
within the CLA mixture used here. The effects of a single isomer might vary 
from those observed when the two isomers are given in combination. It was 
not possible to use the 10, 12 isomer in this study due to its associated 
detrimental effects as discussed previously (250,252,253).  
!
A limitation of this study could be the small sample size. The power 
calculation suggested that the present sample size was large enough to 
detect significant differences in sRAGE expression. However, before any 
firm conclusions can be drawn about the effects of CLA on body composition 
and metabolic variables, the present results should be confirmed by 
conducting larger studies. These studies should target either the CLA 
mixture, that is readily available or the 9, 11 isomer alone as compared to a 
placebo. This would allow specific effects associated to the isomer or the 
CLA mixture to be more readily determined. 
!
A further limitation of this study was that we did not assess dietary intake or 
physical activity during the study and thus the possibility that change in 
dietary habits could affect the results although all subjects were instructed to 
maintain their usual lifestyle habits. This study did not specifically confirm 
changes to cellular membranes associated with increased 9, 11 CLA / CLA 
dietary intake. It has been shown that CLA supplementation, changes the 
fatty acid composition of cell membranes (322). To confirm that the subjects 
involved in this trial, through CLA supplementation were modulating fatty 
acid membrane uptake would have been beneficial. This change in fatty acid 
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composition and hence the ability to regulate PPARs would have been a 
potential mechanism by which at least some of the significant events 
observed here could have been mediated. However, the ability to measure 
this fatty acid uptake through advanced chromatography was not available 
and was not undertaken. It is also important to acknowledge that some of 
these significant effects with CLA may simply reflect changed patient 
behaviour simply as a motivation in taking part in a clinical trial or a placebo 
effect. 
!
Another study limitation is that I did not prove that CLA directly activated 
both PPARα and γ receptors. It is possible to confirm this through 
demonstration of PPARα and γ dependent genes being activated. PPARα 
dependent genes include fatty acid oxidation such as LCFA β-oxidative 
enzymes (323), and for PPARγ the scavenger receptor CD36.  Alternatively, 
increased PPAR activity could have been confirmed using luciferase based 
gene reporter assays. These methods could not be applied during this study, 
but could be considered for future studies involving supplementation with 
PPAR ligands such as those used here. Another important observation from 
this study is that the results do not confirm any hazardous effects of 
consuming CLA, if anything, it seems as if this can protect against 
developing vascular disease. The results from this study therefore could 
have important implications for human nutrition and the food industry. 
!
!
!
!  168
!
Future studies 
 1) Further trials will be needed to corroborate these findings in individuals at 
high risk of cardiovascular disease such as subjects with type 2 diabetes or 
in individuals with previous MI using hard end points e.g. FMD for 
endothelial function / Meal tolerance tests (MTT) for assessment of insulin 
secretion / insulin sensitivity. 
2) Studies should also examine the ability of CLA in inducing solubilisation / 
clarify the role of various splice variants of RAGE gene in subjects with type 
2 diabetes. 
3) Continuing research on gene expression, fatty acid metabolism, and 
immune and inflammatory responses will ultimately help determine the 
efficacy of CLA as a prevention and treatment method for atherosclerosis 
!
Conclusion 
Dietary supplementation with CLA seems to produce a number of beneficial 
vascular effects which are noted to be independent of its metabolic effects 
and possibly caused by attenuation of inflammatory diathesis. This opens up 
another putative mechanism for the role of CLA in regulating RAGE 
expression. It is possible that CLA could be inducing the solubilisation of 
RAGE, which can occur either by the formation of splice products at the 
gene level or by metalloproteinase induced shedding of the RAGE receptor 
from the cells surface with resultant suppression of RAGE mediated 
inflammation providing yet another potential future target for treatment of the 
metabolic syndrome.  
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The following table 4.0 presents the key outcomes from the most recent 
studies. 
Table 4.0  Update on Recent Clinical Trials with CLA in Human subjects   
STUDY OBJECTIVES / 
DESIGN
KEY OUTCOMES
An oil mixture with trans-10, cis-12 
conjugated linoleic acid increases 
markers of inflammation and in vivo 
lipid peroxidation compared with 
c i s - 9 , t r a n s - 1 1 C L A i n 
p o s t m e n o p a u s a l w o m e n . 
JNutr; 2008, 138:1445-1451
7 5 h e a l t h y 
p o s t m e n o p a u s a l 
women were given a 
daily supplement of 
5.5 g of oil rich in 
either CLA mixture, an 
oil rich in the naturally 
occurring c9 , t11 CLA 
( C L A m i l k ) , 
respectively, or olive 
oil for 16 wk in a 
d o u b l e b l i n d , 
randomised, parallel 
intervention study.
In conclusion, oil containing trans-10, 
cis-12 CLA has several adverse 
effects on classical and novel 
markers of coronary vascular 
disease, whereas the c9, t11 CLA 
isomer is more neutral, except for a 
small but significant increase in lipid 
peroxidation compared with olive oil.
Effect of a conjugated linoleic acid 
and omega-3 fatty acid mixture on 
body composition and adiponectin. 
Obesity, 2008, 16:1019-1024
In this double-blind 
placebo-control led, 
randomised, cross-
over study. Subjects 
received either 6 g/day 
control fat or 3 g/day 
CLA (50:50 c is -9 , 
t r a n s - 11 : t r a n s - 1 0 , 
cis-12) and 3 g/day 
n-3 LC-PUFA for 12 
weeks with a 12-week 
w a s h - o u t p e r i o d 
between crossovers
Supplementation with CLA plus n-3 
LC-PUFA prevents increased 
abdominal fat mass and raises fat-
free mass and adiponectin levels in 
younger obese individuals without 
deleter iously affect ing insul in 
s e n s i t i v i t y , w h e r e a s t h e s e 
parameters in young and older lean 
and older obese individuals were 
unaffected, apart from increased 
fasting glucose in older obese men.
Conjugated l inoleic acids as 
functional food: an insight into their 
h e a l t h b e n e f i t s . N u t r i t i o n & 
Metabolism ,2009, 6:36  
As far as human consumption is 
concerned, a definite conclusion for 
CLA safety has not been reached yet 
on anti-obesitic, anti-carcinogenic, 
anti-atherogenic, anti-diabetagenic, 
immunomodulatory, apoptotic and 
osteosynthetic effects.
Comparison of dietary conjugated 
linoleic acid with safflower oil on 
body compos i t i on in obese 
postmenopausal women with type 
2 diabetes mellitus. Am J Clin Nutr 
2009; 90:468–76.
This was a 36-wk 
randomised, double-
masked, crossover 
study. Fifty-five obese 
p o s t m e n o p a u s a l 
women with type 2 
diabetes received SAF 
or CLA (8 g oil/d) 
during two 16-wk diet 
periods separated by a 
4-wk washout period.
Thirty-five women completed the 36-
wk intervention. Supplementation 
with CLA reduced body mass index 
(BMI) (P =0.0022) and total adipose 
mass (P = 0.0187) without altering 
lean mass. The effect of CLA in 
lowering BMI was detected during 
the last 8 wk of each 16-wk diet 
period. In contrast, SAF had no 
effect on BMI or total adipose mass 
but reduced trunk adipose mass (P 
=0.0422) and increased lean mass 
(P = 0.0432). SAF also significantly 
lowered fasting glucose (P = 0.0343) 
and increased adiponectin (P = 
0.0051).
!  170
Effects of a dairy product (pecorino 
cheese) naturally rich in cis 
9, trans-11 conjugated linoleic acid 
o n l i p i d , i n f l a m m a t o r y a n d 
haemorheological variables: A 
dietary intervention study. Nutrition; 
2010 (20): 2; 117-124. 
Ten subjects (6 F; 4 M) 
with a median age of 
51.5 followed for 10 
w e e k s a d i e t 
containing 200 g/week 
of cheese naturally 
r i c h i n C L A 
(intervention period) 
and for the same 
p e r i o d a d i e t 
c o n t a i n i n g a 
commercially available 
cheese of the same 
q u a n t i t y ( p l a c e b o 
period).
Consumption of the dairy product 
naturally rich in cis-9, trans-11 CLA 
determined a significant (p < 0.05) 
r e d u c t i o n i n i n f l a m m a t o r y 
parameters such as IL-6(pre:
8.08 ± 1.57vs.post:4.58 ± 0.94 pg/
mL),IL-8 (pre: 45.02 ± 5.82 vs. post: 
28.59 ± 2.64 pg/mL), and TNF-α 
(pre: 53.58 ± 25.67 vs. post: 
32.09 ± 17.42 pg/mL) whereas no 
significant differences in the placebo 
period were observedDietary short - 
term intake of the tested dairy 
product naturally rich in cis - 
9, trans-11 CLA appeared to cause 
favourable biochemical changes of 
atherosclerotic markers. !!
Dietary supplementation with cis-9, 
trans-11 conjugated linoleic acid 
and aortic stiffness in overweight 
and obese adults. Am J Clin Nutr, 
2010; 91:175–83.
In this  double blind 
randomised , placebo 
cont ro l led para l le l 
group  study, 400 
s u b j e c t s w e r e 
r a n d o m i s e d  t o 
receive  4g  of CLA  / 
placebo  for  6 months
During the intervention, mean PWV 
did not change in the c9, t11 CLA 
group compared with the placebo 
group. There was no effect of c9, t11 
CLA supplementation on BP, body 
composition, insulin resistance, or 
concentrations of lipid, glucose, and 
C-reactive protein. This study does 
not support an anti atherosclerotic 
effect or an effect on CV risk factors 
of c9, t11 CLA.
Effect of conjugated linoleic acid on 
body fat accretion in overweight or 
obese children. Am J Clin Nutr 
2010; 91:1157– 64.
This was a 7 -month 
randomised, double-
b l i n d , p l a c e b o -
controlled trial of CLA 
in 62 pre-pubertal 
children aged 6–10 y 
who were overweight 
or obese but otherwise 
healthy. The subjects 
w e r e r a n d o m l y 
assigned to receive 3 
g / d o f 8 0 % C L A 
mixture or placebo in 
Chocolate milk.
CLA supplementation for 7  months ↓ 
body fatness in 6–10-y-old children 
who were overweight or obese but 
did not improve plasma lipids or 
glucose and ↓ HDL more than in the 
placebo group
E f fec t o f a H igh In take o f 
Conjugated Linoleic Acid on 
Lipoprotein Levels in Healthy 
Human Subjects PLoS ONE 
February 2010 | Volume 5 | Issue 2 
| e9000
S i x t y - o n e h e a l t h y 
women and men were 
sequentially fed each 
of three diets for three 
weeks, in random 
order, for a total of 
nine weeks.Diets were 
identical except for 7% 
ofenergy(approximatel
y 20 g /day), which 
was provided either by 
oleic acid, by industrial 
trans fatty acids, or by 
a mixture of 80% cis-9, 
t rans-11 and 20% 
trans-10, cis-12 CLA.
High intakes of an 80:20 mixture of 
cis-9, trans-11 and trans-10, cis-12 
CLA raise the total to HDL 
cholesterol ratio in healthy 
volunteers
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C o n j u g a t e d L i n o l e i c A c i d 
Supplementation for 8 Weeks Does 
Not Affect Body Composition, Lipid 
Profile, or Safety Biomarkers in 
Overweight, Hyperlipidemic Men 
The Journal of Nutrition; 
2011; 141:1286-1291
A double-blinded, 3-
phase cross-over trial. 
Dur ing three 8-wk 
p h a s e s , e a c h 
separated by a 4-wk 
washout period, 27 
participants consumed 
under supervision in 
random order 3.5 g/d 
o f s a f f l o w e r o i l 
( c o n t r o l ) , a C L A 
mixture, and c9, t11 
isomer. At baseline 
and endpoint of each 
phase, body weight, 
body fat mass, and 
lean body mass were 
measured by DXA. 
Blood lipid profiles, 
insu l in sens i t i v i ty, 
a d i p o n e c t i n , a n d 
inflammatory (hs-crp, 
TNFa, and IL-6) and 
oxidized-LDL, were 
measured.
Compared with the control treatment, 
the CLA treatments did not affect 
changes in body weight, body 
composition, or blood lipids. In 
addition, CLA did not affect the b-
oxidation rate of fatty acids or induce 
significant alterations in the safety 
markers tested. In conclusion, 
although no detrimental effects were 
caused by supplementation, these 
results do not confirm a role for CLA 
in either body weight or blood lipid 
regulation in humans..
CLA Does Not Impair Endothelial 
Function and Decreases Body 
Weight as Compared with 
Safflower Oil in Overweight and 
Obese Male Subjects. J Am Coll 
Nutr. 2011 Feb;30(1):19-28
Eighty-five overweight 
men (aged 45–68 
years , body mass 
index 25–35 kg/m2) 
were randomized to 
receive 4.5 g/d of the 
CLA isomeric mixture, 
safflower oil, heated 
safflower oil, or olive 
oil in a 4-week double 
b l i n d s t u d y . 
Endothelial function 
w a s a s s e s s e d b y 
per iphera l a r ter ia l 
tonometry (PAT) index 
determination in the 
f a s t i n g a n d 
postprandial state
CLA did not impair endothelial 
f u n c t i o n . O t h e r p a r a m e t e r s 
associated with metabolic syndrome 
and oxidative stress were not 
changed or were slightly improved
The efficacy of long-term CLA 
s u p p l e m e n t a t i o n o n b o d y 
composition in overweight and 
obese individuals: a systematic 
review and meta-analysis of 
r a n d o m i s e d c l i n i c a l t r i a l s . 
European Journal of Nutrition, 
March 2012, Volume 51, Issue 
2, pp 127-134 
The evidence from RCT’s does not 
convincingly show that CLA intake 
generates any clinically relevant 
effects on body composition in the 
long term.
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Appendix 1 - Patients Information Sheet - Version 2 (20/08/2005) 
Title of the study  
A study to assess the metabolic, vascular & inflammatory effects of 
Conjugated linoleic acid in patients with the metabolic syndrome. 
!
Introduction 
You are being invited to take part in a research study. Before you decide 
whether to take part, it is important for you to understand why the study is 
being carried out and what it will involve. Please take time to read the 
following information carefully and discuss it with friends and relatives if you 
wish. Ask us if there is anything not clear or if you would like more 
information. Take time to decide whether or not you wish to take part. If you 
do not wish to take part, you may refuse without explanation and this will no 
way affect your current or future medical treatment. 
Consumers for ethics in Research (CERES) publish a leaflet entitled 
‘Medical Research and You’. This leaflet gives more information about 
medical research and looks at some questions you may want to ask. A copy 
of this leaflet is available on request. 
!
What is the purpose of the study? 
Conjugated Linoleic acids (CLA) are a group of isomers of conjugated octa -
dienoic acid (fatty acids) that occur naturally in food, mostly in diary 
products.  CLA has attracted much interest since the discovery that it has 
body fat-lowering, immune enhancing & anti-cancer effects. It is increasingly 
being used as a dietary supplement in patients with the metabolic syndrome. 
(Overweight subjects with high blood pressure, high blood glucose & 
cholesterol related abnormalities) who have an increased risk of developing 
heart disease. An earlier study found that a group of people who took CLA 
had reduction in body fat, along with a reduction in cardiovascular risk 
factors.  
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This study will look at the effects of dietary supplementation of CLA on body 
fat, blood glucose, blood vessel function. The main aim being to answer the 
question whether CLA would improve blood vessel function, thus reducing 
the risk of heart disease.  
!
Why have I been chosen? 
You have been diagnosed to have the metabolic syndrome. This study will 
determine whether CLA taken as dietary supplements is effective in 
improving blood vessel function, thereby reducing cardiovascular risk. 
!
Do I have to take part? 
It is up to you to decide whether or not to take part. If you decide to take part 
you will be given this information sheet to keep and be asked to sign a 
consent form. If you decide to take part you are still free to withdraw at any 
time and without giving a reason. If you decide not to take part or to 
withdraw at any time, you may do so without giving a reason and without 
that decision affecting current or future medical care in any way. 
!
What will happen to me if I take part? 
Before you enter the study your doctor will give you a full explanation of what 
the study will involve and you will be able to ask any questions that you may 
have. You will then be asked to sign the consent form, before any other 
procedures are performed. Please read this carefully before signing. If you 
agree to take part you will be asked about your medical history and 
medicines you are taking. Your doctor will carry out a medical examination 
and a variety of tests described in greater detail below will be carried out. A 
total volume of 40ml (8 teaspoonfuls) of blood will be taken. You should not 
eat or drink anything (except water) for approximately 9 hours before 
attending the clinic (from midnight before the visit). You will then be given the 
study medication. 
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You will be asked to return to the clinic after 8 weeks for blood tests. After 
this, for the next 6 weeks you will not receive any medications. You will be 
asked to return to the clinic at the end of this period and will be given the 
study medication for another 8 weeks. You will have tests before 
commencing the medication and on completion of the study. During this 
period we will be in regular contact with you by telephone to ensure that you 
have no problems. If you have any problems or any questions, you may 
contact us on the telephone numbers given below. Each visit will take no 
longer than 2 hours to complete. 
The table below shows which of the tests and procedures that will be done 
at each visit. The tests are explained below: 
!
• Physical examination: includes measurements of heart rate, blood 
pressure, height, weight and waist measurement. 
• Blood test: up to 40 mls (equal to 8 teaspoons) of blood will be removed 
from a vein in your arm at visits 1, 2, 3 & 4 during the study period 
proper. 
S t u d y 
Procedures
Vis i t 
1
Visit 2 Visit 3 Visit 4
Physical  
Examination
× × × ×
B l o o d 
P r e s s u r e 
and Hear t 
Rate
× × × ×
Blood Test × × × ×
Pulse wave 
analysis
× × × ×
ECG × × × ×
OGTT × × × ×
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• An ECG (Electrocardiogram) will be performed at the first and final visits 
to measure the electrical activity of your heart. 
• During these visits you will undergo pulse wave analysis . These 
investigations are painless and involve an ultrasound device being 
placed over one of the major blood vessels in the arm. These tests will 
provide information on how stiff the arteries are and whether the study 
has any effect on this. 
!
What type of study is this? 
This study is a randomised, double blind, crossover study; sometimes 
because we do not know which way of treating patients is best, we need to 
make comparisons. People will be put into groups and then compared. The 
groups are selected by a computer, which has no information about the 
individual, i.e. by chance. Patients in each group then have a different 
treatment and these are compared. Neither you nor the researchers will 
know which of the treatments you are taking until the end of the study when 
you may be told if you wish. Only in the event of an emergency will the 
medication you are taking be identified before the study is completed. 
!
Treatment Group 1: Conjugated Linoleic acid (C9, t11 isomer)  
Treatment Group 2: Conjugated Linoleic acid mixture (t10, c12 isomer and 
C9, t11 isomers in a 1:1 ratio) 
!
You have a 50% chance of receiving either isomer. Neither you nor your 
doctor will know which treatment group you are in (although if your doctor 
needs to find out he/she can do so). This is to limit the potential for bias 
throughout the study. 
!
It is very important that you take the medications as directed by the study 
doctor. Only the person for whom it was prescribed must take study 
medication. It must be kept out of the reach of children or persons of limited 
capacity to read or understand. 
!
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What are the possible benefits of part? 
We hope that this research will help you by improving blood vessel function. 
However, this cannot be guaranteed. The information we get from this study 
may help us in the future treatment of people with metabolic syndrome. 
!
What are the possible risks of taking part? 
The drug used in the study may involve other risks that are not known at the 
present time. CLA has been used in previous studies and so far no major 
adverse events have been reported. 
!
What if something goes wrong? 
If you become ill as a result of the medical treatment provided and if you are 
harmed by taking part in this research project, there are no special 
compensation arrangements. If you are harmed due to someone’s 
negligence, then you may have grounds for a legal action but you may have 
to pay for it. Regardless of this, if you wish to complain, or have any 
concerns about any aspect of the way you have been approached or treated 
during the course of this study, the normal National Health Service 
complaints mechanism should be available to you. 
!
What if new information becomes available? 
Sometimes during the course of a research project, new information 
becomes available about the treatment/drug that is being studied. If this 
happens, your research doctor will tell you about it and discuss with you 
whether you want to continue in the study. 
!
Will my taking part in this study be kept confidential? 
Your participation in the study will be treated as confidential, that is, any 
personally identifiable information (e.g. initials and date of birth) will be held 
and processed under secure conditions with access limited to appropriate 
staff involved in the study. You will not be referred to by any name in any 
report of the study. Your identity will not be disclosed to any person, except 
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for the purposes described above and in the event of a medical emergency 
or if required by law. 
!
You may be entitled under law to access your personal data and to have any 
justifiable corrections made.  If you chose to take part in this study, Your GP 
or any other doctors involved in your medical care will be informed of your 
participation, with your permission. 
!
What will happen to the results of the research study? 
A report will be written after the study has completed after which your doctor 
may tell you the type of treatment you received. You will not be identified in 
any report or publications. 
!
Who has reviewed the study? 
An independent ethics review board reviewed the protocol. 
!
Who are the people doing this research? 
The team who are conducting this project includes Dr Marc Evans who is 
Consultant Diabetologist at the University Hospital of Wales and Llandough 
Hospitals and Dr Hemanth Bolusani -Clinical Research Fellow Llandough 
Hospital. Full contact addresses are given below: 
Dr Marc Evans 
Consultant Diabetologist 
Llandough Hospital 
Cardiff 
Dr Hemanth Bolusani 
Clinical Research Fellow 
Llandough Hospital 
Cardiff 
!
!
!
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!
If you decide to take part in this research study, you will be given a 
copy of this information to keep. If at any time you have any further 
questions or require any further information, please contact a member 
of the research team whose details are given below. 
!
Name: Dr Marc Evans (Principal research doctor) 
Tel No: 02920716478(Office hours); 07866 528821(24 hours) 
!
Name: Dr Hemanth Bolusani (Clinical Research Fellow) 
Tel No: 07876704538(24 hours) 
!
!
Thank you for taking time to read this information leaflet. You are 
entitled to receive a copy of this form. 
!
!
!
!
!
!
!
!
!
!
!
!
!
!
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Appendix 2 
CONSENT FORM-Version 2.0(20/8/2005) !
A study to assess the metabolic, vascular & inflammatory effects of 
Conjugated Linoleic acid in patients demonstrating insulin resistance. !
Name of Researcher: Dr L M Evans !
              Please initial box 
 
1. I confirm that I have read and understood the full information sheet  
Dated 20/08/2005 for the above study to assess the effects of 
dietary supplementation of conjugated linoleic acid (fatty acids) on 
body fat,blood glucose and blood vessel function and have had the 
opportunity to ask the questions. 
 
2. I understand that my participation is voluntary and that I am free to 
withdraw at any time, without giving any reason without my 
medical care or legal rights being affected. 
 
3. I understand that sections of any of my medical notes may be 
looked at by responsible individuals involved in the study or from 
regulatory authorities where it is relevant to my taking part in 
research. I give permission for these individuals to have access to 
my records. !
4. I agree to take part in the above study.    !!!
Name of Patient   Date    Signature !!
 
Name of Person taking consent Date    Signature 
(If different from researcher) !
 !!
Researcher    Date    Signature !!
 !
. 
 !
1 for patient; 1 for researcher; 1 to be kept with hospital notes 
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Appendix 3 
CLA STUDY 
!
 Discuss and sign consent form 
All patients must be fasted !
Date……………ID No…………………D.O.B…………… !
Name………………………………………………………… !
Address………………………………………………………. !
………………………………………………………………… !!
     Ethnic group: Caucasian…..Indo-Asian….Afro-Carribean… !
     Inclusion Criteria             Exclusion Criteria !
1) Plasma Glucose     > 5.6 Y/N    1)Diabetes                 Y/N 
2)Serum Triglycerides >1.7  Y/N   2)Aspirin /NSAID        Y/N 
3)Serum HDL-C         3)Acute illness    Y/N 
 Males               <1.03 Y/N   4) Renal failure           Y/N 
       Females               <1.30 Y/N                5) Liver failure             Y/N      
       6)Pregnancy/LactationY/N  
4) Blood pressure     >130/85mm 
5) Abdominal obesity   
    Males    >102Cms 
    Females >88Cms !!
 MEDICAL HISTORY.  !
  1.High B.P     Y/N…….Duration…………… 
  2.High Cholesterol  Y/N 
  3.Diabetes      Y/N     
  4.Stroke     Y/N    CVA…….   TIA…… 
  5.CHD     Y/N    Angina……MI….. 
  6.PVD     Y/N !
  ……………………………………………………………………………… !
  ……………………………………………………………………………… !
  ……………………………………………………………………………… !
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!!
Life Style !
  1.Smoker  Y/N .Duration ……. Amount ……  Ex… Pack Years ……… !
  2.Alcohol  Y/N  Units/week ……………………………………………….. !
Family History  !
……………………………………………………………………………… !
……………………………………………………………………………… !
……………………………………………………………………………… !!!
Current Drug Therapy !
Drugs !
……………………………….                        …………………......................  !
……………………………….       ……………………………...... !
……………………………….                        ……………………………….. !
……………………………….                        ……………………………….. !
………………………………                         ……………………………….. !!!
Exercise Y/N . Duration/type………………………………………………. !!
ANTHROPOMETRIC MEASUREMENTS !
Height(cms)…………. Wt(Kg)…………….BMI………………………….. !
Body Composition. % Fat…………………..Body Fat……………………. !
Waist circumference(cms)………………………………………….............. !
       !!!
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!!!!
CARDIOVASCULAR MEASUREMENTS: !
Seated BP      a) ……………..  b)…………….. Avg …………………… !
Seated AIx     a) ……………..  b)…………….. Avg …………………… !
Central Aortic Pressure 
a) ……………..  b)……………...Avg …………………… !
Tr     a)  ……………..  b)……………...Avg …………………… !!
Pulse Wave Velocity     SSN to Carotid ……………………………..mm !
            SSN to Radial   ……………………………..mm !
            SSN to Umbilicus……………………………mm !
                                        SSN to Femoral  …………………………….mm !!
CAROTID RADIAL           a) …………. b)………..  Avg …………. m/s !!
CAROTID FEMORAL      a) ………….. b)……….  Avg …………..m/s !!!!
Bloods and Oral glucose tolerance test  !!!!!!!!!!!!!!
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